Trinity Biotech (TRIB) 20-F 16 May 23 2022 FY Annual report (foreign) Financial data

Document and Entity Information

Document and Entity Information	12 Months Ended
	Dec. 31, 2022 shares
Entity Addresses [Line Items]
Entity Registrant Name	Trinity Biotech plc
Entity Central Index Key	0000888721
Document Type	20-F
Document Period End Date	Dec. 31, 2022
Current Fiscal Year End Date	--12-31
Amendment Flag	false
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2022
Document Registration Statement	false
Document Annual Report	true
Document Transition Report	false
Document Shell Company Report	false
Entity Emerging Growth Company	false
Entity File Number	0-2022
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Common Stock, Shares Outstanding	152,430,284
Entity Incorporation, State or Country Code	L2
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Address, Address Line One	IDA Business Park
Entity Address, City or Town	Bray, County Wicklow
Entity Address, Country	IE
Entity Address, Postal Zip Code	A98 H5C8
Title of 12(b) Security	American Depositary Shares (each representing 4‘A’ Ordinary Shares, par value US$0.0109)
Trading Symbol	TRIB
Security Exchange Name	NASDAQ
ICFR Auditor Attestation Flag	false
Document Accounting Standard	International Financial Reporting Standards
Entity Shell Company	false
Auditor Name	GRANT THORNTON
Auditor Location	Dublin, Ireland
Auditor Firm ID	1402
Business Contact [Member]
Entity Addresses [Line Items]
Contact Personnel Name	John Gillard
City Area Code	353
Local Phone Number	1276 9800
Contact Personnel Fax Number	1276 9888
Entity Address, Address Line One	IDA Business Park
Entity Address, City or Town	Bray, County Wicklow
Entity Address, Country	IE
Entity Address, Postal Zip Code	A98 H5C8

CONSOLIDATED STATEMENT OF OPERA

CONSOLIDATED STATEMENT OF OPERATIONS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disclosure of classes of share capital [line items]
Revenues	$ 74,779	$ 92,965	$ 101,980
Cost of sales	(52,731)	(54,888)	(53,400)
Gross profit	22,048	38,077	48,580
Other operating income	343	4,672	1,860
Research and development expenses	(4,138)	(4,497)	(5,080)
Selling, general and administrative expenses	(29,166)	(24,683)	(26,390)
Selling, general and administrative expenses - closure costs	0	0	(2,425)
Selling, general and administrative expenses - recognition of contingent asset	0	0	1,316
Impairment charges	(5,839)	(6,944)	(17,779)
Operating (loss)/profit	(16,752)	6,625	82
Financial income	303	1,223	36
Financial expenses	(24,745)	(7,097)	(6,751)
Net financing expense	(24,442)	(5,874)	(6,715)
(Loss)/profit before tax	(41,194)	751	(6,633)
Total income tax credit	192	178	620
(Loss)/profit for the year on continuing operations	(41,002)	929	(6,013)
Loss for the year on discontinued operations	(7)	(54)	(375)
(Loss)/profit for the year (all attributable to owners of the parent)	(41,009)	875	(6,388)
American depositary share [Member]
Disclosure of classes of share capital [line items]
(Loss)/profit for the year (all attributable to owners of the parent)	$ 41,009	$ 875	$ (6,388)
Basic (loss)/profit (US Dollars) – continuing operations	$ (1.22)	$ 0.04	$ (0.29)
Diluted (loss)/profit (US Dollars) – continuing operations	(1.22)	0.04	(0.29)
Basic (loss)/profit (US Dollars) – group	(1.22)	0.04	(0.31)
Diluted (loss)/profit (US Dollars) – group	$ (1.22)	$ 0.04	$ (0.31)
Class A Ordinary shares [Member]
Disclosure of classes of share capital [line items]
(Loss)/profit for the year (all attributable to owners of the parent)	$ 41,009	$ 875	$ (6,388)
Basic (loss)/profit (US Dollars) – continuing operations	$ (0.3)	$ 0.01	$ (0.07)
Diluted (loss)/profit (US Dollars) – continuing operations	(0.3)	0.01	(0.07)
Basic (loss)/profit (US Dollars) – group	(0.3)	0.01	(0.08)
Diluted (loss)/profit (US Dollars) – group	$ (0.3)	$ 0.01	$ (0.08)

CONSOLIDATED STATEMENT OF COMPR

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Consolidated Statement Of Comprehensive Income Abstract
(Loss)/profit for the year	$ (41,009)	$ 875	$ (6,388)
Other comprehensive loss
Foreign exchange translation differences	(396)	(86)	(1,360)
Other comprehensive loss	(396)	(86)	(1,360)
Total Comprehensive (Loss)/profit (all attributable to owners of the parent)	$ (41,405)	$ 789	$ (7,748)

CONSOLIDATED STATEMENT OF FINAN

CONSOLIDATED STATEMENT OF FINANCIAL POSITION - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Non-current assets
Property, plant and equipment	$ 5,682	$ 5,918
Goodwill and intangible assets	35,269	35,981
Deferred tax assets	4,218	4,101
Derivative financial instruments	128	0
Other assets	139	207
Total non-current assets	45,436	46,207
Current assets
Inventories	22,503	29,123
Trade and other receivables	15,753	16,116
Income tax receivable	1,834	1,539
Cash and cash equivalents	6,578	25,910
Total current assets	46,668	72,688
TOTAL ASSETS	92,104	118,895
Equity attributable to the equity holders of the parent
Share capital	1,963	1,213
Share premium	46,458	16,187
Treasury shares	(24,922)	(24,922)
Accumulated (deficit)/surplus	(26,695)	12,559
Translation reserve	(5,775)	(5,379)
Equity component of convertible note	6,709	0
Other reserves	86	23
Total deficit	(2,176)	(319)
Current liabilities
Income tax payable	28	22
Trade and other payables	15,375	15,127
Provisions	50	50
Exchangeable notes and other borrowings	210	83,312
Lease liabilities	1,676	1,980
Total current liabilities	17,339	100,491
Non-current liabilities
Senior secured term loan	44,301	0
Derivative financial liability	1,569	0
Convertible Note	13,746	0
Lease liabilities	12,267	13,865
Deferred tax liabilities	5,058	4,858
Total non-current liabilities	76,941	18,723
TOTAL LIABILITIES	94,280	119,214
TOTAL EQUITY AND LIABILITIES	$ 92,104	$ 118,895

CONSOLIDATED STATEMENT OF CHANG

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY - USD ($)	Share Capital 'A' Ordinary shares [Member]	Share premium [Member]	Treasury Shares [Member]	Translation reserve [Member]	Equity Component Of Convertible Note [Member]	Other reserves [member]	Accumulated (deficit)/surplus [Member]	Total
Balance at Dec. 31, 2019	$ 1,213,000	$ 16,187,000	$ (24,922,000)	$ (3,933,000)		$ 23,000	$ 16,145,000	$ 4,713,000
Profit/(Loss) for the period							(6,388,000)	(6,388,000)
Other comprehensive income (loss)				(1,360,000)				(1,360,000)
Total comprehensive profit/(loss)				(1,360,000)			(6,388,000)	(7,748,000)
Share-based payments							816,000	816,000
Balance at Dec. 31, 2020	1,213,000	16,187,000	(24,922,000)	(5,293,000)		23,000	10,573,000	(2,219,000)
Profit/(Loss) for the period							875,000	875,000
Other comprehensive income (loss)				(86,000)				(86,000)
Total comprehensive profit/(loss)				(86,000)			875,000	789,000
Share-based payments							1,111,000	1,111,000
Balance at Dec. 31, 2021	1,213,000	16,187,000	(24,922,000)	(5,379,000)		23,000	12,559,000	(319,000)
Profit/(Loss) for the period							(41,009,000)	(41,009,000)
Other comprehensive income (loss)				(396,000)				(396,000)
Total comprehensive profit/(loss)				(396,000)			(41,009,000)	(41,405,000)
Shares issued in the year	750,000	30,271,000						31,021,000
Shares to be issued						63,000		63,000
Equity component of convertible note					$ 6,709,000			6,709,000
Share-based payments							1,755,000	1,755,000
Balance at Dec. 31, 2022	$ 1,963,000	$ 46,458,000	$ (24,922,000)	$ (5,775,000)	$ 6,709,000	$ 86,000	$ (26,695,000)	$ (2,176,000)

CONSOLIDATED STATEMENT OF CASH

CONSOLIDATED STATEMENT OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Cash flows from operating activities
(Loss)/profit for the year	$ (41,009)	$ 875	$ (6,388)
Adjustments to reconcile net profit/(loss) to cash provided by operating activities:
Depreciation	1,410	1,827	1,674
Amortisation	923	917	1,403
Income tax credit	(192)	(167)	(182)
Financial income	(303)	(1,223)	(36)
Financial expense	24,745	7,097	6,751
Share-based payments (net of capitalized amounts)	1,755	1,100	792
Foreign exchange gains on operating cash flows	(76)	(251)	(663)
Loss/(gain) on disposal or retirement of property, plant and equipment	2	(1)	30
Movement in inventory provision	7,391	5,589	5,059
Impairment of prepayments	482	583	562
Impairment of property, plant and equipment	733	2,508	1,795
Impairment of intangible assets	4,624	3,853	15,422
Other non-cash items	269	(5,317)	(634)
Operating cash flows before changes in working capital	754	17,390	25,585
(Increase)/decrease in trade and other receivables	(966)	6,236	(2,489)
(Increase) in inventories	(877)	(4,406)	(3,419)
Increase/(decrease) in trade and other payables	181	(7,591)	4,994
Cash (used in)/generated from operations	(908)	11,629	24,671
Interest paid	0	(11)	(48)
Interest received	2	1	104
Income taxes (paid)/received	(15)	1,619	(972)
Net cash (used in)/generated by operating activities	(921)	13,238	23,755
Cash flows from investing activities
Payments to acquire intangible assets	(4,876)	(6,879)	(6,990)
Acquisition of property, plant and equipment	(1,101)	(1,812)	(3,178)
Disposal of property, plant and equipment	0	0	(30)
Net cash used in investing activities	(5,977)	(8,691)	(10,198)
Cash flows from financing activities
Issue of ordinary share capital including share premium (net of issuance costs)	25,336	0	0
Proceeds from shares to be issued	63	0	0
Net proceeds from senior secured term loan	80,015	0	0
Proceeds from convertible note issued	20,000	0	0
Expenses paid in connection with debt financing	(2,356)	(848)	0
Purchase of exchangeable notes	(86,730)	0	0
Repayment of senior secured term loan	(34,500)	0	0
Penalty for early settlement of term loan	(3,450)	0	0
Repayment of other loan	(23)	0	0
Interest paid on senior secured term loan	(6,424)	0	0
Interest paid on convertible note	(199)	0	0
Proceeds from Paycheck Protection loans	0	1,764	4,520
Interest paid for exchangeable notes	(1,293)	(3,996)	(3,996)
Payment of lease liabilities	(2,761)	(2,939)	(3,240)
Net cash used in financing activities	(12,322)	(6,019)	(2,716)
(Decrease)/increase in cash and cash equivalents and short-term investments	(19,220)	(1,472)	10,841
Effects of exchange rate movements on cash held	(112)	55	86
Cash and cash equivalents and short-term investments at beginning of year	25,910	27,327	16,400
Cash and cash equivalents and short-term investments at end of year	$ 6,578	$ 25,910	$ 27,327

BASIS OF PREPARATION AND SIGNIF

BASIS OF PREPARATION AND SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2022
Disclosure of basis of preparation and significant accounting policies [Abstract]
BASIS OF PREPARATION AND SIGNIFICANT ACCOUNTING POLICIES	1. BASIS OF PREPARATION AND SIGNIFICANT ACCOUNTING POLICIES The principal accounting policies adopted by Trinity Biotech plc (“the Company”) and its subsidiaries (together the “the Group”) are set out below. i) General information Trinity Biotech develops, acquires, manufactures and markets medical diagnostic products for the clinical laboratory and point-of-care segments of the diagnostic market. These products are used to detect autoimmune, infectious and sexually transmitted diseases, diabetes and disorders of the liver and intestine. Trinity Biotech is a significant provider of raw materials to the life sciences and research industries globally. Trinity Biotech also operates a licenced reference laboratory that specializes in diagnostics for autoimmune diseases. ii) Statement of compliance The consolidated financial statements have been prepared in accordance with International Financial Reporting Standards (“IFRS”) both as issued by the International Accounting Standards Board (“IASB”) and as subsequently adopted by the European Union (“EU”) (together “IFRS”). The IFRS applied are those effective for accounting periods beginning January 1, 2022. Consolidated financial statements are required by Irish law to comply with IFRS as adopted by the EU which differ in certain respects from IFRS as issued by the IASB. These differences predominantly relate to the timing of adoption of new standards by the EU. However, in relation to the 2022 consolidated financial statements there are no differences regarding the effective date of new IFRS relevant to Trinity Biotech as issued by the IASB and as adopted by the EU. In relation to prior periods presented, none of the differences are relevant in the context of Trinity Biotech and the consolidated financial statements comply with IFRS both as issued by the IASB and as adopted by the EU. iii) Basis of preparation The consolidated financial statements have been prepared in United States Dollars (US$), rounded to the nearest thousand, under the historical cost basis of accounting, except for derivative financial instruments, certain balances arising on acquisition of subsidiary entities and share-based payments which are initially recorded at fair value. Derivative financial instruments are also subsequently revalued and carried at fair value. The preparation of financial statements in conformity with IFRS requires management to make judgements, estimates and assumptions that affect the application of policies and amounts reported in the financial statements and accompanying notes. The estimates and associated assumptions are based on historical experience and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis of making the judgements about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates. The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised if the revision affects only that period or in the period of the revision and future periods if the revision affects both current and future periods. Judgements made by management that have a significant effect on the financial statements and estimates with a significant risk of material adjustment in the next year are discussed in Note 29. The directors have considered the Group’s current financial position and cash flow projections, taking into account all known events and developments. The directors believe that the Group will be able to continue its operations for at least the next 12 months from the date of this report and that it is appropriate to continue to prepare the consolidated financial statements on a going concern basis. At December 31, 2022, the Group had net current assets of US$29.3 million. At the date of this report, the Group’s liquidity position has substantially improved following the sale of its Fitzgerald life sciences business for cash proceeds of approximately US$30 million (subject to customary adjustments). This transaction substantially improves the Group’s capital structure by reducing gross debt by approximately US$10 million; with the balance of the proceeds (net of costs) providing significant capital for growth, transformation, and potentially further debt reduction. There are no material debt maturities until 2026. The accounting policies set out below have been applied consistently to all periods presented in these consolidated financial statements. The accounting policies have been applied consistently by all Group entities. iv) Basis of consolidation Subsidiaries Subsidiaries are entities controlled by the Company. Control exists when the Company has the power, directly or indirectly, to govern the financial and reporting policies of an entity so as to obtain benefits from its activities. In assessing control, potential voting rights that presently are exercisable or convertible are taken into account. The financial statements of subsidiaries are included in the consolidated financial statements from the date that control commences until the date that control ceases. Transactions eliminated on consolidation Intra-group balances and any unrealised gains or losses or income and expenses arising from intra-group transactions are eliminated in preparing the consolidated financial statements. v) Property, plant and equipment Owned assets Items of property, plant and equipment are stated at cost less any accumulated depreciation and any impairment losses (see Note 1(viii)). The cost of self-constructed assets includes the cost of materials, direct labour and attributable overheads. It is not Group policy to revalue any items of property, plant and equipment. Depreciation is charged to the statement of operations on a straight-line basis to write-off the cost of the assets over their expected useful lives as follows: • Leasehold improvements 5-15 years • Buildings 50 years • Office equipment and fittings 10 years • Computer equipment 3-5 years • Plant and equipment 5-15 years Land is not depreciated. The residual values, if not insignificant, useful lives and depreciation methods of property, plant and equipment are reviewed and adjusted if appropriate on a prospective basis, at each balance sheet date. There were no changes to useful lives in the year. The Group considers whether a contract is or contains a lease. A lease is defined as ‘a contract, or part of a contract, that conveys the right to use an asset (the underlying asset) for a period of time in exchange for consideration’. To apply this definition the Group assesses whether the contract meets three key evaluations which are whether: • the contract contains an identified asset, which is either explicitly identified in the contract or implicitly specified by being identified at the time the asset is made available to the Group • the Group has the right to obtain substantially all of the economic benefits from use of the identified asset throughout the period of use, considering its rights within the defined scope of the contract • the Group has the right to direct the use of the identified asset throughout the period of use. The Group assess whether it has the right to direct ‘how and for what purpose’ the asset is used throughout the period of use. At lease commencement date, the Group recognises a right-of-use asset and a lease liability on the balance sheet. The right-of-use asset is measured at cost, which is made up of the initial measurement of the lease liability, any initial direct costs incurred by the Group, an estimate of any costs to dismantle and remove the asset at the end of the lease, and any lease payments made in advance of the lease commencement date (net of any incentives received). The Group depreciates the right-of-use assets on a straight-line basis from the lease commencement date to the earlier of the end of the useful life of the right-of-use asset or the end of the lease term. The Group also assesses the right-of-use asset for impairment when such indicators exist. At the commencement date, the Group measures the lease liability at the present value of the lease payments unpaid at that date, discounted using the interest rate implicit in the lease if that rate is readily available or the Group’s incremental borrowing rate. Lease payments included in the measurement of the lease liability are made up of fixed payments (including in substance fixed), variable payments based on an index or rate, amounts expected to be payable under a residual value guarantee and payments arising from options reasonably certain to be exercised. Subsequent to initial measurement, the liability will be reduced for payments made and increased for interest. It is remeasured to reflect any reassessment or modification, or if there are changes in in-substance fixed payments. When the lease liability is remeasured, the corresponding adjustment is reflected in the right-of-use asset, or profit and loss if the right-of-use asset is already reduced to zero. The Group has elected to account for short-term leases and leases of low-value assets using the practical expedients. Instead of recognising a right-of-use asset and lease liability, the payments in relation to these are recognised as an expense in profit or loss on a straight-line basis over the lease term. On the statement of financial position, right-of-use assets have been included in property, plant and equipment and lease liabilities have been included in separate lines within the current liabilities and non-current liabilities sections. Leased assets - as lessor The Group’s accounting policy under IFRS 16 has not changed from the comparative period. As a lessor, the Group classifies its leases as either operating or finance leases. A lease is classified as a finance lease if it transfers substantially all the risks and rewards incidental to ownership of the underlying asset, and classified as an operating lease if it does not. vi) Goodwill In respect of business combinations that have occurred since January 1, 2004 (being the transition date to IFRS), goodwill represents the difference between the cost of the acquisition and the fair value of the net identifiable assets acquired. In respect of acquisitions prior to this date, goodwill is included on the basis of its deemed cost, which represents the amount recorded under the old basis of accounting, Irish GAAP, (“Previous GAAP”). Save for retrospective restatement of deferred tax as an adjustment to retained earnings in accordance with IAS 12, Income Taxes, To the extent that the Group’s interest in the net fair value of the identifiable assets, liabilities and contingent liabilities acquired exceeds the cost of a business combination, the identification and measurement of the related assets, liabilities and contingent liabilities are revisited accompanied by a reassessment of the cost of the transaction, and any remaining balance is immediately recognised in the statement of operations. At the acquisition date, any goodwill is allocated to each of the cash-generating units expected to benefit from the combination’s synergies. Following initial recognition, goodwill is stated at cost less any accumulated impairment losses (see Note 1(viii)). vii) Intangibles, including research and development (other than goodwill) An intangible asset, which is an identifiable non-monetary asset without physical substance, is recognised to the extent that it is probable that the expected future economic benefits attributable to the asset will flow to the Group and that its cost can be measured reliably. The asset is deemed to be identifiable when it is separable (that is, capable of being divided from the entity and sold, transferred, licenced, rented or exchanged, either individually or together with a related contract, asset or liability) or when it arises from contractual or other legal rights, regardless of whether those rights are transferable or separable from the Group or from other rights and obligations. Intangible assets acquired as part of a business combination are capitalised separately from goodwill if the intangible asset meets the definition of an asset and the fair value can be reliably measured on initial recognition. Subsequent to initial recognition, these intangible assets are carried at cost less any accumulated amortisation and any accumulated impairment losses (Note 1(viii)). Intangible assets with definite useful lives are reviewed for indicators of impairment annually while intangible assets with indefinite useful lives and those not yet brought into use are tested for impairment at least annually, either individually or at the cash-generating unit level. Expenditure on development activities, whereby research findings are applied to a plan or design for the production of new or substantially improved products and processes, is capitalised if the product or process is technically and commercially feasible and the Group has sufficient resources to complete the development. The expenditure capitalised includes the cost of materials, direct labour and attributable overheads and third party costs. Subsequent expenditure on capitalised intangible assets is capitalised only when it increases the future economic benefits embodied in the specific asset to which it relates. The technical feasibility of a new product is determined by a specific feasibility study undertaken at the first stage of any development project. The majority of our new product developments involve the transfer of existing product know-how to a new application. Since the technology is already proven in an existing product which is being used by customers, this facilitates the proving of the technical feasibility of that same technology in a new product. The results of the feasibility study are reviewed by a design review committee comprising senior managers. The feasibility study occurs in the initial research phase of a project and costs in this phase are not capitalised. The commercial feasibility of a new product is determined by preparing a discounted cash flow projection. This projection compares the discounted sales revenues for future periods with the relevant costs. As part of preparing the cash flow projection, the size of the relevant market is determined, feedback is sought from customers and the strength of the proposed new product is assessed against competitors’ offerings. Once the technical and commercial feasibility has been established and the project has been approved for commencement, the project moves into the development phase. All other development expenditure is expensed as incurred. Subsequent to initial recognition, the capitalised development expenditure is carried at cost less any accumulated amortisation and any accumulated impairment losses (Note 1(viii)). Expenditure on research activities, undertaken with the prospect of gaining new scientific or technical knowledge and understanding, is recognised in the statement of operations as an expense as incurred. Expenditure on internally generated goodwill and brands is recognised in the statement of operations as an expense as incurred. Amortisation Amortisation is charged to the statement of operations on a straight-line basis over the estimated useful lives of intangible assets, unless such lives are indefinite. Intangible assets are amortised from the date they are available for use in its intended market. The estimated useful lives are as follows: • Capitalised development costs 15 years • Patents and licences 6-15 years • Other (including acquired customer and supplier lists) 6-15 years The Group uses a useful economic life of 15 years for capitalised development costs. This is a conservative estimate of the likely life of the products. The Group is confident that products have a minimum of 15 years life given the inertia that characterizes the medical diagnostics industry and the barriers to enter into the industry. The following factors have been considered in estimating the useful life of developed products: (a) once a diagnostic test becomes established, customers are reluctant to change to new technology until it is fully proven, thus resulting in relatively long product life cycles. There is also reluctance in customers to change to a new product as it can be costly both in terms of the initial changeover cost and as new technology is typically more expensive. (b) demand for the diagnostic tests is enduring and robust within a wide geographic base. The diseases that the products diagnose are widely prevalent (HIV, Diabetes and Chlamydia being just three examples) in many countries. There is a general consensus that these diseases will continue to be widely prevalent in the future. (c) there are significant barriers to new entrants in this industry. Patents and/or licences are in place for several of our products, though this is not the only barrier to entry. There is a significant cost and time to develop new products, it is necessary to obtain regulatory approval and tests are protected by proprietary know-how, manufacturing techniques and trade secrets. Certain trade names acquired are deemed to have an indefinite useful life as there is no foreseeable limit to the period over which these assets are expected to generate cash inflows for the Group. Where amortisation is charged on assets with finite lives, this expense is taken to the statement of operations through the ‘selling, general and administrative expenses’ line. Useful lives are examined on an annual basis and adjustments, where applicable, are made on a prospective basis. viii) Impairment The carrying amount of the Group’s assets, other than inventories, accounts receivable, cash and cash equivalents, short-term investments and deferred tax assets, are reviewed at each balance sheet date to determine whether there is any indication of impairment. If any such indication exists, the asset’s recoverable amount (being the greater of fair value less costs to sell and value in use) is assessed at each balance sheet date. Fair value less costs to sell is defined as the amount obtainable from the sale of an asset or cash-generating unit in an arm’s length transaction between knowledgeable and willing parties, less the costs that would be incurred on disposal. Value in use is defined as the present value of the future cash flows expected to be derived through the continued use of an asset or cash-generating unit. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset for which the future cash flow estimates have not yet been adjusted. The estimates of future cash flows exclude cash inflows or outflows attributable to financing activities. For an asset that does not generate largely independent cash flows, the recoverable amount is determined by reference to the cash-generating unit to which the asset belongs. For goodwill, assets that have an indefinite useful life and intangible assets that are not yet available for use, the recoverable amount is estimated at each balance sheet date at the cash-generating unit level. The goodwill and indefinite-lived assets were reviewed for impairment at December 31, 2021 and December 31, 2022. See Note 12. In-process research and development (IPR&D) is tested for impairment on an annual basis, in the periodically and always at year end, or more frequently if impairment indicators are present, using projected discounted cash flow models. If IPR&D becomes impaired or is abandoned, the carrying value of the IPR&D is written down to its revised fair value with the related impairment charge recognised in the period in which the impairment occurs. If the fair value of the asset becomes impaired as the result of unfavorable data from any ongoing or future clinical trial, changes in assumptions that negatively impact projected cash flows, or because of any other information regarding the prospects of successfully developing or commercializing our programs, we could incur significant charges in the period in which the impairment occurs. The valuation techniques utilized in performing impairment tests incorporate significant assumptions and judgments to estimate the fair value, as described above. The use of different valuation techniques or different assumptions could result in materially different fair value estimates. An impairment loss is recognised whenever the carrying amount of an asset or its cash-generating unit exceeds its recoverable amount. Impairment losses are recognised in the statement of operations. Impairment losses recognised in respect of cash-generating units are allocated first to reduce the carrying amount of any goodwill allocated to cash-generating units and then to reduce the carrying amount of other assets in the cash-generating units on a pro-rata basis. An impairment loss is reversed only to the extent that the asset’s carrying amount does not exceed the carrying amount that would have been determined, net of depreciation or amortisation, if no impairment loss had been recognised. An impairment loss in respect of goodwill is not reversed. Following recognition of any impairment loss (and on recognition of an impairment loss reversal), the depreciation or amortisation charge applicable to the asset or cash-generating unit is adjusted prospectively with the objective of systematically allocating the revised carrying amount, net of any residual value, over the remaining useful life. ix) Inventories Inventories are stated at the lower of cost and net realisable value. Cost is based on the first-in, first-out principle and includes all expenditure which has been incurred in bringing the products to their present location and condition and includes an appropriate allocation of manufacturing overhead based on the normal level of operating capacity. Net realisable value is the estimated selling price of inventory on hand in the ordinary course of business less all further costs to completion and costs expected to be incurred in selling these products. The Group provides for inventory, based on estimates of the expected realisability. The estimated realisability is evaluated on a case-by-case basis and any inventory that is approaching its “use-by” date and for which no further re-processing can be performed is written off. Any reversal of an inventory provision is recognised in the statement of operations in the year in which the reversal occurs. x) Trade and other receivables Trade receivables are amounts due from customers for products sold or services provided in the ordinary course of business. Trade and other receivables are stated at their amortised cost less impairment losses incurred. Cost approximates fair value given the short-term nature of these assets. The Group records the loss allowance as lifetime expected credit losses. These are the expected shortfalls in contractual cash flows, considering the potential for default at any point during the life of the financial instrument. Expected credit losses are recorded on all of trade receivables based on an assessment of the probability of default or delinquency in payments and the probability that debtor will enter into financial difficulties or bankruptcy. xi) Trade and other payables Trade payables are obligations to pay for goods or services that have been acquired in the ordinary course of business. Trade and other payables are stated at cost. Cost approximates fair value given the short term nature of these liabilities. xii) Cash and cash equivalents Cash and cash equivalents comprise cash balances and short-term deposits which are readily available at year-end. Deposits with maturities less than six months as at the year-end date are recognised as cash and cash equivalents and are carried at fair value when there is no expected loss in value on early termination. The Group has no short-term bank overdraft facilities. Where restrictions are imposed by third parties, such as lending institutions, on cash balances held by the Group these are treated as financial assets in the financial statements. xiii) Short-term investments Short-term investments comprise short-term bank deposits which have maturities greater than six months as at the year-end date. Short-term deposits made for varying periods depending on the immediate cash requirements of the Group and earn interest at the respective deposit rates in place. Where restrictions are imposed by third parties, such as lending institutions, on short-term deposits held by the Group these are treated as financial assets in the financial statements. xiv) Share-based payments For equity-settled share-based payments (share options), the Group measures the services received and the corresponding increase in equity at fair value at the measurement date (which is the grant date) using a trinomial model. Given that the share options granted do not vest until the completion of a specified period of service, the fair value, which is assessed at the grant date, is recognised on the basis that the services to be rendered by employees as consideration for the granting of share options will be received over the vesting period. Certain share options have been granted for which there is a condition that the options only become exercisable into ADSs when the market price of an ADS reaches a certain level. This is deemed to be a non-vesting condition. The term ‘non-vesting condition’ is not explicitly defined in IFRS 2, Share based Payment, but is inferred to be any condition that does not meet the definition of a vesting condition. The only condition for these options to vest is that the option holder continues service and there were no other conditions which would be considered non-vesting conditions. Non-vesting conditions are reflected in measuring the grant-date fair value of the share-based payment and there is no true-up in the measurement of the share-based payment for differences between the expected and the actual outcome of non-vesting conditions. If all service conditions are met, then the share-based payment cost will be recognized even if the option holder does not receive the share-based payment due to a failure to meet the non-vesting condition. The expense in the consolidated statement of operations in relation to share options represents the product of the total number of options anticipated to vest and the fair value of those options; this amount is allocated to accounting periods on a straight-line basis over the vesting period. Share based payments, to the extent they relate to direct labour involved in development activities, are capitalised. The proceeds received net of any directly attributable transaction costs are credited to share capital (nominal value) and share premium when the options are exercised. The Group does not operate any cash-settled share-based payment schemes or share-based payment transactions with cash alternatives as defined in IFRS 2. xv) Government grants and financial support The Group received government-backed Covid-19 financial supports in the form of forgivable loans. Under IAS 20, Accounting for Government Grants, a forgivable loan from government is treated as a government grant when there is reasonable assurance that the terms for forgiveness of the loan will be met. Where a loan was received in the financial year but not yet forgiven within the financial year, the loan is treated as a current liability. The Group has opted to present government grant income for loans that have been forgiven as Other operating income in the consolidated statement of operations. Grants that compensate the Group for expenses incurred such as research and development, employment and training are recognised as income in the statement of operations on a systematic basis in the same periods in which the expenses are incurred. Grants that compensate the Group for the cost of an asset are recognised in the statement of operations as other operating income on a systematic basis over the useful life of the asset. xvi) Revenue recognition Goods sold and services rendered The Group recognises revenue when it transfers control over a good or service to a customer. Revenue is recognised to the extent that it is probable that economic benefit will flow to the Group and the revenue can be measured. No revenue is recognised if there is uncertainty regarding recovery of the consideration due at the outset of the transaction. Revenue, including any amounts invoiced for shipping and handling costs, represents the value of goods and services supplied to external customers, net of discounts and rebates and excluding sales taxes. Revenue from products is generally recorded as of the date of shipment, consistent with typical ex-works shipment terms. Where the shipment terms do not permit revenue to be recognised as of the date of shipment, revenue is recognised when the Group has satisfied all of its performance obligations to the customer in accordance with the shipping terms. Some contracts oblige the Group to ship product to the customer ahead of the agreed payment schedule. For these shipments, a contract asset is recognised when control over the goods has transferred to the customer. The financing component is insignificant as invoicing for these shipments occurs within a short period of time after shipment has occurred and standard 30 day credit terms typically apply. The Group operates a licenced referenced laboratory in the US, which provides testing services to institutional customers and insurance companies. In the US, there are rules requiring all insurance companies to be billed the same amount per test. However, the amount that each insurance company pays for a particular test varies according to their own internal policies and this can typically be considerably less than the amount invoiced. We recognise lab services revenue for insurance companies by taking the invoiced amount and reducing it by an estimated percentage based on historical payment data. We review the percentage reduction annually based on the latest data. As a practical expedient, and in accordance with IFRS, we apply a portfolio approach to the insurance companies as they have similar characteristics. We judge that the effect on the financial statements of using a portfolio approach for the insurance companies will not differ materially from applying IFRS 15 to the individual contracts within that portfolio. Revenue from services rendered is recognised in the statement of operations in proportion to the stage of completion of the transaction at the balance sheet date. The Group leases instruments to customers typically as part of a bundled package. Where a contract has multiple performance obligations and its duration is greater than one year, the transaction price is allocated to the performance obligations in the contract by reference to their relative standalone selling prices. For contracts where control of the instrument is transferred to the customer, the fair value of the instrument is recognised as revenue at the commencement of the lease and is matched by the related cost of sale. Fair value is determined on the basis of standalone selling price. In the case where control of the instrument does not transfer to the customer, revenue is recognised on the basis of customer usage of the instrument. See also Item 18, Note 1(v). In obtaining these contracts, the Group incurs a number of incremental costs, such as sales bonus paid to sales staff commissions paid to distributors and royalty payments. As the amortisation period of these costs, if capitalised, would be less than one year, the Group makes use of the practical expedient in IFRS 15.94 and expenses them as they incur. A receivable is recognised when the goods are delivered as this is the point in time that the consideration is unconditional because only the passage of time is required before the payment is due. The Group’s obligation to provide a refund for faulty products under the standard warranty terms is recognised as a provision, see Item 18, Note 21 for details. Other operating income Other operating income includes income for the provision of canteen services. This income has not been treated as revenue since the canteen activities are incidental to the main revenue-generating activities of the Group. Other operating income also includes government-backed Covid-19 financial supports and government

SEGMENT INFORMATION

SEGMENT INFORMATION	12 Months Ended
	Dec. 31, 2022
Disclosure of operating segments [abstract]
SEGMENT INFORMATION	2. SEGMENT INFORMATION Operating segments are reported in a manner consistent with the internal reporting provided to the chief operating decision-maker. The chief operating decision-maker, who is responsible for allocating resources and assessing the performance of the operating segments, has been identified as the Board of Directors. Management has determined the operating segments based on the reports reviewed by the Board of Directors, which are used to make strategic decisions. The Board considers the business from a geographic perspective based on the Group’s management and internal reporting structure. Sales of product between companies in the Group are made on commercial terms which reflect the nature of the relationship between the relevant companies. Segment results, assets and liabilities include items directly attributable to a segment as well as those that can be allocated on a reasonable basis. Unallocated items comprise interest-bearing loans, borrowings and expenses and corporate expenses. Segment capital expenditure is the total cost during the year to acquire segment plant, property and equipment and intangible assets that are expected to be used for more than one period, whether acquired on acquisition of a business combination or through acquisitions as part of the current operations. The Group comprises two main geographical segments (i) the Americas and (ii) Rest of World - Ireland. The Group’s geographical segments are determined by the location of the Group’s assets and operations. The Group has also presented a geographical analysis of the segmental data for Ireland as is consistent with the information used by the Board of Directors. The reportable operating segments derive their revenue primarily from one source (i.e., the market for diagnostic tests for a range of diseases and other medical conditions). In determining the nature of its segmentation, the Group has considered the nature of the products, their risks and rewards, the nature of the production base, the customer base and the nature of the regulatory environment. The Group acquires, manufactures and markets a range of diagnostic products. The Group’s products are sold to a similar customer base and the main body whose regulation the Group’s products must comply with is the Food and Drug Administration (“FDA”) in the US. The following presents revenue and profit information and certain asset and liability information regarding the Group’s geographical segments. i) The distribution of revenue by geographical area based on location of assets was as follows: Revenue Americas Rest of World Ireland Eliminations Total Year ended December 31, 2022 US$‘000 US$‘000 US$’000 US$‘000 Revenue from external customers 50,508 24,271 - 74,779 Inter-segment revenue 26,110 828 (26,938 ) - Total revenue 76,618 25,099 (26,938 ) 74,779 Revenue Americas Rest of World Ireland Eliminations Total Year ended December 31, 2021 US$‘000 US$‘000 US$’000 US$‘000 Revenue from external customers 67,249 25,716 - 92,965 Inter-segment revenue 49,059 2,517 (51,576 ) - Total revenue 116,308 28,233 (51,576 ) 92,965 Revenue Americas Rest of World Ireland Eliminations Total Year ended December 31, 2020 US$‘000 US$‘000 US$’000 US$‘000 Revenue from external customers 77,688 24,292 - 101,980 Inter-segment revenue 59,304 1,095 (60,399 ) - Total revenue 136,992 25,387 (60,399 ) 101,980 ii) The distribution of revenue by customers’ geographical area was as follows: Revenue December 31, 2022 US$‘000 December 31, 2021 US$‘000 December 31, 2020 US$‘000 Americas 40,176 57,799 70,408 Asia / Africa 25,022 25,504 22,567 Europe (including Ireland) * 9,581 9,662 9,005 74,779 92,965 101,980 * Revenue from customers in Ireland is not disclosed separately due to the immateriality of these revenues. iii) The distribution of revenue by major product group was as follows: Revenue December 31, 2022 US$‘000 December 31, 2021 US$‘000 December 31, 2020 US$‘000 Clinical laboratory goods 58,294 74,700 84,280 Clinical laboratory services 7,272 7,928 8,485 Point-of-Care 9,213 10,337 9,215 74,779 92,965 101,980 iv) The group has recognised the following amounts relating to revenue in the consolidated statement of operations: Revenue December 31, 2022 US$‘000 December 31, US$‘000 December 31, US$‘000 Revenue from contracts with customers (a) 74,779 92,965 101,980 74,779 92,965 101,980 (v) Disaggregation of revenue from contracts with customers: The Group derives revenue from the transfer of goods and services over time and at a point in time in the following geographical areas: Timing of revenue recognition Americas Rest of World Ireland Rest of World Other Total Year ended December 31, 2022 US$‘000 US$‘000 US$‘000 US$‘000 At a point in time 50,174 24,271 - 74,445 Over time 334 - - 334 Total 50,508 24,271 - 74,779 Timing of revenue recognition Americas Rest of World Ireland Rest of World Other Total Year ended December 31, 2021 US$‘000 US$‘000 US$‘000 US$‘000 At a point in time 66,806 25,716 - 92,522 Over time 443 - - 443 Total 67,249 25,716 - 92,965 Timing of revenue recognition Americas Rest of World Ireland Rest of World Other Total Year ended December 31, 2020 US$‘000 US$‘000 US$‘000 US$‘000 At a point in time 77,060 24,292 - 101,352 Over time 628 - - 628 Total 77,688 24,292 - 101,980 (vi) The Group derives revenue from the transfer of goods and services over time and at a point in time based on customers’ geographical area as follows: Timing of revenue recognition Americas Asia / Africa Europe Total Year ended December 31, 2022 US$‘000 US$‘000 US$‘000 US$‘000 At a point in time 39,842 25,022 9,581 74,445 Over time 334 - - 334 Total 40,176 25,022 9,581 74,779 Timing of revenue recognition Americas Asia / Africa Europe Total Year ended December 31, 2021 US$‘000 US$‘000 US$‘000 US$‘000 At a point in time 57,356 25,504 9,662 92,522 Over time 443 - - 443 Total 57,799 25,504 9,662 92,965 Timing of revenue recognition Americas Asia / Africa Europe Total Year ended December 31, 2020 US$‘000 US$‘000 US$‘000 US$‘000 At a point in time 69,780 22,567 9,005 101,352 Over time 628 - - 628 Total 70,408 22,567 9,005 101,980 vii) The distribution of segment results by geographical area was as follows: Rest of World Americas Ireland Other Total Year ended December 31, 2022 US$‘000 US$‘000 US$‘000 US$‘000 Result before impairment and unallocated expenses (5,891 ) (2,516 ) (33 ) (8,440 ) Impairment charges (2,331 ) (3,508 ) - (5,839 ) Result after impairment (8,222 ) (6,024 ) (33 ) (14,279 ) Unallocated expenses * (2,473 ) Operating loss (16,752 ) Net financing expense (Note 6) (24,442 ) Loss before tax (41,194 ) Income tax credit (Note 7) 192 Loss for the year on continuing operations (41,002 ) Loss for the year on discontinued operations (Note 8) (7 ) Loss for the year (41,009 ) Rest of World Americas Ireland Other Total Year ended December 31, 2021 US$‘000 US$‘000 US$‘000 US$‘000 Result before impairment and unallocated expenses 9,276 5,084 (12 ) 14,348 Impairment charges (6,088 ) (856 ) - (6,944 ) Result after impairment 3,188 4,228 (12 ) 7,404 Unallocated expenses * (779 ) Operating profit 6,625 Net financing expense (Note 6) (5,874 ) Profit before tax 751 Income tax credit (Note 7) 178 Profit for the year on continuing operations 929 Loss for the year on discontinued operations (Note 8) (54 ) Profit for the year 875 Rest of World Americas Ireland Other Total Year ended December 31, 2020 US$‘000 US$‘000 US$‘000 US$‘000 Result before impairment and unallocated expenses 14,495 4,264 (71 ) 18,688 Impairment (17,779 ) - - (17,779 ) Result after impairment (3,284 ) 4,264 (71 ) 909 Unallocated expenses * (827 ) Operating profit 82 Net financing expense (Note 6) (6,715 ) Loss before tax (6,633 ) Income tax credit (Note 7) 620 Loss for the year on continuing operations (6,013 ) Loss for the year on discontinued operations (Note 8) (375 ) Loss for the year (6,388 ) * Unallocated expenses represent head office general and administration costs of the Group, which cannot be allocated to the results of any specific geographical area. viii) The distribution of segment assets and segment liabilities by geographical area was as follows: Rest of World Americas Ireland Other Total As at December 31, 2022 US$‘000 US$‘000 US$‘000 US$‘000 Assets and liabilities Segment assets 41,779 37,695 - 79,474 Unallocated assets: Income tax assets (current and deferred) 6,052 Cash and cash equivalents and short-term investments 6,578 Total assets as reported in the Group balance sheet 92,104 Segment liabilities 58,307 30,845 42 89,194 Unallocated liabilities: Income tax liabilities (current and deferred) 5,086 Total liabilities as reported in the Group balance sheet 94,280 Rest of World Americas Ireland Other Total As at December 31, 2021 US$‘000 US$‘000 US$‘000 US$‘000 Assets and liabilities Segment assets 45,891 41,453 1 87,345 Unallocated assets: Income tax assets (current and deferred) 5,640 Cash and cash equivalents and short-term investments 25,910 Total assets as reported in the Group balance sheet 118,895 Segment liabilities 12,382 101,927 25 114,334 Unallocated liabilities: Income tax liabilities (current and deferred) 4,880 Total liabilities as reported in the Group balance sheet 119,214 ix) The distribution of long-lived assets, which are property, plant and equipment, goodwill and intangible assets and other non-current assets (excluding deferred tax assets and derivative financial instruments), by geographical area was as follows: December 31, 2022 US$‘000 December 31, 2021 US$‘000 Rest of World – Ireland 21,180 22,617 Americas 19,910 19,489 41,090 42,106 x) The distribution of depreciation and amortisation by geographical area was as follows: December 31, 2022 US$‘000 December 31, 2021 US$‘000 December 31, 2020 US$‘000 Depreciation: Rest of World – Ireland 128 204 127 Americas 1,282 1,662 1,587 1,410 1,866 1,714 Amortisation: Rest of World – Ireland 123 69 32 Americas 800 848 1,371 923 917 1,403 xi) The distribution of share-based payment expense by geographical area was as follows: December 31, 2022 US$‘000 December 31, 2021 December 31, 2020 Rest of World – Ireland 632 1,072 722 Americas 1,123 28 70 1,755 1,100 792 See Note 19 for further information on share-based payments. xii) The distribution of taxation (expense)/credit by geographical area was as follows: December 31, 2022 US$‘000 December 31, 2021 US$‘000 December 31, 2020 US$‘000 Rest of World – Ireland 284 540 293 Rest of World – Other (4 ) (2 ) (8 ) Americas (88 ) (360 ) 335 192 178 620 xiii) During 2022 and 2020 there were no customers generating 10% or more of total revenues. In 2021, one customer accounted for more than 10% of total revenues. xiv) The distribution of capital expenditure by geographical area was as follows: December 31 2022 US$‘000 December 31, 2021 US$‘000 Rest of World – Ireland 2,443 3,826 Rest of World – Other - - Americas 4,370 4,776 6,813 8,602

EMPLOYMENT

EMPLOYMENT	12 Months Ended
	Dec. 31, 2022
Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [abstract]
EMPLOYMENT	3. EMPLOYMENT The average number of persons employed by the Group is as follows: December 31, 2022 December 31, 2021 December 31, 2020 Research and development 30 41 52 Administration and sales 119 134 148 Manufacturing and quality 249 302 343 398 477 543 Employment costs charged in the consolidated statement of operations for continuing operations are analysed as follows: December 31, 2022 US$‘000 December 31, 2021 US$‘000 December 31, 2020 US$‘000 Wages and salaries 23,608 26,561 26,187 Social welfare costs 2,036 2,403 2,195 Pension costs 352 352 447 Share-based payments 1,755 1,100 792 Restructuring Cost 274 270 388 Recognition of contingent asset (Note 24) - - (1,316 ) 28,025 30,686 28,693 Employment costs are shown net of capitalisations and Irish government wage subsidies. Total employment costs, inclusive of amounts capitalised for wages and salaries, social welfare costs and pension costs, for the year ended December 31, 2022 amounted to US$28,848,000 (2021: US$33,366,000) (2020: US$33,347,000). Total share-based payments, inclusive of amounts capitalised in the balance sheet, amounted to US$1,755,000 for the year ended December 31, 2022 (2021: US$1,111,000) (2020: US$816,000). See Note 19 for further details. The Group operates defined contribution pension schemes for certain of its full-time employees. The benefits under these schemes are financed by both Group and employee contributions. Total contributions made by the Group in the financial year and charged against income amounted to US$352,000 (2021: US$352,000) (2020: US$447,000). The pension accrual for the Group at December 31, 2022 was US$44,000 (2021: US$47,000), (2020: US$47,000).

OTHER OPERATING INCOME

OTHER OPERATING INCOME	12 Months Ended
	Dec. 31, 2022
Disclosure of other operating income [Abstract]
OTHER OPERATING INCOME	4. OTHER OPERATING INCOME December 31, 2022 US$‘000 December 31, 2021 US$‘000 December 31, 2020 US$‘000 Government supports - COVID-19 7 4,668 1,840 Government grants 333 - - Other income - - 17 Rental income from premises 3 4 3 343 4,672 1,860 In 2020, the Company received an interest-free loan received under the Canada Emergency Business Account (“CEBA”). The CEBA loans were provided by the Canadian Government to mitigate the financial impact of the Covid-19 outbreak. This interest-free loan was repaid in the year ended December 31, 2022 and an amount of CAD$10,000 (US$7,000) was forgiven, which has been recognised as income. In 2021 and 2020, government supports - COVID-19 comprised funding received under the U.S. government’s Cares Act, specifically its Paycheck Protection Program and its Provider Relief Fund. Six Paycheck Protection Program (“PPP”) loans received by the Company, amounting to US$4,668,000 were forgiven during 2021 and recognised as Other Operating Income in that year. Two PPP loans received by the Company in 2020, amounting to US$1,615,000 were forgiven during 2020 and recognised as Other Operating Income. In addition, in 2020 the Company received US$225,000 under the U.S. government’s Provider Relief Fund and recognised as Other Operating Income. No funding was received under the Provider Relief Fund in either 2021 or 2022.

IMPAIRMENT CHARGES

IMPAIRMENT CHARGES	12 Months Ended
	Dec. 31, 2022
Disclosure of impairment charges and inventory provisioning [Abstract]
IMPAIRMENT CHARGES	5. IMPAIRMENT CHARGES In accordance with IAS 36, Impairment of Assets The impact of the above items on the consolidated statement of operations for the year ended December 31, 2022, December 31, 2021, December 31, 2020 was as follows: December 31, December 31, December 31, 2022 2021 2020 US$’000 US$’000 US$’000 Selling, general & administration expenses Impairment of PP&E (Note 11) 733 2,508 1,795 Impairment of goodwill and other intangible assets (Note 12) 4,624 3,853 15,422 Impairment of prepayments (Note 16) 482 583 562 Total impairment loss 5,839 6,944 17,779

FINANCIAL INCOME AND EXPENSES

FINANCIAL INCOME AND EXPENSES	12 Months Ended
	Dec. 31, 2022
Disclosure Of Financing Income Expenses Net Abstract
FINANCIAL INCOME AND EXPENSES	6. FINANCIAL INCOME AND EXPENSES December 31, 2022 US$‘000 December 31, 2021 US$‘000 December 31, 2020 US$‘000 Financial income: Non-cash financial income 303 1,220 - Interest income - 3 36 303 1,223 36 Financial expense: Interest on leases (Note 27) (657 ) (815 ) (896 ) Loss on disposal of exchangeable notes (Note 22, 27) (9,678 ) - - Penalty for early partial settlement of senior secured term loan (Note 22) (3,450 ) - - Cash interest payable on senior secure term loan (7,039 ) - - Cash interest payable on convertible note (199 ) - - Cash interest on exchangeable notes (296 ) (3,996 ) (3,996 ) Loan origination costs - (1,638 ) - Non-cash interest on exchangeable notes (84 ) (648 ) (643 ) Non-cash interest on senior secured term loan (2,772 ) - - Non-cash interest on convertible note (495 ) - - Non-cash financial expense (74 ) - (1,216 ) Other (1 ) - - (24,745 ) (7,097 ) (6,751 ) Net Financing Expense (24,442 ) (5,874 ) (6,715 ) For more information on the senior secured term loan, convertible note and exchangeable notes, refer to Note 22, Interest-Bearing Loans and Borrowings.

INCOME TAX CREDIT

INCOME TAX CREDIT	12 Months Ended
	Dec. 31, 2022
Disclosure of income tax credit [Abstract]
INCOME TAX CREDIT	7. INCOME TAX CREDIT December 31, US$‘000 December 31, US$‘000 December 31, US$‘000 Current tax (credit)/expense Irish Corporation tax (331 ) (511 ) (480 ) Foreign taxes (a) (5 ) 296 179 Adjustment in respect of prior years 61 - (152 ) Total current tax credit (275 ) (215 ) (453 ) Deferred tax credit Origination and reversal of temporary differences (see Note 13) 321 620 48 Origination and reversal of net operating losses (see Note 13) (238 ) (583 ) (215 ) Total deferred tax charge/(credit) 83 37 (167 ) Total income tax credit on continuing operations in statement of operations (192 ) (178 ) (620 ) Tax charge on discontinued operations (see Note 8) - 12 438 Total tax credit (192 ) (166 ) (182 ) (a) In 2022, the foreign taxes relate primarily to USA and Canada. (b) In 2022, there was a deferred tax charge of US$109,000 (2021: charge of US$118,000) (2020: credit of US$444,000) recognised in respect of Ireland and a deferred tax credit of US$26,000 (2021: credit of US$81,000) (2020: credit of US$397,000) recognised in respect of overseas tax jurisdictions. Effective tax rate December 31, December 31, December 31, (Loss)/profit before taxation – continuing operations (US$‘000) (41,194 ) 751 (6,633 ) As a percentage of (loss)/profit before tax: Current tax % (0.67 )% (28.63 ) % (6.83 )% Total (current and deferred) % (0.47 )% (23.70 ) % (9.35 )% The following table reconciles the applicable Republic of Ireland statutory tax rate to the effective total tax rate for the Group: December 31, 2022 December 31, 2021 December 31, 2020 Irish corporation tax (12.5 )% 12.5 % (12.5 )% Effect of current year net operating losses and temporary differences for which no deferred tax asset was recognised (a) 11.66 % 49.63 % 24.13 % Effect of tax rates on overseas earnings (7.76 )% (0.22 )% (9.92 )% Effect of Irish income taxable at higher tax rate 4.17 % 98.68 % 5.92 % Adjustments in respect of prior years 0.15 % (0.01 )% (10.66 )% R&D tax credits (0.81 )% (79.22 )% (11.00 )% Other items (b) 4.62 % (105.06 )% 4.68 % Effective tax rate (0.47 )% (23.70 )% (9.35 )% (a) No deferred tax asset was recognised because there was no reversing deferred tax liability in the same jurisdiction reversing in the same period and insufficient future projected taxable income in the same jurisdiction. (b) Other items comprise items not chargeable to tax and expenses not deductible for tax purposes. This was a significant number in 2021 because the US$4.7 million income from the Paycheck Protection Program loans was not chargeable for tax purposes. There is no Paycheck Protection Program income in 2022. In 2022, other items mainly relate to the loss on disposal of the exchangeable notes. The distribution of (loss)/profit before taxes by geographical area was as follows: December 31, 2022 US$‘000 December 31, 2021 US$‘000 December 31, 2020 US$‘000 Rest of World – Ireland (19,768 ) 1,862 296 Rest of World – Other (33 ) 3,939 3,304 Americas (21,393 ) (5,050 ) (10,233 ) (41,194 ) 751 (6,633 ) At December 31, 2022, the Group had unutilised net operating losses for continuing operations as follows: December 31, 2022 US$‘000 December 31, 2021 US$‘000 December 31, 2020 US$‘000 Rest of World – Ireland 62,731 68,132 78,700 Rest of World – Other 448 1,000 2,185 Americas 12,778 4,761 4,313 75,957 73,893 85,198 At December 31, 2022, the Group had unrecognised deferred tax assets in respect of unused tax losses and unused tax credits as follows: December 31, 2022 US$‘000 December 31, 2021 US$‘000 December 31, 2020 US$‘000 Rest of World – Ireland – unused tax losses 7,489 9,272 12,514 Rest of World – Other – unused tax losses 124 279 546 Americas – unused tax losses 3,163 5,891 1,466 Americas – unused tax credits 4,658 3,368 2,862 Unrecognised deferred tax asset 15,434 18,810 17,388 The accounting policy for deferred tax is to calculate the deferred tax asset that is deemed recoverable, considering all sources for future taxable profits. The deferred tax assets in the above table have not been recognised due to uncertainty regarding the full utilization of these losses in the related tax jurisdiction in future periods. Only when it is probable that future profits will be available to utilize the forward losses or temporary differences is a deferred tax asset recognised. When there is a reversing deferred tax liability in that jurisdiction that reverses in the same period, the deferred tax asset is restricted so that it equals the reversing deferred tax liability.

LOSS FOR THE YEAR ON DISCONTINU

LOSS FOR THE YEAR ON DISCONTINUED OPERATION	12 Months Ended
	Dec. 31, 2022
Disclosure of loss on discontinued operations [Abstract]
LOSS FOR THE YEAR ON DISCONTINUED OPERATION	8 . LOSS FOR THE YEAR ON DISCONTINUED OPERATION In 2016, management decided to cease the development of Cardiac point-of-care tests on the Meritas platform. These products were being developed by the Group’s subsidiary Fiomi Diagnostics (“Fiomi”) located in Sweden. Expenses, gains and losses relating to the discontinuation of the Cardiac point-of-care tests operation have been eliminated from profit or loss from the Group’s continuing operations and are shown as a single line item (net of related taxes) on the face of the consolidated statement of operations. The discontinued operation had no revenues since commencement as the products were still in their development phase. In 2022, administrative expenses of US$7,000 were incurred. The operating loss for the Cardiac point-of-care tests operation in Sweden and the loss on re-measurement of its assets and liabilities are summarised as follows: December 31, 2022 US$‘000 December 31, 2021 US$‘000 December 31, 2020 US$‘000 Administrative expenses (7 ) - - Closure provision - (42 ) 127 Foreign currency translation reserve - - (64 ) Tax expense - (12 ) (438 ) Total loss (7 ) (54 ) (375 ) Loss for the year from discontinued operations (7 ) (54 ) (375 ) Basic loss per ordinary share – discontinued operations Basic loss per ordinary share for discontinued operations is computed by dividing the loss after taxation on discontinued operations of US$7,000 (2021: loss US$54,000) (2020: loss US$375,000) for the financial year by the weighted average number of ‘A’ ordinary shares in issue. As at December 31, 2022, this amounted to 134,939,327 shares (2021: 83,606,810 shares) (2020: 83,606,810 shares), see note 10 for further details. Diluted loss per ordinary share – discontinued operations Diluted loss per ordinary share for discontinued operations is computed by dividing the loss after taxation on discontinued operations of US$7,000 (2021: loss US$54,000) (2020: loss US$375,000) for the financial year by the diluted weighted average number of ordinary shares in issue of 134,939,327 (2021: 83,606,810 shares) (2020: 83,606,810 shares), see note 10 for further details. Under IAS 33 Earnings per Share, diluted earnings per share cannot be anti-dilutive. Therefore, diluted loss per ADS in accordance with IFRS is equal to basic earnings per ADS. Loss per ADS In June 2005, Trinity Biotech adjusted its ADS ratio from 1 ADS: 1 ordinary share to 1 ADS: 4 ordinary shares. Earnings per ADS for all periods presented have been restated to reflect this exchange ratio. Basic loss per ADS for discontinued operations is computed by dividing the loss after taxation on discontinued operations of US$7,000 (2021: loss US$54,000) (2020: loss US$375,000) for the financial year by the weighted average number of ADS in issue of 33,734,832 (2021: 20,901,703) (2020: 20,901,703), see note 10 for further details. Diluted loss per ADS for discontinued operations is computed by dividing the loss after taxation on discontinued operations of US$7,000 (2021: loss US$54,000) (2020: loss US$375,000) for the financial year, by the diluted weighted average number of ADS in issue of 33,734,832 (2021: 20,901,703) (2020: 20,901,703), see note 10 for further details. December 31, 2022 December 31, 2021 December 31, 2020 Basic loss per ADS (US Dollars) – discontinued operations 0.00 0.00 (0.02 ) Diluted loss per ADS (US Dollars) – discontinued operations 0.00 0.00 (0.02 ) Basic loss per ‘A’ share (US Dollars) – discontinued operations 0.00 0.00 0.00 Diluted loss per ‘A’ share (US Dollars) – discontinued operations 0.00 0.00 0.00 Cash flows The cash flows attributable to discontinued operations are as follows: December 31, 2022 December 31, 2021 December 31, US$000 US$000 US$000 Cash flows from operating activities (10 ) (40 ) (22 ) There were no cash flows from investing or financing activities attributable to discontinued operations for the years ended December 31, 2022, 2021 or 2020.

(LOSS)_PROFIT BEFORE TAX

(LOSS)/PROFIT BEFORE TAX	12 Months Ended
	Dec. 31, 2022
Disclosure of loss profit before tax [Abstract]
(LOSS)/PROFIT BEFORE TAX	9. (LOSS)/PROFIT BEFORE TAX The following amounts were charged / (credited) to the statement of operations: December 31, US$‘000 December 31, US$‘000 December 31, US$‘000 Directors’ emoluments (including non- executive directors): Remuneration 1,639 1,391 2,020 Pension 24 24 41 Share based payments 1,707 986 678 Auditor’s remuneration Audit fees 888 580 558 Tax fees 89 77 146 Depreciation (Note 11) 1 1,410 1,827 1,674 Amortisation (Note 12) 923 917 1,403 Loss/(profit) on the disposal of property, plant and equipment 2 (1 ) 30 Selling, General and Administrative Expenses – Closure Costs - - 2,425 Net foreign exchange differences (1,210 ) (789 ) 583 1 Selling, General and Administrative Expenses – Closure Costs - in early 2020, management decided to close a production facility in Carlsbad, California facility which specialized in Western Blot manufacturing. The preceding number of years had seen a steady migration of customers away from using the Western Blot testing format for diagnosing Lyme in favour of alternative testing platforms. Production volumes declined steadily at the plant to the extent that it no longer made economic sense to continue. The plant was closed on June 30, 2020. Production of remaining products was transferred to other locations in the Group. The charge for closing the facility was US$2,425,000 which comprised redundancy costs, the write-off of inventory, the cost of exiting lease obligations and other costs associated with the closure of the facility.

(LOSS)_EARNINGS PER SHARE

(LOSS)/EARNINGS PER SHARE	12 Months Ended
	Dec. 31, 2022
Earnings per share [abstract]
(LOSS)/EARNINGS PER SHARE	10. (LOSS)/EARNINGS PER SHARE Basic (loss)/earnings per ordinary share Basic (loss)/earnings per ordinary share is calculated by dividing the net (loss)/earnings attributable to owners of the parent of US$41,009,000 (2021: profit of US$875,000) (2020: loss of US$6,388,000) by the weighted average number of ‘A’ ordinary shares in issue, net of any Treasury Shares, during the year. Basic (loss)/earnings per ordinary share from continuing operations is calculated by dividing the loss from continuing operations attributable to owners of the parent of US$41,002,000 (2021: profit of US$929,000) (2020: loss of US$6,013,000) by the weighted average number of ‘A’ ordinary shares in issue, net of any Treasury Shares, during the year. As at December 31, 2022, the number of ‘A’ ordinary shares for the purposes of the calculation of basic (loss)/earnings per share are 134,939,327 shares (2021: 83,606,810 shares) (2020: 83,606,810 shares). December 31, 2022 December 31, 2021 December 31, 2020 ‘A’ ordinary shares 134,939,327 83,606,810 83,606,810 Basic (loss)/earnings per share denominator 134,939,327 83,606,810 83,606,810 Reconciliation to weighted average (loss)/earnings per share denominator: Number of ‘A’ ordinary shares at January 1 (Note 18) 96,162,410 96,162,410 96,162,410 Weighted average number of ‘A’ ordinary shares issued during the year 51,332,517 - - Weighted average number of treasury shares (12,555,600 ) (12,555,600 ) (12,555,600 ) Basic (loss)/earnings per share denominator 134,939,327 83,606,810 83,606,810 Diluted (loss)/earnings per ordinary share Diluted (loss)/earnings per ordinary share is calculated by dividing the net (loss)/earnings attributable to owners of the parent by the weighted average number of ‘A’ ordinary shares in issue, net of any Treasury Shares, during the year, plus the weighted average number of ‘A’ ordinary shares that would be issued on the conversion of all the dilutive potential ‘A’ ordinary shares into ‘A’ ordinary shares. As the potentially dilutive instruments were anti-dilutive in all periods presented, basic (loss)/earnings per ‘A’ ordinary share and diluted (loss)/earnings per ‘A’ ordinary share are equivalent. The following potential ‘A’ ordinary shares are anti-dilutive and are therefore excluded from the weighted average number of ‘A’ ordinary shares for the purposes of calculating diluted (loss)/earnings per ‘A’ ordinary share. December 31, 2022 December 31, 2021 December 31, 2020 Potentially Dilutive Instruments: Issuable on exercise of options (Note 19) 44,814,672 18,727,990 19,485,990 Issuable on exercise of warrants to Perceptive (Note 22) 10,000,000 - - Issuable on conversion of Exchangeable notes (Note 22) 38,391 18,263,254 18,263,254 Issuable on conversion of Convertible notes (Note 22) 24,691,358 - - Total number of potentially dilutive instruments excluded from the weighted average number of ‘A’ ordinary shares in calculating dilutive (loss)/earnings per ‘A’ ordinary share 79,544,421 36,991,244 37,749,244 Of the ‘A’ ordinary shares issuable on exercise of options, 16,800,000 are contingently issuable as their issue is contingent upon satisfaction of specified performance conditions in addition to the passage of time. The conditions governing their exercisability have not been satisfied as at the end of the reporting period. Subsequent to the end of the reporting period, the following ordinary share transactions or potential ordinary share transactions occurred: o Options over 3,000,000 ‘A’ ordinary shares were granted, of which 1,400,000 are contingently issuable as their issue is contingent upon satisfaction of specified performance conditions in addition to the passage of time. o Options over 280,000 ‘A’ ordinary shares lapsed unexercised. o 400,000 ‘A’ ordinary shares were issued on the exercise of options. o Warrants over 10,000,000 ‘A’ ordinary shares held by Perceptive were repriced from an exercise price of $0.325 per ‘A’ ordinary share to $0.268 per ‘A’ ordinary share. (Loss)/earnings per ADS Trinity Biotech’s ADS to ‘A’ ordinary share ratio is 1 ADS: 4 ‘A’ ordinary shares. Basic (loss)/earnings per ADS is calculated by dividing the (loss)/earnings attributable to owners of the parent of US$41,009,000 (2021: profit of US$875,000) (2020: loss of US$6,388,000) by the weighted average number of ADS in issue, net of any Treasury Shares, during the year. Basic (loss)/earnings per ADS from continuing operations is calculated by dividing the (loss)/earnings of US$41,002,000 (2021: profit of US$929,000) (2020: loss of US$6,013,000) by the weighted average number of ADS in issue, net of any Treasury Shares, during the year. As at December 31, 2022, the number of ADS for the purposes of the calculation of basic (loss)/earnings per ADS were 33,734,832 ADS (2021: 20,901,703 ADS) (2020: 20,901,703 ADS). December 31, 2022 December 31, 2021 December 31, 2020 ADS 33,734,832 20,901,703 20,901,703 Basic (loss)/earnings per ADS denominator 33,734,832 20,901,703 20,901,703 Reconciliation to weighted average (loss)/earnings per ADS denominator: Number of ADS at January 1 (Note 18) 24,040,602 24,040,602 24,040,602 Weighted average number of shares issued during the year* 12,833,129 - - Weighted average number of treasury shares (3,138,899 ) (3,138,899 ) (3,138,899 ) Basic (loss)/earnings per ADS denominator 33,734,832 20,901,703 20,901,703 Diluted (loss)/earnings per ADS Diluted (loss)/earnings per ADS is calculated by dividing the net (loss)/earnings attributable to owners of the parent by the weighted average number of ADS in issue, net of any Treasury Shares, during the year, plus the weighted average number of ADS that would be issued on the conversion of all the dilutive potential ADS into ADS. As the potentially dilutive instruments were anti-dilutive in all periods presented, basic (loss)/earnings per ADS and diluted earnings per ADS are equivalent. The following potential ADS are anti-dilutive and are therefore excluded from the weighted average number of ADS for the purposes of calculating dilutive (loss)/earnings per ADS. December 31, 2022 December 31, 2021 December 31, 2020 Potentially Dilutive Instruments: Issuable on exercise of options (Note 19) 11,203,668 4,681,998 4,871,498 Issuable on exercise of warrants to Perceptive (Note 22) 2,500,000 - - Issuable on conversion of Exchangeable notes (Note 22) 9,598 4,565,814 4,565,814 Issuable on conversion of Convertible notes (Note 22) 6,172,840 - - Total number of potentially dilutive instruments excluded from the weighted average number of ADS in calculating dilutive (loss)/earnings per ADS 19,886,106 9,247,812 9,437,312 Of the ADS issuable on exercise of options, 4,200,000 are contingently issuable as their issue is contingent upon satisfaction of specified performance conditions in addition to the passage of time. The conditions governing their exercisability have not been satisfied as at the end of the reporting period. Subsequent to the end of the reporting period, the following ordinary share transactions or potential ordinary share transactions occurred: o Options over 750,000 ADS were granted, of which 350,000 are contingently issuable as their issue is contingent upon satisfaction of specified performance conditions in addition to the passage of time. o Options over 70,000 ADS lapsed unexercised. o 100,000 ADS were issued on the exercise of options. o Warrants over 2,500,000 ADS held by Perceptive were repriced from an exercise price of $1.30 per ADS to $1.071 per ADS.

PROPERTY, PLANT AND EQUIPMENT

PROPERTY, PLANT AND EQUIPMENT	12 Months Ended
	Dec. 31, 2022
Disclosure of detailed information about property, plant and equipment [abstract]
PROPERTY, PLANT AND EQUIPMENT	11. PROPERTY, PLANT AND EQUIPMENT Land & Buildings US$‘000 Leasehold Improvements US$‘000 Computer & Office Equipment US$‘000 Plant & Equipment US$‘000 Total US$‘000 Cost At January 1, 2021 24,287 2,670 4,309 33,839 65,105 Additions 46 126 144 1,392 1,708 Disposals or retirements - (186 ) (255 ) (2,410 ) (2,851 ) Exchange adjustments 1 (18 ) 2 (484 ) (499 ) At December 31, 2021 24,334 2,592 4,200 32,337 63,463 At January 1, 2022 24,334 2,592 4,200 32,337 63,463 Additions 379 93 362 1,100 1,934 Disposals or retirements - - (25 ) (42 ) (67 ) Reallocations/ reclassifications - - (2 ) 2 - Exchange adjustments (31 ) 16 5 286 276 At December 31, 2022 24,682 2,701 4,540 33,683 65,606 Accumulated amortisation and Impairment losses At January 1, 2021 (19,629 ) (1,884 ) (3,946 ) (31,099 ) (56,558 ) Charge for the year (628 ) (149 ) (115 ) (974 ) (1,866 ) Disposals or retirements - 186 255 2,410 2,851 Impairment losses (1,196 ) (279 ) (98 ) (935 ) (2,508 ) Exchange adjustments 21 (5 ) (46 ) 566 536 At December 31, 2021 (21,432 ) (2,131 ) (3,950 ) (30,032 ) (57,545 ) At January 1, 2022 (21,432 ) (2,131 ) (3,950 ) (30,032 ) (57,545 ) Charge for the year (414 ) (133 ) (214 ) (649 ) (1,410 ) Disposals or retirements - - 22 43 65 Impairment losses (48 ) (4 ) (31 ) (650 ) (733 ) Exchange adjustments 9 (16 ) (5 ) (289 ) (301 ) At December 31, 2022 (21,885 ) (2,284 ) (4,178 ) (31,577 ) (59,924 ) Carrying amounts At December 31, 2022 2,797 417 362 2,106 5,682 At December 31, 2021 2,902 461 250 2,305 5,918 The assets of the Group are pledged as security for the senior secured term loan from Perceptive Advisors. Right-of-use assets Additional information on the right-of-use assets by class of assets is as follows: Carrying amount Depreciation Charge Impairment Charge At December 31, 2022 Year ended December 31, 2022 Year ended December 31, 2022 US$000 US$000 US$000 Buildings 2,482 (398 ) (48 ) Computer equipment 217 (40 ) - Plant and Equipment, vehicles - (17 ) (200 ) 2,699 (455 ) (248 ) Carrying amount Depreciation Charge Impairment Charge At December 31, 2021 Year ended December 31, 2021 Year ended December 31, 2021 US$000 US$000 US$000 Buildings 2,549 (609 ) (1,089 ) Computer equipment 23 (5 ) - Plant and Equipment, vehicles - - - 2,572 (614 ) (1,089 ) Income from sub-letting right-of-use buildings amounted to US$3,000 in the year ended December 31, 2022 (2021: US$3,000). Right-of-Use assets at 31 December 2022 No. of Right-of-Use leased assets Range of remaining term in years Average remaining lease term (years) No. of Leases with extension options No. of Leases with options to purchase No. of leases with variable payments linked to index No. of leases with termination options Building 9 1 to 11 5 2 - - - Vehicle 20 0.4 to 3 2 - 20 - 20 I.T. and office equipment 5 4 4 - - - - Right-of-Use assets at 31 December 2021 No. of Right-of-Use leased assets Range of remaining term in years Average remaining lease term (years) No. of Leases with extension options No. of Leases with options to purchase No. of leases with variable payments linked to index No. of leases with termination options Building 11 1 to 12 3 1 - 2 - Vehicle 16 1 to 3 2 - 16 - 16 I.T. and office equipment 2 1 to 5 4 - - - - The details of the impairment review are described in Note 12. When an impairment loss is identified in a cash-generating unit, it must be first allocated to reduce the carrying amount of any goodwill allocated to the cash-generating unit and then to the other assets of the unit pro rata on the basis of the carrying amount of each asset in the unit. In this manner, an impairment loss of US$733,000 was allocated to property, plant and equipment as at December 31, 2022 (2021: US$2,508,000). The recoverable amount of property, plant and equipment was determined to be the value in use of each cash-generating unit. Assets held under operating leases (where the Company is the lessor) The Company has a number of assets included in plant and equipment which generate operating lease revenue for the Group. The net book value of these assets as at December 31, 2022 and 2021 is US$ Nil Property, plant and equipment under construction There were no assets under construction included in property, plant and equipment at December 31, 2022 (2021: US$Nil).

GOODWILL AND INTANGIBLE ASSETS

GOODWILL AND INTANGIBLE ASSETS	12 Months Ended
	Dec. 31, 2022
Disclosure Of Goodwill And Intangible Assets [Abstract]
GOODWILL AND INTANGIBLE ASSETS	12. GOODWILL AND INTANGIBLE ASSETS Goodwill US$‘000 Development costs US$‘000 Patents and licenses US$‘000 Other US$‘000 Total US$‘000 Cost At January 1, 2021 79,182 128,977 8,947 33,311 250,417 Additions - 6,771 102 21 6,894 Disposals or retirements - (14,576 ) (342 ) (134 ) (15,052 ) Exchange adjustments - 1 - - 1 At December 31, 2021 79,182 121,173 8,707 33,198 242,260 At January 1, 2022 79,182 121,173 8,707 33,198 242,260 Additions - 4,475 22 382 4,879 Exchange adjustments - (64 ) - - (64 ) At December 31, 2022 79,182 125,584 8,729 33,580 247,075 Accumulated amortisation and Impairment losses At January 1, 2021 (66,591 ) (115,533 ) (8,790 ) (25,643 ) (216,557 ) Charge for the year - (482 ) (7 ) (428 ) (917 ) Disposals or retirements - 14,573 342 132 15,047 Impairment losses (54 ) (2,053 ) (106 ) (1,640 ) (3,853 ) Exchange adjustments - 1 - - 1 At December 31, 2021 (66,645 ) (103,494 ) (8,561 ) (27,579 ) (206,279 ) At January 1, 2022 (66,645 ) (103,494 ) (8,561 ) (27,579 ) (206,279 ) Charge for the year (479 ) (9 ) (435 ) (923 ) Impairment losses - (4,623 ) - (1 ) (4,624 ) Exchange adjustments - 20 - - 20 At December 31, 2022 (66,645 ) (108,576 ) (8,570 ) (28,015 ) (211,806 ) Carrying amounts At December 31, 2022 12,537 17,008 159 5,565 35,269 At December 31, 2021 12,537 17,679 146 5,619 35,981 Included within development costs are projects with a carrying value of US$6,982,000 which were not amortised in 2022 (2021: US$7,994,000) (2020: US$6,980,000). These development costs are not being amortised as the projects to which the costs relate were not fully complete at the end of the financial year. As at December 31, 2022 these projects are expected to be completed during the period from January 1, 2023 to December 31, 2025 at an expected further cost of approximately US$1,100,000. The following represents the costs incurred during each period presented for each of the principal development projects: Product Name 2022 US$’000 2021 US$’000 Premier Instruments for A1c and haemoglobinopathies testing 1,904 2,538 COVID-19 tests 1,378 1,320 Mid-tier haemoglobins instrument 484 303 HIV screening rapid test 379 1,488 Tri-stat point-of-care instrument 163 245 Uni-gold raw material stabilisation 42 144 Autoimmune Smart Reader 82 550 Other projects 43 183 Total capitalised development costs 4,475 6,771 Other intangible assets Other intangible assets consist primarily of acquired customer and supplier lists, trade names, website and software assets. Amortisation Amortisation is charged to the consolidated statement of operations through the selling, general and administrative expenses line. Impairment testing for intangibles including goodwill and indefinite lived assets Goodwill and other intangibles are subject to impairment testing on a periodic basis and whenever there are indicators of impairment. Specific assets are assessed for impairment when there are indicators of impairment. If any such indication exists, the Company estimates the recoverable amount of the asset. The recoverable amount of seven CGUs is determined based on a value-in-use computation at June 30 and December 31. Among other macroeconomic considerations, the impact of the COVID-19 pandemic has been factored into our impairment testing. The value-in-use calculations use cash flow projections based on the 2023 projections for each CGU and a further four years projections using estimated revenue and cost average growth rates of between 0% and 5%. At the end of the five year forecast period, terminal values for each CGU, based on a long-term growth rate of 2%, are used in the value-in-use calculations. The value-in-use represents the present value of the future cash flows, including the terminal value, discounted at a rate appropriate to each CGU. The pre-tax discount rates used range from 16% to 24% (2021: 16% to 25%). Sources of estimation uncertainty The cash flows have been arrived at taking into account the Group’s financial position, its recent financial results and cash flow generation and the nature of the medical diagnostic industry, where product obsolescence can be a feature. However, expected future cash flows are inherently uncertain and are therefore liable to material change over time. The key assumptions employed in arriving at the estimates of future cash flows factored into impairment testing are subjective and include projected EBITDA margins, net cash flows, discount rates used and the duration of the discounted cash flow model. Significant under-performance in any of the Group’s major CGUs may give rise to a material impairment which would have a substantial impact on the Group’s income and equity. Specific asset impairment charges In the year ended December 31, 2022, four internally developed intangible assets were fully impaired, as shown in the table below. Asset name Entity 2022 US$’000 Rapid COVID-19 antigen test Trinity Biotech Manufacturing Ltd 2,214 Autoimmune smart reader Trinity Biotech Manufacturing Ltd 1,265 Tri-stat instrument Primus Corp. 1,024 COVID-19 ELISA test Trinity Biotech Manufacturing Ltd 120 Total 4,623 The rapid COVID-19 test is approved for professional use in the EU. However, as previously disclosed by the Company, the demand for our COVID-19 portfolio of products is highly uncertain and very difficult to predict and in our experience the market has moved to over the counter (“OTC”) rapid COVID-19 tests, for which this product is not yet approved. As such the Company’s efforts to commercialise this test have been unsuccessful. In addition, pricing for rapid COVID-19 tests in the EU is relatively weak, with stronger pricing available in, for example, the US market, for which this product is not yet approved. Given the market outlook for rapid COVID-19 testing products and continued uncertainty regarding regulatory approval pathways in key markets, including the US, the Company has chosen to not immediately pursue further regulatory approvals but does intend to monitor these markets and regulatory pathways with a view to potentially seeking additional regulatory approvals. As the Company has no imminent plans to pursue these regulatory approvals, this development project was written down from US$2,214,000 to zero in 2022. For similar reasons, the carrying value of our internally developed COVID-19 ELISA test was fully impaired and the impairment charge for this project was US$120,000. The development project for the autoimmune smart reader was paused in 2022 as management reviewed other options, including the potential to proceed with a third-party reader instead of our own internally developed reader. Following this review, we determined that there were likely greater opportunities to capture more market share in a more capital efficient manner through partnering with a third-party reader manufacturer rather than pursuing an independent strategy. There is significant uncertainty if we will complete the project to develop our own in-house autoimmune smart reader and thus while we may re-visit this decision in the future, in the interests of prudence the project’s carrying value of US$1,265,000 was impaired to zero. In 2022, there was a strategic review of our Tri-stat instrument as part of a broader review of our haemoglobins product portfolio. In order to rationalise the haemoglobins product portfolio and to allow us to focus our resources on the higher growth products within that portfolio, management decided that Tri-stat sales would be restricted to only certain targeted partnerships, and this led to the carrying value for the Tri-stat intangible asset of US$1,024,000 being written down to zero. In the year ended December 31, 2021, there was a specific asset impairment charge related to the carrying value of the intangible asset for the COVID-19 antibody rapid test, which was written off in full. This product development was an asset of Trinity Biotech Manufacturing Limited and the impairment charge recorded for this asset was US$856,000. Impairment tests of cash-generating units The impairment tests performed at June 30, 2022 and at December 31, 2022 identified an impairment loss in three CGUs, Clark Laboratories Inc, Trinity Biotech Do Brasil and Biopool US Inc. The table below sets forth the impairment loss recorded for each of the CGU’s, comprising both the specific asset impairment charges (as per the above table) and the impairments arising from the CGU impairment tests: December 31, 2022 December 31, 2021 US$’000 US$’000 Trinity Biotech Manufacturing Limited 3,599 856 Primus Corp 1,024 - Trinity Biotech Do Brasil 454 956 Clark Laboratories Inc. 407 - Biopool US Inc. 355 153 Immco Diagnostics Inc - 4,979 Total impairment loss 5,839 6,944 The table below sets forth the breakdown of the impairment loss for each class of asset: December 31, 2022 December 31, 2021 US$’000 US$’000 Goodwill and other intangible assets 4,624 3,853 Property, plant and equipment (see Note 11) 733 2,508 Prepayments (see Note 16) 482 583 Total impairment loss 5,839 6,944 The value-in-use calculation is subject to significant estimation, uncertainty and accounting judgements and the following sensitivity analysis has been performed: • In the event that there was a reduction of 10% in the assumed level of future growth in revenue growth rate, which would represent a reasonably likely range of outcomes, there would be no additional impairment loss recorded at December 31, 2022. • In the event there was a 10% increase in the discount rate used to calculate the potential impairment of the carrying values, which would represent a reasonably likely range of outcomes, there would be no additional impairment loss recorded at December 31, 2022. Significant Goodwill and Intangible Assets with Indefinite Useful Lives CGUs or combinations of CGUs for which the carrying amount of goodwill is significant for the purposes of impairment testing periodically, in comparison with the Group’s total carrying amount of goodwill are those where the percentage is greater than 20% of the total. The additional disclosures required for the CGU with significant goodwill are as follows: Fitzgerald Industries December 31, 2022 December 31, 2021 Carrying amount of goodwill (US$’000) 12,591 12,591 Discount rate applied (real pre-tax) 15.77 % 19.66 % Excess value-in-use over carrying amount (US$’000) 7,432 3,496 % EBITDA would need to decrease for an impairment to arise 31.28 % 18.15 % Long-term growth rate 2.0 % 2.0 % The key assumptions and methodology used in respect of this CGU are consistent with those described above. The assumptions and estimates used are specific to the individual CGU and were derived from a combination of internal and external factors based on historical experience. Intangible Assets with Indefinite Useful lives (included in other intangibles) December 31, 2022 US$‘000 December 31, 2021 US$‘000 Fitzgerald Industries International CGU Fitzgerald trade name 970 970 RDI trade name 560 560 Primus Corporation CGU Primus trade name 365 365 Immco Diagnostic CGU Immco Diagnostic trade name 2,069 2,069 Total 3,964 3,964 The trade name assets purchased as part of the acquisition of Fitzgerald in 2004, Primus and RDI in 2005 and Immco Diagnostics in 2013 were valued using the relief from royalty method and based on factors such as (1) the market and competitive trends and (2) the expected usage of the name. It was considered that these trade names will generate net cash inflows for the Group for an indefinite period. In 2021, an impairment loss of US$869,000 was allocated against the Immco Diagnostic trade name as the carrying value of the CGU’s net assets exceeded its discounted future cashflows.

DEFERRED TAX ASSETS AND LIABILI

DEFERRED TAX ASSETS AND LIABILITIES	12 Months Ended
	Dec. 31, 2022
Disclosure of deferred tax assets and liabilities [Abstract]
DEFERRED TAX ASSETS AND LIABILITIES	13. DEFERRED TAX ASSETS AND LIABILITIES Recognised deferred tax assets and liabilities Deferred tax assets and liabilities of the Group are attributable to the following: Assets Liabilities Net 2022 US$’000 2021 US$’000 2022 2021 2022 2021 Property, plant and equipment 229 477 (5 ) (11 ) 224 466 Intangible assets - - (3,950 ) (3,969 ) (3,950 ) (3,969 ) Inventories 423 620 - - 423 620 Provisions 2,194 1,871 - - 2,194 1,871 Tax value of loss carry-forwards 1,254 1,016 - - 1,254 1,016 Other items 118 117 (1,103 ) (878 ) (985 ) (761 ) Deferred tax assets/(liabilities) 4,218 4,101 (5,058 ) (4,858 ) (840 ) (757 ) The deferred tax asset in 2022 is mainly due to deductible temporary differences relating to provisions, loss carry-forwards, property, plant and equipment and the elimination of unrealised intercompany inventory profit. In 2022, the deferred tax asset increased by US$117,000 mainly due to an increase in deductible temporary differences principally attributable to provisions and loss carry-forwards. The deferred tax liability is caused by the net book value of non-current assets being greater than the tax written down value of non-current assets, temporary differences due to the acceleration of the recognition of certain charges in calculating taxable income permitted in Ireland and the US. The deferred tax liability increased by US$200,000 in 2022, principally because of other items. Deferred tax assets and liabilities are only offset when the entity has a legally enforceable right to set off current tax assets against current tax liabilities and where the intention is to settle current tax liabilities and assets on a net basis or to realise the assets and settle the liabilities simultaneously. At December 31, 2022 and at December 31, 2021 no deferred tax assets and liabilities are offset as it is not certain as to whether there is a legally enforceable right to set off current tax assets against current tax liabilities and it is also uncertain as to what current tax assets may be set off against current tax liabilities and in what periods. Most temporary differences are expected to reverse after 2024. Movement in temporary differences during the year Balance January, 1 2022 Recognised in income Balance December 31, 2022 US$’000 US$’000 US$’000 Property, plant and equipment 466 (242 ) 224 Intangible assets (3,969 ) 19 (3,950 ) Inventories 620 (197 ) 423 Provisions 1,871 323 2,194 Tax value of loss carry-forwards 1,016 238 1,254 Other items (761 ) (224 ) (985 ) (757 ) (83 ) (840 ) Balance January, 1 2021 Recognised in income Balance December 31, 2021 US$’000 US$’000 US$’000 Property, plant and equipment 724 (258 ) 466 Intangible assets (4,072 ) 103 (3,969 ) Inventories 750 (130 ) 620 Provisions 2,159 (288 ) 1,871 Tax value of loss carry-forwards 433 583 1,016 Other items (714 ) (47 ) (761 ) (720 ) (37 ) (757 ) Unrecognised deferred tax assets Deferred tax assets have not been recognised by the Group in respect of the following items, which have not been tax effected: December 31, 2022 December 31, 2021 US$’000 US$’000 Capital losses 8,293 8,293 Net operating losses 75,957 73,893 US alternative minimum tax credits 1,906 1,704 Other temporary timing differences 38,960 21,301 US state credit carryforwards 2,753 1,664 127,869 106,855

OTHER NON-CURRENT ASSETS

OTHER NON-CURRENT ASSETS	12 Months Ended
	Dec. 31, 2022
Other Non-current Assets
OTHER NON-CURRENT ASSETS	14. OTHER NON-CURRENT ASSETS December 31, 2022 US$‘000 December 31, 2021 US$‘000 Finance lease receivables (see Note 16) 84 151 Other assets 55 56 139 207 The Group leases instruments as part of its business. For details of future minimum finance lease receivables with non-cancellable terms, please refer to Note 16.

INVENTORIES

INVENTORIES	12 Months Ended
	Dec. 31, 2022
Classes of current inventories [abstract]
INVENTORIES	15. INVENTORIES December 31, US$‘000 December 31, US$‘000 Raw materials and consumables 12,094 13,650 Work-in-progress 3,948 5,546 Finished goods 6,461 9,927 22,503 29,123 The assets of the Group, including inventories have been pledged as security for the term loan from Perceptive Advisors. All inventories are stated at the lower of cost or net realisable value. Total inventories for the Group are shown net of provisions of US$16,274,000 (2021: US$12,063,000) (2020: US$9,781,000). Cost of sales in 2022 includes inventories expensed of US$45,340,000 (2021: US$49,299,000) (2020: US$48,342,000). The movement on the inventory provision for the three-year period to December 31, 2022 is as follows: December 31, 2022 US$‘000 December 31, 2021 US$‘000 December 31, 2020 US$‘000 Opening provision at January 1 12,063 9,781 6,716 Charged during the year 7,391 5,589 5,179 Utilised during the year (3,180 ) (3,307 ) (1,994 ) Released during the year - - (120 ) Closing provision at December 31 16,274 12,063 9,781 During 2022, US$Nil (2021: US$Nil) (2020: US$120,000) of inventory provision relating to net realisable value was released to the statement of operations following a current year review of inventory usage.

TRADE AND OTHER RECEIVABLES

TRADE AND OTHER RECEIVABLES	12 Months Ended
	Dec. 31, 2022
Trade and other current receivables [abstract]
TRADE AND OTHER RECEIVABLES	16. TRADE AND OTHER RECEIVABLES December 31, 2022 US$‘000 December 31, 2021 US$‘000 Trade receivables, net of impairment losses 12,620 13,290 Prepayments 1,932 1,945 Contract assets 739 739 Value added tax 43 - Finance lease receivables 86 142 Grant receivable 333 - 15,753 16,116 Trade receivables are shown net of an impairment losses provision of US$2,691,000 (2021: US$2,986,000) (2020: US$3,922,000) (see Note 26). Prepayments are shown after impairment charges of US$482,000 (2021: US$583,000) (2020: US$562,000) (see Note 5). Long-term contract receivable (i) Finance lease commitments – Group as lessor The Group leases instruments as part of its business. Future minimum receivables with non-cancellable terms are as follows: December 31, 2022 US$‘000 Gross Unearned Minimum Less than one year 180 6 86 Between one and five years (Note 14) 173 6 84 353 12 170 December 31, 2021 US$‘000 Gross Unearned Minimum Less than one year 292 11 142 Between one and five years (Note 14) 310 11 151 602 22 293 The Group classified future minimum lease receivables between one and five years of US$84,000 (2021: US$151,000) as Other Assets, see Note 14. Under the terms of the lease arrangements, no contingent rents are receivable. (ii) Operating lease commitments – Group as lessor The Group leases instruments under operating leases as part of its business. Future minimum rentals receivable under non-cancellable operating leases are as follows: December 31, 2022 US$‘000 Instruments Total Less than one year 1,589 1,589 1,589 1,589 (ii) Operating lease commitments – Group as lessor December 31, 2021 Instruments Total Less than one year 3,953 3,953 Between one and five years 171 171 4,124 4,124

CASH AND CASH EQUIVALENTS

CASH AND CASH EQUIVALENTS	12 Months Ended
	Dec. 31, 2022
Cash and cash equivalents [abstract]
CASH AND CASH EQUIVALENTS	17. CASH AND CASH EQUIVALENTS December 31, US$’000 December 31, US$’000 Cash at bank and in hand 6,578 22,790 Short-term deposits - 3,120 Cash and cash equivalents 6,578 25,910

CAPITAL AND RESERVES

CAPITAL AND RESERVES	12 Months Ended
	Dec. 31, 2022
Disclosure of classes of share capital [abstract]
CAPITAL AND RESERVES	18. CAPITAL AND RESERVES Share capital December 31, 2022 December 31, 2021 Class ‘A’ ‘000s Class ‘A’ ‘000s In thousands of shares In issue at January 1 96,162 96,162 Issued for cash (a) 47,492 - Issued as consideration for Exchangeable Notes purchase (b) 21,332 - At period end 164,986 96,162 December 31, 2022 December 31, 2021 ADS ADS In thousands of ADSs Balance at January 1 24,041 24,041 Issued for cash 11,873 - Issued as consideration for Exchangeable Notes purchase 5,333 - At period end 41,247 24,041 The amounts in the tables above are inclusive of Treasury Shares. The number of Treasury Shares is as follows: December 31, 2022 December 31, 2021 Class ‘A’ ‘000s Class ‘A’ ‘000s In thousands of shares Balance at January 1 12,556 12,556 Purchased during period - - At period end 12,556 12,556 December 31, 2022 December 31, 2021 Class ‘A’ ‘000s Class ‘A’ ‘000s In thousands of ADSs Balance at January 1 3,139 3,139 Purchased during period - - At period end 3,139 3,139 (a) During the year ended December 31, 2022, the Company issued 47,492,000 ‘A’ Ordinary shares for a consideration of US$25,707,000 settled in cash. The Company incurred US$606,000 in connection with the issues of shares. The total shares issued for cash comprises 44,759,000 ‘A’ Ordinary shares issued to MiCo and 2,733,328 ‘A’ Ordinary from the exercise of employee share options. For more information on the investment by MiCo, refer to Note 22. (b) During the year ended December 31, 2022, the Company issued 21,332,000 ‘A’ Ordinary shares, with a market value of US$6,133,000, as partial consideration for the purchase of Exchangeable Notes. The Company incurred US$213,000 in connection with this issue of shares. For more information on the purchase of Exchangeable Notes, refer to Note 22. Translation reserve The translation reserve comprises all foreign exchange differences arising from the translation of the financial statements of foreign currency denominated operations of the Group since January 1, 2004. Other reserves Other reserves comprise the hedging reserve of US$23,000 and shares to be issued of US$63,000. The hedging reserve comprises the effective portion of the cumulative net change in the fair value of cash flow hedging instruments related to hedged transactions entered into but not yet crystallised. The hedging reserve is shown within Other Reserves in the Consolidated Statement of Financial Position. Shares to be issued as at December 31, 2022 have been issued in 2023. Equity component of Convertible Note In May 2022, the Company announced the successful closure of a US$45.2 million investment from MiCo Ltd (“MiCo”). MiCo, a KOSDAQ-listed and Korea-based company. The investment consisted of an equity investment of US$25.2 million and a seven-year, unsecured junior convertible note of US$20.0 million. The convertible note mandatorily converts into ADSs if the volume weighted average price of the Company’s ADSs is at or above US$3.24 for any five consecutive NASDAQ trading days. The convertible loan is accounted for as a compound financial instrument containing both an equity and liability element. The equity component of the convertible note is US$6.7 million. There is no remeasurement of the equity element following initial recognition. Treasury shares During 2022, the Group did not purchase any ‘A’ Ordinary shares (2021: nil) (2020: nil) ‘Treasury shares’.

SHARE OPTIONS

SHARE OPTIONS	12 Months Ended
	Dec. 31, 2022
Disclosure Of Share Options And Share Warrants [Abstract]
SHARE OPTIONS	19. SHARE OPTIONS Options Under the terms of the Company’s Employee Share Option Plans, options to purchase 44,814,672 ‘A’ Ordinary Shares (11,203,668 ADS’s) were outstanding at December 31, 2022. Under these Plans, options are granted to officers and employees of the Group at the discretion of the Compensation Committee (designated by the Board of Directors), under the terms outlined below. In the past, share options were granted to consultants of the Group and, where this was the case, the Group measured the fair value of the services provided by these consultants by reference to the fair value of the equity instruments granted. This approach was adopted in these cases as it was impractical for the Group to reliably estimate the fair value of such services. There are no outstanding options for consultants at December 31, 2022. The terms and conditions of the grants are as follows, whereby all options are settled by physical delivery of shares: Vesting conditions The options vest following a period of service by the officer or employee. The required period of service is determined by the Board and Remuneration Committee at the date of grant of the options (usually the date of approval by the Compensation Committee) and it is generally over a two to four-year period. Non-vesting conditions In 2022, share options were granted to certain directors for which there is a condition that the options only become exercisable into ADSs when the market price of an ADS reaches a certain level. This is deemed to be a non-vesting condition. The term ‘non- vesting condition’ is not explicitly defined in IFRS 2, Share based Payment Contractual life The term of an option is determined by the Board, Compensation Committee and Remuneration Committee provided that the term may not exceed a period of between seven to ten years from the date of grant. All options will terminate 90 days after termination of the option holder’s employment, service or consultancy with the Group (or one year after such termination because of death or disability) except where a longer period is approved by the Board of Directors. Under certain circumstances involving a change in control of the Group, the Compensation Committee may accelerate the exercisability and termination of options. The number and weighted average exercise price of share options per ordinary share is as follows: Share Weighted- US$ Range US$ Options ‘A’ Ordinary Shares Per ‘A’ Ordinary Share Per ‘A’ Ordinary Outstanding January 1, 2020 12,303,990 1.31 0.46 –4.36 Granted 9,100,000 0.38 0.19 –1.10 Exercised - - - Expired / Forfeited (1,918,000 ) 2.14 0.19-4.21 Outstanding at end of year 19,485,990 0.79 0.19-4.36 Exercisable at end of year 7,959,323 1.27 0.66-4.36 Outstanding January 1, 2021 19,485,990 0.79 0.19-4.36 Granted - - - Exercised - - - Expired / Forfeited (758,000 ) 1.07 0.19-4.21 Outstanding at end of year 18,727,990 0.78 0.19-4.36 Exercisable at end of year 13,401,322 0.93 0.19-4.36 Outstanding January 1, 2022 18,727,990 0.78 0.19-4.36 Granted 29,400,000 0.27 0.27-0.29 Exercised (2,733,328 ) 0.19 0.19-0.19 Expired / Forfeited (579,990 ) 1.87 0.69-4.36 Outstanding at end of year 44,814,672 0.47 0.19-2.43 Exercisable at end of year 14,138,004 0.89 0.19-2.43 Share Options ‘ADS’ Weighted- exercise price US$ Range US$ Equivalent Per ‘ADS’ Per ‘ADS’ Outstanding January 1, 2020 3,075,998 5.24 1.83 - 17.45 Granted 2,275,000 1.52 0.77 - 4.41 Exercised - - - Expired / Forfeited (479,500 ) 8.56 0.77 - 16.84 Outstanding at end of year 4,871,498 3.15 0.77-17.45 Exercisable at end of year 1,989,831 5.08 2.64 -17.45 Outstanding January 1, 2021 4,871,498 3.15 0.77-17.45 Granted - - - Exercised - - - Expired / Forfeited (189,500 ) 4.28 0.76 - 16.84 Outstanding at end of year 4,681,998 3.12 0.76 - 17.44 Exercisable at end of year 3,350,331 3.72 0.76 –17.44 Outstanding January 1, 2022 4,681,998 3.12 0.76 - 17.44 Granted 7,350,000 1.09 1.07-1.14 Exercised (683,332 ) 0.77 0.77-0.77 Expired / Forfeited (144,998 ) 7.48 2.76 - 17.44 Outstanding at end of year 11,203,668 1.88 0.77-9.73 Exercisable at end of year 3,534,501 3.56 0.77-9.73 In 2022, 2,733,328 share options were exercised in 2022 at an average share price of US$0.28 or US$1.13 per ADS at the date of exercise. There were no share options exercised during 2021 or 2020. The opening share price per ‘A’ Ordinary share at the start of the financial year was US$0.36 or US$1.43 per ADS (2021: US$0.95 or US$3.81 per ADS) (2020: US$0.27 or US$1.07 per ADS) and the closing share price at December 31, 2022 was US$0.25 or US$0.99 per ADS (2021: US$0.36 or US$1.43 per ADS) (2020: US$0.95 or US$3.81 per ADS). The average share price for the year ended December 31, 2022 was US$0.30 per ‘A’ Ordinary share or US$1.22 per ADS. A summary of the range of prices for the Company’s share options for the year ended December 31, 2022 follows: Outstanding Exercisable Exercise price range No. of Weighted– Weighted- No. of Weighted– Weighted- US$0.19-US$0.99 39,546,672 0.35 6.10 8,930,004 0.59 4.05 US$1.00-US$1.74 4,988,000 1.34 1.78 4,928,000 1.34 1.74 US$1.75- US$2.43 280,000 2.43 0.15 280,000 2.43 0.15 44,814,672 14,138,004 Outstanding Exercisable Exercise price range No. of Weighted– Weighted- No. of Weighted– Weighted- US$0.77-US$3.96 9,886,668 1.39 6.10 2,232,501 2.37 4.05 US$4.00-US$6.94 1,247,000 5.37 1.78 1,232,000 5.38 1.74 US$6.95- US$9.73 70,000 9.73 0.15 70,000 9.73 0.15 11,203,668 3,534,501 The weighted-average remaining contractual life of options outstanding at December 31, 2022 was 5.58 years (2021: 4.35 years). A summary of the range of prices for the Company’s share options for the year ended December 31, 2021 follows: Outstanding Exercisable Exercise price range No. of Weighted– Weighted- No. of Weighted– Weighted- US$0.19-US$0.99 13,000,006 0.48 3.54 7,960,004 0.55 2.92 US$1.00-US$2.05 5,228,000 1.34 0.79 4,941,334 1.35 0.99 US$2.06- US$2.99 439,984 2.53 0.03 439,984 2.53 0.04 US$3.00 -US$4.36 60,000 4.17 0.00 60,000 4.17 0.00 18,727,990 13,401,322 Outstanding Exercisable Exercise price range No. of Weighted– Weighted- No. of Weighted– Weighted- US$0.77-US$3.96 3,250,002 1.94 3.54 1,990,001 2.19 2.92 US$4.00-US$8.20 1,307,000 5.36 0.79 1,235,334 5.40 0.99 US$8.24- US$11.96 109,996 10.13 0.03 109,996 10.13 0.04 US$12.00 -US$17.45 15,000 16.67 0.00 15,000 16.67 0.00 4,681,998 3,350,331 Charge for the year under IFRS 2 The charge for the year is calculated based on the fair value of the options granted which have not yet vested. The fair value of the options is expensed over the vesting period of the option. US$1,755,000 was charged to the statement of operations in 2022, (2021: US$1,100,000) (2020: US$792,000) split as follows: December 31, 2022 US$‘000 December 31, 2021 US$‘000 December 31, 2020 US$‘000 Share-based payments – cost of sales - 5 12 Share-based payments – selling, general and administrative 1,755 1,095 780 Total – continuing operations 1,755 1,100 792 Share-based payments – discontinued operations - - - Total 1,755 1,100 792 No share-based payments expense was capitalised in intangible development project assets during the year. In 2021, US$11,000, (2020: US$24,000) of share-based payments was capitalised in intangible development project assets. The total share-based payments charge gross of any capitalisations for 2021 was US$1,111,000 (2020: US$816,000). The fair value of services received in return for share options granted are measured by reference to the fair value of share options granted. The estimate of the fair value of services received is measured based on a Black-Scholes model. The following are the input assumptions used in determining the fair value of share options granted in 2022, 2021 and 2020: Key management personnel Other employees Key management personnel Other employees Key management personnel Other employees 2022 2022 2021 2021 2020 2020 Weighted average fair value at measurement date per ‘A’ share / (per ADS) US$0.19 / (US$0.77 ) - / - - / - - / - US$0.20 / (US$0.80 ) US$0.27 / (US$1.08 ) Total ‘A’ share options granted / (ADS’s equivalent) 29,400,000 / (7,350,000 ) - / - - / - - / - 8,480,000 / (2,120,000 ) 620,000 / (155,000 ) Weighted average share price per ‘A’ share / (per ADS) US$0.27 / (US$1.09 ) - / - - / - - / - US$0.38 / (US$1.52 ) US$0.48 / (US$1.96 ) Weighted average exercise price per ‘A’ share / (per ADS) US$0.27 / (US$1.09 ) - / - - / - - / - US$0.38 / (US$1.52 ) US$0.48 / (US$1.96 ) Weighted average expected volatility 76.79 % - % - % - % 66.98 % 65.89 % Weighted average expected life 6.82 - - - 4.34 4.35 Weighted average risk-free interest rate 3.59 % - % - % - % 0.44 % 0.42 % The expected life of the options is based on historical data and is not necessarily indicative of exercise patterns that may occur. The expected volatility is based on the historic volatility (calculated based on the expected life of the options). The Group has considered how future experience may affect historical volatility. The profile and activities of the Group are not expected to change in the immediate future and therefore Trinity Biotech would expect estimated volatility to be consistent with historical volatility.

TRADE AND OTHER PAYABLES

TRADE AND OTHER PAYABLES	12 Months Ended
	Dec. 31, 2022
Trade and other current payables [abstract]
TRADE AND OTHER PAYABLES	20. TRADE AND OTHER PAYABLES December 31, 2022 US$’000 December 31, 2021 US$’000 Trade payables 6,205 6,763 Accruals and other liabilities 8,585 7,595 Payroll taxes 368 398 Employee related social insurance 103 130 Deferred income 114 141 Deferred government grants - 69 Other payables - 31 15,375 15,127 Included in trade and other payables at December 31, 2022 was US$176,000 (2021: US$Nil) relating to contracted licence payments. Other payables Other payables at December 31, 2021 related to an interest-free loan received under the Canada Emergency Business Account (“CEBA”). The CEBA loans were provided by the Canadian Government to mitigate the financial impact of the Covid-19 outbreak. This interest-free loan was repaid and partly forgiven in the year ended December 31, 2022. For more information, refer to Note 4.

PROVISIONS

PROVISIONS	12 Months Ended
	Dec. 31, 2022
Provisions [abstract]
PROVISIONS	21. PROVISIONS December 31, 2022 US$’000 December 31, 2021 US$’000 Product warranty provision 50 50 50 50 During 2022 and 2021 the Group experienced no significant product warranty claims. However, the Group believes that it is appropriate to retain a product warranty provision to cover any future claims. The provision at December 31, 2022 represents the estimated cost of product warranties, the exact amount which cannot be determined. US$50,000 represents management’s best estimate of these obligations at December 31, 2022.

INTEREST-BEARING LOANS AND BORR

INTEREST-BEARING LOANS AND BORROWINGS	12 Months Ended
	Dec. 31, 2022
Disclosure Of Interest-bearing Loans And Borrowings [Abstract]
INTEREST-BEARING LOANS AND BORROWINGS	22. INTEREST-BEARING LOANS AND BORROWINGS The carrying value of interest-bearing loans, borrowings and related balances is as follows: December 31, 2022 US$’000 December 31, 2021 US$’000 Current liabilities Exchangeable senior notes 210 83,312 Total 210 83,312 December 31, US$’000 December 31, US$’000 Non-Current liabilities Senior secured term loan 44,301 - Derivative financial liability 1,569 - Convertible Note 13,746 - Total non-current liabilities 59,616 - December 31, 2022 US$’000 December 31, 2021 US$’000 Non-Current assets Derivative financial asset 128 - Total non-current assets 128 - Exchangeable senior notes In January 2022, the Company retired approximately US$99.7 million of the Exchangeable Notes as part of a debt re-financing. This represented approximately 99.7% of the total Exchangeable Notes. Consideration was in cash and an issue of ‘A’ Ordinary shares. The cash paid was US$86.73 million with each holder that was party to the agreement receiving US$0.87 of cash per US$1 nominal value of the Exchangeable Notes. The shares consideration was 5,333,000 ADSs (21,332,000 ‘A’ Ordinary shares) representing the equivalent of US$0.08 of the Company’s ADS (based upon the 5-day trailing VWAP of the ADSs on NASDAQ on December 10, 2021, discounted by 13%) per US$1 nominal value of the Exchangeable Notes, as partial consideration for the exchange of the Exchangeable Notes. The shares consideration is valued at US$6.1 million based on market price on the date of issue. The Exchangeable Notes were treated as a host debt instrument under IFRS with embedded derivatives attached. The embedded derivatives related to a number of put and call options which were measured at fair value in the consolidated statement of operations. On initial recognition in 2015, the host debt instrument was recognised at the residual value of the total net proceeds of the note issue less fair value of the embedded derivatives. Subsequently, the host debt instrument was measured at amortised cost using the effective interest rate method. At date of disposal, the carrying value of the extinguished Exchangeable Notes was US$83.2m. As the IFRS measure of consideration was higher by US$9.7 million, the resulting loss on disposal was recorded as a financial expense in the year ended December 31, 2022. The remaining nominal value of the Exchangeable Notes at December 31, 2022 is US$210,000 and this is shown within Current Liabilities. The movement in the Exchangeable Notes balance was as follows: December 31, 2022 US$000 December 31, 2021 US$000 Balance at January 1 (83,312 ) (82,664 ) Accretion interest (83 ) (648 ) Repaid to Note holders 86,730 0 Shares issued to Note holders as consideration 6,133 0 Loss on disposal (9,678 ) 0 Liability (210 ) (83,312 ) During the year ended December 31, 2022, the Company acquired two new debt liabilities, as follows: (i) Senior secured term loan The Company and its subsidiaries entered into a US$81.3 million senior secured term loan credit facility in December 2021 (the “Term Loan”) with Perceptive Credit Holdings III, LP (“Perceptive”, an investment manager with an expertise in healthcare. The Term Loan was drawn down in January 2022, when the necessary shareholder approvals were obtained. The term loan is secured by a charge over the Group’s assets. The 48-month term loan will mature in January 2026 and accrues interest at an annual rate equal to 11.25% plus the greater of (a) one-month LIBOR (later changed to the Term SOFR Reference Rate effective from October 28, 2022) and (b) one percent per annum, and interest is payable monthly in arrears in cash. The term loan does not require any amortization, and the entire unpaid balance will be payable upon maturity. In connection with the Term Loan the Company agreed to issue warrants to Perceptive for 2.5 million of the Company’s ADSs. The per ADS exercise price of the Warrants was US$1.30. In February 2023, in connection with an increased Term Loan facility, the Company agreed to reprice the 2,500,000 warrants originally issued to Perceptive, with the Warrants now having a per ADS price of US$1.071. The warrants are exercisable, in whole or part, until the seventh anniversary of the date of drawdown of the funding under the Term Loan. At the discretion of the Company, the Term Loan can be repaid, in part or in full, at a premium before the end of the four-year term. In May 2022, the Company repaid US$34.5 million of the term loan principal and incurred an early payment penalty of approximately US$3.5 million, which has been recorded as a financial expense in the year ended December 31, 2022. In accordance with IFRS accounting standards, the Term Loan is represented by three separate balances in the statement of financial position. US$44.3 million is shown in non-current liabilities as a senior secured term loan. At initial recognition, the balance comprised the principal loan amount of US$81.25 million less loan origination costs of US$3.6 million, less two derivative financial balances totaling US$1.7 million to give a balance of US$76.0 million. During the year ended December 31, 2022 accretion interest of US$2.8 million was accrued and the repayment of US$34.5 million reduced the liability to leave a closing carrying value of US$44.3 million. The early repayment of a portion of the Term Loan necessitated an accretion interest adjustment of US$2.1 million in the year ended December 31, 2022, recognised as a financial expense, to discount the revised expected future cash flows for the loan. The other two balances related to the Term Loan are: a) a derivative financial asset and b) a derivative financial liability. The fair value of the derivative financial asset is estimated at US$128,000 at December 31, 2022 and represents the value to the Company of being able to repay the Term Loan early and potentially refinance at a lower interest rate. The fair value of the derivative financial liability is estimated at US$1,569,000 at December 31, 2022 and represents the fair value of the warrants issued to Perceptive. The fair value remeasurement for these two derivative financial balances resulted in a net financial income of US$0.2m being recognised in the consolidated statement of operations. (ii) 7-year convertible note In May 2022, the Company announced a US$45.2 million investment from MiCo Ltd (“MiCo”). MiCo, a KOSDAQ-listed and Korea-based company, is engaged in the biomedical business through its affiliate MiCo BioMed. The investment consists of an equity investment of US$25.2 million and a seven-year, unsecured junior convertible note of US$20.0 million. The convertible note has an interest rate of 1.5%. The convertible note mandatorily converts into ADSs if the volume weighted average price of the Company’s ADSs is at or above US$3.24 for any five consecutive NASDAQ trading days. For further details on the convertible note, refer to the Company’s Form 6-K filings with the SEC on April 11, 2022. The convertible loan note is accounted for as a compound financial instrument containing both an equity and liability element. The debt component is accounted for at amortised cost in accordance with IFRS 9. At December 31, 2022, the carrying value of the convertible note’s debt component was US$13.7 million and accretion interest of US$0.5 million has been recognised as a financial expense in the year ended December 31, 2022. The equity component of the convertible note is US$6.7 million and has been recorded in the equity section of the statement of financial position as Equity component of convertible note. There is no remeasurement of the equity element following initial recognition. The movement in the Term Loan and the 7-year convertible notes in the year ended December 31, 2022 is summarised as follows: Senior secured term loan US$000 7-year Convertible Note US$000 Balance at January 1, 2022 - - Principal amount loaned (81,250 ) (20,000 ) Loan origination costs 3,551 40 Derivative financial liability at date of issue 1,872 - Derivative financial asset at date of issue (202 ) - Equity component at date of issue - 6,709 Accretion interest (2,772 ) (495 ) Cash repayment of principal 34,500 - Non-current liability at December 31, 2022 (44,301 ) (13,746 ) The movement in the derivative financial liability in the year ended December 31, 2022 was as follows: US$000 Balance at January 1, 2022 - Derivative financial liability at date of issue of Term Loan (1,872 ) Fair value adjustments in the period 303 Non-current liability at December 31, 2022 (1,569 ) The movement in the derivative financial asset in the year ended December 31, 2022 was as follows: US$000 Balance at January 1, 2022 - Derivative financial asset at date of issue of Term Loan 202 Fair value adjustments in the period (74 ) Non-current asset at December 31, 2022 128

LEASE LIABILITIES

LEASE LIABILITIES	12 Months Ended
	Dec. 31, 2022
Disclosure of finance lease liabilities [Abstract]
LEASE LIABILITIES	23. LEASE LIABILITIES The Group has leases for some of its manufacturing plants, all warehouses, offices, motor vehicles and some IT equipment. With the exception of short-term leases and leases of low-value underlying assets, each lease is reflected on the balance sheet as a right-of-use asset (net of any depreciation and/or impairment) and a lease liability. Variable lease payments which do not depend on an index or a rate (such as lease payments based on a percentage of Group sales) are excluded from the initial measurement of the lease liability and asset. The Group classifies its right-of-use assets in a consistent manner to its property, plant and equipment (see Note 11). Each lease generally imposes a restriction that, unless there is a contractual right for the Group to sublet the asset to another party, the right-of-use asset can only be used by the Group. Leases are either non-cancellable or may only be cancelled by incurring a substantive termination fee. Some leases contain an option to purchase the underlying leased asset outright at the end of the lease, or to extend the lease for a further term. The Group is prohibited from selling or pledging the underlying leased assets as security. For leases over office buildings and factory premises the Group must keep those properties in a good state of repair and return the properties in their original condition at the end of the lease. Further, the Group must insure items of property, plant and equipment and incur maintenance fees on such items in accordance with the lease contracts. Lease liabilities Lease liabilities are payable as follows: December 31, 2022 US$’000 December 31, 2021 US$’000 Current liabilities Lease liabilities related to Right of Use assets 1,631 1,878 Sale and leaseback liabilities 45 102 1,676 1,980 Non-Current liabilities Lease liabilities related to Right of Use assets 12,267 13,790 Sale and leaseback liabilities - 75 12,267 13,865 December 31, 2022 December 31, 2022 Lease liabilities related to Right of Use assets Sale and leaseback Liabilities Minimum lease payments Interest Principal Minimum lease payments Interest Principal Less than one year 2,249 618 1,631 46 1 45 In more than one year, but not more than two 2,240 561 1,679 - - - In more than two years but not more than five 5,739 1,217 4,522 - - - more than five years 6,968 902 6,066 - - - 17,196 3,298 13,898 46 1 45 December 31, 2021 US$’000 December 31, 2021 US$’000 Lease liabilities related to Right of Use assets Sale and leaseback Liabilities Minimum lease payments Interest Principal Minimum lease payments Interest Principal Less than one year 2,575 697 1,878 109 7 102 In more than one year, but not more than two 2,175 621 1,554 77 2 75 In more than two years but not more than five 5,985 1,469 4,516 - - - more than five years 8,992 1,272 7,720 - - - 19,727 4,059 15,668 186 9 177 Lease payments not recognised as a liability No short-term lease expenses were incurred for the year ended December 31, 2022. Payments made under such leases are expensed on a straight-line basis. In addition, certain variable lease payments are not permitted to be recognised as lease liabilities and are expensed as incurred. Terms and debt repayment schedule The terms and conditions of outstanding interest-bearing loan and borrowing at December 31, 2022 are shown in the table below. A Euro-denominated sale and leaseback liability, which had a maturity date in 2023, was settled in full in 2022. Facility Currency Nominal interest Year of maturity Fair Value Carrying Value Sale and leaseback liabilities USD 5.51 % 2023 45 45 The terms and conditions of outstanding interest bearing loans and borrowings at December 31, 2021 are as follows: Facility Currency Nominal interest Year of maturity Fair Value Carrying Value Sale and leaseback liabilities Euro 4.53 % 2023 65 65 Sale and leaseback liabilities USD 5.51 % 2023 111 111 Total 176 176 The total paid in respect of lease liabilities in the year ended December 31, 2022 was US$2,761,000 (2021: US$2,938,000).

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Dec. 31, 2022
Disclosure Of Commitments And Contingent Liability Abstract
COMMITMENTS AND CONTINGENCIES	24. COMMITMENTS AND CONTINGENCIES (a) Capital Commitments The Group has capital commitments authorised and contracted for of US$Nil as at December 31, 2022 (2021: US$440,000). (b) Leasing Commitments The Group’s leasing commitments are shown in Note 23. (c) Bank Security The Credit Agreement for the senior secured term loan is secured by substantially all of our property and assets, including our equity interests in our subsidiaries, refer to Note 22. At December 31, 2022, the Group’s sale and leaseback borrowings were at fixed rates of interest and consisted of USD denominated borrowings, refer to Note 23. The bank providing the financing has a charge over the equipment for which the borrowing pertains. (d) Group Company Guarantees Pursuant to the provisions of Section 357, Irish Companies Act, 2014, the Company has guaranteed the liabilities of Trinity Biotech Manufacturing Limited, Trinity Research Limited and Trinity Biotech Financial Services Limited subsidiary undertakings in the Republic of Ireland, for the financial year to December 31, 2022 and, as a result, these subsidiary undertakings have been exempted from the filing provisions of Section 357, Irish Companies Act, 2014. Where the Company enters into these guarantees of the indebtedness of other companies within its Group, the Company considers these to be insurance arrangements and accounts for them as such. The Company treats the guarantee contract as a contingent liability until such time as it becomes probable that the company will be required to make a payment under the guarantee. The Company does not enter into financial guarantees with third parties. (e) Contingent Asset In the 2019 financial statements, a contingent asset of US$1,231,000 was disclosed in connection with the 2019 tax audit settlement payable by Darnick Company. This balance was settled in the year ended December 31, 2020 and has been credited to the Statement of Operations within Selling, General and Administrative Expenses. The underlying amount was denominated in Euro. Due to a depreciation in the US Dollar since 2019, the US Dollar equivalent amount increased from US$1,231,000 to US$1,316,000. The settlement amount received by the Company was US$177,000 more than the balance owed and this overpayment was recorded as a related party current liability for the benefit of Ronan O’Caoimh as at December 31, 2020. The amount was settled by the Group in January 2021. There are no contingent assets as of December 31, 2022 (2021: US$Nil). (f) Government Grant Contingencies The Group has received training and employment grant income from Irish development agencies. Subject to existence of certain conditions specified in the grant agreements, this income may become repayable. No such conditions existed as at December 31, 2022. However, if the income were to become repayable, the maximum amounts repayable as at December 31, 2022 would amount to US$3,259,509 (2021: US$3,095,000). To mitigate the financial impact of the Covid-19 outbreak, the Group availed of governmental supports. In 2020, the Group received US$4.5 million of Paycheck Protection Program (“PPP”) loans and in 2021, a further US$1.8 million of PPP loans were received. All of the loans received to date under the program have been forgiven by the US government before December 31, 2022 and therefore no liability for these loans exists at December 31, 2022. (g) Other Contingencies The Company has other contingencies primarily relating to claims and legal proceedings, onerous contracts, product warranties and employee related provisions. The status of each significant claim and legal proceeding in which the Company is involved is reviewed by management on a periodic basis and the Group’s potential financial exposure is assessed. If the potential loss from any claim or legal proceeding is considered probable, and the amount can be reliably estimated, a liability is recognised for the estimated loss. Because of the uncertainties inherent in such matters, the related provisions are based on the best information available at the time; the issues taken into account by management and factored into the assessment of legal contingencies include, as applicable, the status of settlement negotiations, interpretations of contractual obligations, prior experience with similar contingencies/claims, and advice obtained from legal counsel and other third parties. The Group expects the majority of these provisions will be utilised within one to three years of the balance sheet date; however due to the nature of the legal provisions there is a level of uncertainty in the timing of settlement as the Group generally cannot determine the extent and duration of the legal process.

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	12 Months Ended
	Dec. 31, 2022
Disclosure of transactions between related parties [abstract]
RELATED PARTY TRANSACTIONS	25. RELATED PARTY TRANSACTIONS The Group has related party relationships with its subsidiaries, and with its directors and executive officers. Leasing arrangements with related parties The following is a description of our related party transactions since January 1, 2022. The Group has entered into various arrangements with JRJ Investments (“JRJ”), a partnership owned by Mr O’Caoimh and Dr Walsh, directors of Trinity Biotech, and directly with Mr O’Caoimh, to provide premises at IDA Business Park, Bray, County Wicklow, Ireland. The Group entered into an agreement with JRJ for a 25-year lease commencing in December 2003 for offices that were adjacent to its then premises at IDA Business Park, Bray, County Wicklow, Ireland with an annual rent of €381,000 (US$406,000). Upward-only rent reviews are carried out every five years and there have been no increases arising from these rent reviews. In 2007, the Group entered into a 25-year lease agreement with Mr O’Caoimh and Dr Walsh for a 43,860 square foot manufacturing facility in Bray, Ireland with an annual rent of €787,000 (US$838,000). Subsequent to the signing of this lease, the ownership of the building transferred from JRJ to Mr O’Caoimh solely. In 2016, the Group also entered into a 10-year lease agreement with Mr O’Caoimh for a warehouse of 16,000 square feet adjacent to the leased manufacturing facility in Bray, Ireland. The annual rent for the warehouse is €144,000 (US$153,000). At the time, independent valuers advised the Group that the rent in respect of each of the leases represented a fair market rent. Upward-only rent reviews are carried out every five years and there have been no increases to date arising from these rent reviews, although a rent review for the 43,860 square foot facility is currently ongoing. In late 2020, the Group occupied some additional space adjoining the warehouse owned by Mr O’Caoimh. This was a short-term arrangement, and no payments were made for the additional space during 2020 and 2021. The Company vacated this space in 2021. In 2022, the rent payable to Mr O’Caoimh of US$90,000 was settled. Trinity Biotech and its directors (excepting Mr O’Caoimh and Dr Walsh who express no opinion on this point) believe at the time that the arrangements were entered into represented a fair and reasonable basis on which the Group could meet its ongoing requirements for premises. Dr Walsh has no ownership interest in the additional space adjoining the warehouse owned by Mr O’Caoimh and was therefore entitled to express an opinion on this arrangement. Compensation of key management personnel of the Group During the year ended December 31, 2022, the key management personnel of the Group were made up of the executive directors; Mr. Ronan O’Caoimh, Dr Jim Walsh, Mr. John Gillard and Mr. Aris Kekedjian. For the year ended December 31, 2021, the key management personnel of the Group were made up of the executive directors; Mr. Ronan O’Caoimh, Dr Jim Walsh, Mr. John Gillard and Mr. Kevin Tansley. Compensation for the year ended December 31, 2022 of these personnel is detailed below: December 31, 2022 December 31, 2021 US$’000 US$’000 Short-term employee benefits 1,074 1,065 Performance related bonus 512 227 Post-employment benefits 24 24 Share-based compensation benefits as calculated under IFRS 2 1,690 965 3,300 2,281 The amounts disclosed in respect of directors’ emoluments in Note 9 includes non-executive directors’ fees of US$53,000 (2021: US$98,000) and share-based compensation benefits of US$17,000 (2021: US$61,000). Total directors’ remuneration is also included in “employment” (Note 3) and “(Loss)/profit before tax” (Note 9). The performance bonuses for Mr. Kekedjian and Mr. Gillard in respect of fiscal year 2022 have been accrued as at December 31, 2022. Directors’ interests in the Company’s shares and share option plan ‘A’ Ordinary Shares Share options At January 1, 2022 9,077,713 16,738,000 Shares of retired director (626,600 ) - Options of retired director - (2,924,000 ) Shares purchased during the year 2,666,664 (2,666,664 ) Shares sold during the year - - Granted - 29,400,000 Expired / forfeited - - At December 31, 2022 11,117,777 40,547,336 ‘A’ Ordinary Shares Share options At January 1, 2021 9,077,713 17,394,000 Shares of retired director - - Options of retired director - (656,000 ) Shares purchased during the year - - Shares sold during the year - - Granted - - Expired / forfeited - - At December 31, 2021 9,077,713 16,738,000 Rayville Limited, an Irish registered company, which was wholly owned by three executive directors and certain other former executives of the Group, owned all of the ‘B’ non-voting Ordinary Shares in Trinity Research Limited, one of the Group’s subsidiaries, and these ‘B’ shares were surrendered through Trinity Research Limited in 2021. The ‘B’ shares do not entitle the holders thereof to receive any assets of the company on a winding up. All of the ‘A’ voting ordinary shares in Trinity Research Limited are held by the Group. All liabilities in relation to Rayville Limited and Trinity Research Limited were extinguished as at December 31, 2021 and December 31, 2022.

CAPITAL AND FINANCIAL RISK MANA

CAPITAL AND FINANCIAL RISK MANAGEMENT	12 Months Ended
	Dec. 31, 2022
Disclosure of detailed information about financial instruments [abstract]
CAPITAL AND FINANCIAL RISK MANAGEMENT	26. CAPITAL AND FINANCIAL RISK MANAGEMENT Capital Management The Group’s policy is to maintain a strong capital base to maintain investor, creditor and market confidence and to sustain future development of the business. The Board of Directors monitors (loss)/earnings per share as a measure of performance, which the Group defines as (loss)/profit after tax divided by the weighted average number of shares in issue. Fair Values The table below sets out the Group’s classification of each class of financial assets/liabilities, their fair values and under which valuation method they are valued: Level 1 Level 2 Total carrying amount Fair Value Note US$’000 US$’000 US$’000 US$’000 December 31, 2022 Loans and receivables at amortised cost Trade receivables 16 12,620 - 12,620 12,620 Cash and cash equivalents 17 6,578 - 6,578 6,578 Finance lease receivable 14, 16 170 - 170 170 19,368 - 19,368 19,368 Liabilities at amortised cost Senior secured term loan 22 - (44,301 ) (44,301 ) (44,301 ) Convertible note 22 - (13,746 ) (13,746 ) (13,746 ) Exchangeable note 22 (210 ) - (210 ) (210 ) Lease liabilities 23 (13,943 ) - (13,943 ) (13,943 ) Trade and other payables (excluding deferred income) 20 (15,261 ) - (15,261 ) (15,261 ) Provisions 21 (50 ) - (50 ) (50 ) (29,464 ) (58,047 ) (87,511 ) (87,511 ) Fair value through profit and loss (FVPL) Derivative liability - warrants 22 - (1,569 ) (1,569 ) (1,569 ) Derivative asset – prepayment option 22 - 128 128 128 - (1,441 ) (1,441 ) (1,441 ) (10,096 ) (59,488 ) (69,584 ) (69,584 ) For financial reporting purposes, fair value measurements are categorized into Level 1, 2 or 3 based on the degree to which inputs to the fair value measurements are observable and the significance of the inputs to the fair value measurement in its entirety, which are described as follows: Level 1: quoted prices (unadjusted) in active markets for identical assets or liabilities Level 2: valuation techniques for which the lowest level of inputs which have a significant effect on the recorded fair value are observable, either directly or indirectly Level 3: valuation techniques for which the lowest level of inputs that have a significant effect on the recorded fair value are not based on observable market data. Level 1 Level 2 Total carrying amount Fair Value Note US$’000 US$’000 US$’000 US$’000 December 31, 2021 Loans and receivables at amortised cost Trade receivables 16 13,290 - 13,290 13,290 Cash and cash equivalents 17 25,910 - 25,910 25,910 Finance lease receivable 14, 16 293 - 293 293 39,493 - 39,493 39,493 Liabilities at amortised cost Exchangeable note¹ 22 - (83,312 ) (83,312 ) (83,312 ) Lease liabilities 23 (15,845 ) - (15,845 ) (15,845 ) Trade and other payables (excluding deferred income) 20 (14,986 ) - (14,986 ) (14,986 ) Provisions 21 (50 ) - (50 ) (50 ) (30,881 ) (83,312 ) (114,193 ) (114,193 ) Fair value through profit and loss (FVPL) Exchangeable note bond call option 22 - - - - Exchangeable note equity conversion option 22 - - - - - - - - 8,612 (83,312 ) (74,700 ) (74,700 ) The valuation techniques used for instruments categorised as level 2 are described below: The fair values of the options associated with the exchangeable notes are calculated in consultation with third-party valuation specialists due to the complexity of their nature. There are a number of inputs utilised in the valuation of the options, including share price, historical share price volatility, risk-free rate and the expected borrowing cost spread over the risk-free rate. Financial Risk Management The Group uses a range of financial instruments (including cash, finance leases, receivables, payables and derivatives) to fund its operations. These instruments are used to manage the liquidity of the Group. Working capital management is a key additional element in the effective management of overall liquidity. The Group does not trade in financial instruments or derivatives. The main risks arising from the utilization of these financial instruments are interest rate risk, liquidity risk and credit risk. Interest rate risk Effective and repricing analysis The following table sets out all interest-earning financial assets and interest-bearing financial liabilities held by the Group at December 31, indicating their effective interest rates and the period in which they re-price: As at December 31, 2022 Note Effective interest Total US$’000 6 mths or less US$’000 6 –12 mths US$’000 1-2 years US$’000 2-5 years US$’000 > 5 years US$’000 Cash and cash equivalents 17 0.00 % 6,578 6,578 - - - - Lease receivable 14,16 4.0 % 170 46 41 49 34 - Exchangeable note 22 4.8 % (210 ) - - - - (210 ) Senior secured term loan 1 22 15.4 % (44,301 ) - - - (44,301 ) - Convertible note 2 22 1.5 % (13,746 ) - - - - (13,746 ) Lease payable on Right of Use assets 23 5.0 % (13,898 ) (812 ) (819 ) (1,679 ) (4,522 ) (6,066 ) Lease payable on sale & leaseback transactions 23 5.0 % (45 ) (35 ) (10 ) - - - Total (65,452 ) 5,777 (788 ) (1,630 ) (48,789 ) (20,022 ) ¹ The senior secured term loan is a variable instrument which bears interest at an annual rate equal to 11.25% plus the greater of (a) one-month Term SOFR Reference Rate and (b) one percent per annum. 2 3 As at December 31, 2021 Note Effective interest Total US$’000 6 mths or less US$’000 6 -12 mths US$’000 1-2 years US$’000 2-5 years US$’000 > 5 years US$’000 Cash and cash equivalents 17 0.01 % 25,910 25,910 - - - - Lease receivable 14,16 4.0 % 293 81 61 89 62 - Exchangeable note¹ 22 4.8 % (83,312 ) - - - - (83,312 ) Other borrowings 0 % (31 ) - (31 ) - - - Lease payable on Right of Use assets 23 5.0 % (15,668 ) (973 ) (905 ) (1,554 ) (4,516 ) (7,720 ) Lease payable on sale & leaseback transactions 23 5.0 % (177 ) (51 ) (51 ) (75 ) - - Total (72,985 ) 24,967 (926 ) (1,540 ) (4,454 ) (91,032 ) ¹ The maturity of the Exchangeable Notes is based on the contractual maturity date of April 1, 2045. In broad terms, a one-percentage point increase in interest rates would increase interest income by US$Nil (2021: US$31,000) as, at December 31, 2022 the Company holds no funds in interest-bearing accounts; while the annual impact on the interest expense would be an increase of US$467,500 (2021: nil) on the costs of servicing the senior secured term loan. In accordance with the UK Financial Conduct Authority’s announcement in March 2021, LIBOR benchmark rates were discontinued after 31 December 2022. The Group’s cash flows were affected by the interest rate benchmark reform. The senior secured Term Loan originally varied by reference to one-month LIBOR. During 2022, LIBOR was replaced by the Term SOFR Reference Rate as part of the inter-bank offer rate reform. This change did not have a material financial impact. Interest rate profile of financial assets / liabilities The interest rate profile of financial assets/liabilities of the Group was as follows: December 31, 2022 US$‘000 December 31, 2021 US$‘000 Variable rate instruments Cash at bank and in hand 6,578 22,790 Short-term deposits - 3,120 Variable rate financial liabilities (senior secured term loan) (44,301 ) - (37,723 ) 25,910 Fixed rate instruments Fixed rate financial liabilities (exchangeable note) (210 ) (83,312 ) Fixed rate financial liabilities (convertible note) (13,746 ) - Fixed rate financial liabilities (borrowings) - (31 ) Fixed rate financial liabilities (lease payables) (13,943 ) (15,844 ) Financial assets (short-term deposits and short-term investments) - 3,121 Financial assets (lease receivables) 170 293 (27,729 ) (95,773 ) Fair value sensitivity analysis for fixed rate instruments The Group does not account for any fixed rate financial liabilities at fair value through profit and loss. Therefore, a change in interest rates at December 31, 2022 or December 31, 2021 would not affect profit or loss. There was no significant difference between the fair value and carrying value of the Group’s trade receivables and trade and other payables at December 31, 2022 and December 31, 2021 as all fell due within 6 months. Liquidity risk The following are the contractual maturities of financial liabilities, including estimated interest payments: As at December 31, 2022 US$’000 Carrying US$’000 Contractual US$’000 6 mths or US$’000 6 mths – 12 mths US$’000 1-2 years US$’000 2-5 years US$’000 >5 years US$’000 Financial liabilities Trade & other payables 15,261 15,261 15,261 - - - - Lease payable on Right of Use assets 13,898 17,196 1,120 1,130 2,240 5,739 6,967 Lease payable on sale & leaseback transactions 45 46 36 10 - - - Senior secured term loan 44,301 69,519 4,194 3,595 7,190 54,540 - Convertible note 13,746 21,900 150 150 300 900 20,400 Exchangeable notes 210 397 4 4 8 24 357 87,461 124,319 20,765 4,889 9,738 61,203 27,724 The contractual cash flows of interest on the senior secured term loan is estimated based on the prevailing interest rate at December 31, 2022 As at December 31, 2021 US$’000 Carrying US$’000 Contractual US$’000 6 mths or US$’000 6 mths – 12 mths US$’000 1-2 years US$’000 2-5 years US$’000 >5 years US$’000 Financial liabilities Trade & other payables 15,127 15,127 15,127 - - - - Lease payable on Right of Use assets 15,668 15,668 973 905 1,554 4,516 7,720 Lease payable on sale & leaseback transactions 177 177 51 51 75 - - Other borrowings 31 31 - 31 - - - Exchangeable notes ¹ 83,312 99,900 - - - - 99,900 Exchangeable note interest 999 93,906 1,998 1,998 3,996 11,988 73,926 115,314 224,809 18,149 2,985 5,625 16,504 181,546 ¹ The maturity of the Exchangeable Notes is based on the contractual maturity date of April 1, 2045. Foreign exchange risk The majority of the Group’s activities are conducted in US Dollars. Foreign exchange risk arises from the fluctuating value of the Group’s Euro denominated expenses as a result of the movement in the exchange rate between the US Dollar and the Euro. There were no forward contracts in place as at December 31, 2022 or December 31, 2021. Foreign currency financial assets and liabilities which expose the Group to currency risk are disclosed below. The amounts shown are those reported to key management translated into US Dollars at the closing rate: EUR GBP SEK CAD BRL Other As at December 31, 2022 US$‘000 US$‘000 US$‘000 US$‘000 US$‘000 US$‘000 Cash 700 199 5 2,061 756 - Trade and other receivable 1,001 27 - 950 1,443 - Trade and other payables (3,481 ) (5 ) (6 ) (473 ) (662 ) - Lease liabilities (9,024 ) - - - (277 ) - Total exposure (10,804 ) 221 (1 ) 2,538 1,260 - EUR GBP SEK CAD BRL Other As at December 31, 2021 US$‘000 US$‘000 US$‘000 US$‘000 US$‘000 US$‘000 Cash 327 115 5 4,617 1,370 - Trade and other receivable 464 58 - 488 1,538 - Trade and other payables (2,456 ) (28 ) (11 ) (166 ) (629 ) - Lease liabilities (10,629 ) - - - (139 ) - Total exposure (12,294 ) 145 (6 ) 4,939 2,140 - Sensitivity analysis A 10% strengthening of the US Dollar against the Euro at December 31, 2022 would have increased profit and other equity by the amounts shown below. This analysis assumes that all other variables, in particular interest rates, remain constant. Profit or Loss US$’000 December 31, 2022 Euro 982 December 31, 2021 Euro 780 A 10% weakening of the US Dollar against the Euro at December 31, 2022 would have decreased profit and other equity by the amounts shown below. This analysis assumes that all other variables, in particular interest rates, remain constant. Profit or Loss US$000 December 31, 2022 Euro (1,200 ) December 31, 2021 Euro (953 ) Credit Risk The Group has no significant concentrations of credit risk. Exposure to credit risk is monitored on an ongoing basis. The Group maintains specific provisions for potential credit losses. To date such losses have been within management’s expectations. Due to the large number of customers and the geographical dispersion of these customers, the Group has no significant concentrations of accounts receivable. With respect to credit risk arising from the other financial assets of the Group, which comprise cash and cash equivalents, the Group’s exposure to credit risk arises from default of the counterparty, with a maximum exposure equal to the carrying amount of these instruments. The Group’s management considers that all of the above financial assets that are not impaired or past due for each of the 31 December reporting dates under review are of good credit quality. The Group maintains cash and cash equivalents with various financial institutions. The Group performs regular and detailed evaluations of these financial institutions to assess their relative credit standing. The carrying amount reported in the balance sheet for cash and cash equivalents approximate their fair value. Exposure to credit risk The carrying amount of financial assets represents the maximum credit exposure. The maximum exposure to credit risk is as follows: Carrying Value 2022 Carrying Value 2021 Third party trade receivables (Note 16) 12,620 13,290 Finance lease income receivable (Note 16) 170 293 Cash and cash equivalents (Note 17) 6,578 25,910 19,368 39,493 The maximum exposure to credit risk for trade receivables and finance lease income receivable by geographic location is as follows: Carrying Value 2022 Carrying Value 2021 United States 6,061 5,822 Euro-zone countries 1,183 1,072 United Kingdom 67 118 Other regions 5,479 6,571 12,790 13,583 The maximum exposure to credit risk for trade receivables and finance lease income receivable by type of customer is as follows: Carrying Value 2022 Carrying Value 2021 End-user customers 7,365 6,923 Distributors 4,630 6,220 Non-governmental organisations 795 440 12,790 13,583 Due to the large number of customers and the geographical dispersion of these customers, the Group has no significant concentrations of accounts receivable. Impairment Losses The ageing of trade receivables at December 31, 2022 is as follows: Gross Impairment Expected Credit Loss Rate Gross Impairment Expected Credit Loss Rate 2022 2022 2022 2021 2021 2021 US$’000 US$’000 % US$’000 US$’000 % Not past due 8,341 - - % 8,461 - - % Past due 0-30 days 1,622 - - % 2,423 1 0.1 % Past due 31-120 days 1,564 23 1.5 % 1,981 97 4.9 % Greater than 120 days 3,783 2,668 70.5 % 3,011 2,888 73.0 % 15,310 2,691 - 15,876 2,986 - The movement in the allowance for impairment in respect of trade receivables during the year was as follows: 2022 2021 US$’000 US$’000 Balance at January 1 2,986 3,922 Charged to costs and expenses 1,240 76 Amounts written off during the year (1,535 ) (1,012 ) Balance at December 31 2,691 2,986 The allowance for impairment in respect of trade receivables is used to record impairment losses unless the Group is satisfied that no recovery of the account owing is possible. At this point the amount is considered irrecoverable and is written off against the financial asset directly.

RECONCILIATION OF LIABILITIES A

RECONCILIATION OF LIABILITIES ARISING FROM FINANCING ACTIVITIES	12 Months Ended
	Dec. 31, 2022
Disclosure of reconciliation of liabilities arising from financing activities [abstract]
RECONCILIATION OF LIABILITIES ARISING FROM FINANCING ACTIVITIES	27. RECONCILIATION OF LIABILITIES ARISING FROM FINANCING ACTIVITIES The changes in the Group’s liabilities arising from financing activities can be classified as follows: Note Borrowings & derivative financial instruments Lease liabilities Balance at January 1, 2022 20,22,23 83,343 15,845 Cash-flows: Principal amount loaned – term loan 81,250 Principal amount loaned – convertible note 20,000 - Loan origination costs paid (3,591 ) - Interest paid for term loan (6,424 ) - Interest paid for convertible note (199 ) Interest paid for exchangeable notes (1,293 ) Repayment of exchangeable notes (86,730 ) Repayment of term loan (34,500 ) Repayment of CEBA loan (23 ) (2,761 ) Penalty paid for early settlement of term loan (3,450 ) - Non-cash: Interest charged 7,914 - Penalty for early settlement charged 3,450 - Shares issued as consideration for purchase of Exchangeable Notes (6,133 ) - Equity component of convertible note at date of issue (6,709 ) - Derivative financial asset at date of issue 202 - Loss on disposal of Exchangeable Notes 9,678 - Additions (related to Right of Use assets) - 830 Exchange adjustment - (628 ) Loan forgiven (7 ) - Accretion interest 3,351 657 Fair value of derivative liability - warrants (303 ) - Balance at December 31, 2022 22,23 59,826 13,943 Note Borrowings & derivative financial instruments Lease liabilities Balance at January 1, 2021 20, 22,23 84,065 18,741 Cash-flows: Interest paid (3,996 ) (11 ) Repayment - (2,939 ) Non-cash: - Interest charged 3,996 - Additions (related to Right of Use assets) - 71 Exchange adjustment - (820 ) Accretion interest 648 803 Fair value 6 (1,370 ) - Balance at December 31, 2021 22,23 83,343 15,845

POST BALANCE SHEET EVENTS

POST BALANCE SHEET EVENTS	12 Months Ended
	Dec. 31, 2022
Disclosure of non-adjusting events after reporting period [abstract]
POST BALANCE SHEET EVENTS	28. POST BALANCE SHEET EVENTS Strategic Partnership with imaware TM On January 9, 2023, a subsidiary of the Company entered into a strategic partnership with imaware, Inc. (“imaware”) that combines their built-to-partner digital health platform with Trinity Biotech’s advanced reference laboratory facilities to power the Digital Health Industry with at-home and remote testing programs. A subsidiary of the Company entered into a 5-year agreement to become the lab testing partner for imaware, starting later in 2023. In connection with the arrangement, a subsidiary of the Company committed to make a US$1.5 million convertible note investment in imaware. Our New York reference laboratory will have additional capacity for the increased testing volumes resulting from this strategic partnership since an existing customer, a local healthcare provider to whom our laboratory has provided transplant testing services, informed the Company recently that it was moving to a different service provider. Amendment and restatement of Term Loan On February 21, 2023, the Company and certain of its subsidiaries entered into an amended and restated senior secured term loan credit facility with Perceptive. The amendment to the Term Loan allows for an immediate US$5.0 million increase to its outstanding term loan and provides for a US$20 million facility to fund potential acquisitions. In connection with the increased Term Loan facility, the Company agreed to reprice the 2,500,000 warrants originally issued to Perceptive under the Term Loan, with the Warrants now having a per ADS price of US$1.071 compared to their initial per ADS exercise price of US$1.30. The financial impact of the repricing of the warrants is not yet known. TrinScreen HIV’s inclusion in the new Kenyan HIV testing algorithm On March 22, 2023, the Kenyan Ministry of Health announced the adoption of a new HIV rapid testing algorithm. This new algorithm establishes Trinity Biotech’s TrinScreen HIV as the screening testing. The Kenyan HIV screening programme is one of the largest in Africa, with an estimated annual number of screening tests of between 7 million and 9 million. Trinity Biotech has been preparing for large scale manufacturing of TrinScreen HIV at its automated WHO standard, ISO13485 certified lateral flow test facility in Bray, Ireland and the Company expects to scale workforce capacity at the facility in the second quarter of 2023 as orders ramp up. Divestiture of Fitzgerald Life Sciences business and partial repayment of term loan On April 20, 2023, the Company announced it had entered into an agreement to sell its Fitzgerald Industries life sciences supply business, consisting of Benen Trading Ltd and Fitzgerald Industries International, Inc, to Biosynth for cash proceeds of approximately US$30 million subject to customary adjustments. The Fitzgerald life sciences supply business generated revenue of approximately US$12 million in the year ended 31 December 2022, and was EBITDA positive. The cash proceeds from Biosynth includes funding to Fitzgerald Industries to allow it repay intercompany loans owed to Trinity Biotech. The Fitzgerald Industries life sciences supply business is included in the Rest of World - Ireland segment in the Company’s segmental disclosures. Management considered that life sciences supply was no longer core to the Group’s refined long-term strategy and pursued this transaction as part of its plan to transform into a high growth innovator in diabetes care and decentralised diagnostic solutions. On April 27, 2023 the Company announced it had closed the sale of Fitzgerald Industries. The Company has used approximately US$11 million of the proceeds of this sale to repay approximately US$10.1 million of its senior secured debt held by Perceptive plus an approximately US$0.9 million early repayment penalty. In connection with this transaction, the Company has entered into an amendment to its senior secured term loan credit facility with Perceptive Advisors, which significantly reduces the Company’s minimum revenue covenants under that loan.

ACCOUNTING ESTIMATES AND JUDGEM

ACCOUNTING ESTIMATES AND JUDGEMENTS	12 Months Ended
	Dec. 31, 2022
Disclosure of accounting estimates and judgements [Abstract]
ACCOUNTING ESTIMATES AND JUDGEMENTS	29. ACCOUNTING ESTIMATES AND JUDGEMENTS The preparation of these financial statements requires the Group to make estimates and judgements that affect the reported amount of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an on-going basis, the Group evaluates these estimates, including those related to intangible assets, contingencies and litigation. The estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgements about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. Key sources of estimation uncertainty Note 12 contains information about the assumptions and the risk factors relating to goodwill impairment. Note 19 outlines information regarding the valuation of share options. Note 22 outlines the valuation techniques used by the Company in determining the fair value of the Group’s interest-bearing loans and borrowings. In Note 26, detailed analysis is given about the interest rate risk, credit risk, liquidity risk and foreign exchange risk of the Group. Critical accounting judgements in applying the Group’s accounting policies Certain critical accounting judgements in applying the Group’s accounting policies are described below: Revenue Recognition No revenue is recognised if there is uncertainty regarding recovery of the consideration due at the outset of the transaction. We make a judgement as to the collectability of invoiced sales based on an assessment of the individual debtor taking into account past payment history, the probability of default or delinquency in payments and the probability that debtor will enter into financial difficulties or bankruptcy. Some customer contracts could be regarded as offering the customer a right of return. Due to the uncertainty of the magnitude and likelihood of product returns, there is a level of estimation involved in assessing the amount of revenue to be recognized for these types of contracts. In accordance with IFRS 15, when estimating the effect of an uncertainty on an amount of variable consideration to which the Group will be entitled, all information that is reasonably available, including historical, current and forecast, is considered. We operate a licenced reference laboratory in New York, USA that specializes in diagnostics for autoimmune diseases. The laboratory provides testing services to two types of customers. Firstly, institutional customers, such as hospitals and commercial diagnostic testing providers, and secondly insurance companies on behalf of their policyholders. The revenue recognition for services provided to insurance companies requires some judgement. In the US, there are rules requiring all insurance companies to be billed the same amount per test. However, the amount that each insurance company pays for a particular test varies according to their own internal policies and this can typically be considerably less than the amount invoiced. We recognise lab services revenue for insurance companies by taking the invoiced amount and reducing it by an estimated percentage based on historical payment data. We review the percentage reduction annually based on the latest data. As a practical expedient, and in accordance with IFRS, we apply a portfolio approach to the insurance companies as they have similar characteristics. We judge that the effect on the financial statements of using a portfolio approach for the insurance companies will not differ materially from applying IFRS 15 to the individual contracts within that portfolio. At December 31, 2022 US$114,000 (2021: US$141,000) (2020: US$4,445,000) of revenue was deferred in accordance with IFRS15. For further information, refer to Note 20. Research and development expenditure – capitalized development costs Under IFRS as issued by IASB, the Group writes off research and development expenditure as incurred, with the exception of expenditure on projects whose outcome has been assessed with reasonable certainty as to technical feasibility, commercial viability and recovery of costs through future revenues. Such expenditure is capitalised at cost within intangible assets and amortised over its expected useful life of 15 years, which commences when commercial production starts. For further information, refer to Note 12. Acquired in-process research and development (IPR&D) is valued at its fair value at acquisition date in accordance with IFRS 3. The Company determines this fair value by adopting the income approach valuation technique. Once the fair value has been determined, the Company will recognise the IPR&D as an intangible asset when it: (a) meets the definition of an asset and (b) is identifiable (i.e., is separable or arises from contractual or other legal rights). Factors which impact our judgement to capitalise certain research and development expenditure include the degree of regulatory approval for products and the results of any market research to determine the likely future commercial success of products being developed. We review these factors each year to determine whether our previous estimates as to feasibility, viability and recovery should be changed. At December 31, 2022 the carrying value of capitalised development costs was US$17,008,000 (2021: US$17,679,000) (see Item 18, Note 12 to the consolidated financial statements). The decrease in 2022 was mainly as a result, an impairment charge of US$4,623,000 and amortisation of US$479,000, partially offset by additions of US$4,475,000. Impairment of intangible assets and goodwill Definite lived intangible assets are reviewed for indicators of impairment periodically while goodwill and indefinite lived assets are tested for impairment at least annually, individually or at the cash-generating unit level. Factors considered important, as part of an impairment review, include the following: • Significant underperformance relative to expected historical or projected future operating results; • Significant changes in the manner of our use of the acquired assets or the strategy for our overall business; • Obsolescence of products; • Significant decline in our stock price for a sustained period; and • Our market capitalisation relative to net book value. When we determine that the carrying value of intangibles, non-current assets and related goodwill may not be recoverable based upon the existence of one or more of the above indicators of impairment, any impairment is measured based on our estimates of projected net discounted cash flows expected to result from that asset, including eventual disposition. Our estimated impairment could prove insufficient if our analysis overestimated the cash flows or conditions change in the future. The impairment testing performed during the year ended December 31, 2022 identified an impairment loss in three CGUs, namely Biopool US Inc, Clark Laboratories Inc, and Trinity Biotech Do Brasil totalling US$1.2 million. For further information, refer to Note 12. Allowance for slow-moving and obsolete inventory We evaluate the realisability of our inventory on a case-by-case basis and make adjustments to our inventory provision based on our estimates of expected losses. We write off inventory that is approaching its “use-by” date and for which no further re-processing can be performed. We also consider recent trends in revenues for various inventory items and instances where the realisable value of inventory is likely to be less than its carrying value. Given the allowance is calculated on the basis of the actual inventory on hand at the particular balance sheet date, there were no material changes in estimates made during 2022, 2021 or 2020 which would have an impact on the carrying values of inventory during those periods, except as discussed below. At December 31, 2022 our allowance for slow moving and obsolete inventory was US$16.3 million which represents approximately 42.0% of gross inventory value. At December 31, 2021 our allowance for slow moving and obsolete inventory was US$12.1 million which represented approximately 29.3% of gross inventory value and at December 31, 2020 the provision was US$9.8 million, or approximately 24.5% of gross inventory value. The estimated allowance for slow moving and obsolete inventory as a percentage of gross inventory has increased between 2022 and 2021 due to significant increases in the provision for the following categories of inventory: (i) VTM inventory – there has been no evidence during the winter season of 2022-23 of significant peaks in demand for VTM products. This has led management to revisit the strategy of maintaining significant levels of raw materials inventory to meet demand peaks. Consequently, the provision for this inventory was increased by US$3.5 million in 2022 reflecting our estimate of its net realisable value. (ii) Tri-stat inventory – the Company undertook a strategic review of our Tri-stat instrument line as part of a broader review of our haemoglobins product portfolio. Management decided to limit sales of Tri-stat to certain targeted partnerships and as a consequence the value of this inventory was written down by US0.3 million to reflect the revised outlook. (iii) Raw materials and work in progress failing to meet our revised quality policy - the value of certain excess raw materials and work in progress was written down by US$0.9 million in 2022 following a review and an update to our relevant quality assurance policy. Management is satisfied that the assumptions made with respect to future sales and production levels of these products are reasonable to ensure the adequacy of this provision. In the event that the estimate of the provision required for slow moving and obsolete inventory was to increase or decrease by 2% of gross inventory, which would represent a reasonably likely range of outcomes, then a change in allowance of US$0.8 million at December 31, 2022 (2021: US$0.8 million) (2020: US$0.8 million) would result. For further information, refer to Note 15. Going Concern The directors have considered the Group’s current financial position and cash flow projections, taking into account all known events and developments. The directors believe that the Group will be able to continue its operations for at least the next 12 months from the date of this report and that it is appropriate to continue to prepare the consolidated financial statements on a going concern basis. At December 31, 2022, the Group had net current assets of US$29.3 million. At the date of this report, the Group’s liquidity position has substantially improved following the sale of its Fitzgerald life sciences business for cash proceeds of approximately US$30 million (subject to customary adjustments). This transaction substantially improves the Group’s capital structure by reducing gross debt by approximately US$10 million; with the balance of the proceeds (net of costs) providing significant capital for growth, transformation, and potentially further debt reduction. There are no material debt maturities until 2026.

GROUP UNDERTAKINGS

GROUP UNDERTAKINGS	12 Months Ended
	Dec. 31, 2022
Disclosure of group undertakings [Abstract]
GROUP UNDERTAKINGS	30. GROUP UNDERTAKINGS The consolidated financial statements include the financial statements of Trinity Biotech plc and the following principal subsidiary undertakings: Name and registered office Principal activity Principal Country of Group % holding Trinity Biotech Manufacturing Limited IDA Business Park, Bray County Wicklow, Ireland Manufacture and sale Ireland 100% Trinity Research Limited IDA Business Park, Bray County Wicklow, Ireland Research and Ireland 100% Benen Trading Limited IDA Business Park, Bray County Wicklow, Ireland Trading Ireland 100% Trinity Biotech Manufacturing Services Limited IDA Business Park, Bray County Wicklow, Ireland Dormant Ireland 100% Trinity Biotech Luxembourg Sarl 1, rue Bender, L-1229 Luxembourg Investment and Luxembourg 100% Trinity Biotech Inc Girts Road, Jamestown, NY 14702, USA Holding Company U.S.A. 100% Clark Laboratories Inc Trading as Trinity Biotech (USA) Girts Road, Jamestown NY14702, USA Manufacture and sale U.S.A. 100% Mardx Diagnostics Inc 5919 Farnsworth Court Carlsbad CA 92008, USA Dormant U.S.A. 100% Fitzgerald Industries International, Inc 2711 Centerville Road, Suite 400 Wilmington, New Castle Delaware, 19808, USA Management services U.S.A. 100% Biopool US Inc (trading as Trinity Biotech Distribution) Girts Road, Jamestown NY14702, USA Sale of diagnostic test U.S.A. 100% Primus Corporation 4231 E 75 th Kansas City, MO 64132, USA Manufacture and sale U.S.A. 100% Name and registered office Principal activity Principal Country of Group % holding Phoenix Bio-tech Corp. 1166 South Service Road West Oakville, ON L6L 5T7 Canada. Dormant Canada 100% Fiomi Diagnostics Holding AB Dag Hammarskjöldsv 52A SE-752 37 Uppsala Sweden Holding Company Sweden 100% Fiomi Diagnostics AB Dag Hammarskjöldsv 52A SE-752 37 Uppsala Sweden Discontinued operation Sweden 100% Trinity Biotech Do Brasil Comercio e Importacao Ltda Rua Silva Bueno 1.660 – Cj. 101/102 Ipiranga Sao Paulo Brazil Sale of diagnostic test Brazil 100% Trinity Biotech (UK) Ltd Mills and Reeve LLP Botanic House 100 Hills Road Cambridge, CB2 1PH United Kingdom Sales & marketing UK 100% Immco Diagnostics Inc 60 Pineview Drive Buffalo NY 14228, USA Manufacture and sale of U.S.A. 100% Nova Century Scientific Inc 5022 South Service Road Burlington Ontario Canada Manufacture and sale of Canada 100% Trinity Biotech Investment Ltd PO Box 309 Ugland House Grand Cayman KY1-1104 Cayman Islands Investment and Cayman Islands 100%

AUTHORISATION FOR ISSUE

AUTHORISATION FOR ISSUE	12 Months Ended
	Dec. 31, 2022
Disclosure of authorisation for issue [Abstract]
AUTHORISATION FOR ISSUE	31. AUTHORISATION FOR ISSUE These Group consolidated financial statements were authorised for issue by the Board of Directors on May 16, 2023.

BASIS OF PREPARATION AND SIGN_2

BASIS OF PREPARATION AND SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Dec. 31, 2022
Disclosure of basis of preparation and significant accounting policies [Abstract]
General information	i) General information Trinity Biotech develops, acquires, manufactures and markets medical diagnostic products for the clinical laboratory and point-of-care segments of the diagnostic market. These products are used to detect autoimmune, infectious and sexually transmitted diseases, diabetes and disorders of the liver and intestine. Trinity Biotech is a significant provider of raw materials to the life sciences and research industries globally. Trinity Biotech also operates a licenced reference laboratory that specializes in diagnostics for autoimmune diseases.
Statement of compliance	ii) Statement of compliance The consolidated financial statements have been prepared in accordance with International Financial Reporting Standards (“IFRS”) both as issued by the International Accounting Standards Board (“IASB”) and as subsequently adopted by the European Union (“EU”) (together “IFRS”). The IFRS applied are those effective for accounting periods beginning January 1, 2022. Consolidated financial statements are required by Irish law to comply with IFRS as adopted by the EU which differ in certain respects from IFRS as issued by the IASB. These differences predominantly relate to the timing of adoption of new standards by the EU. However, in relation to the 2022 consolidated financial statements there are no differences regarding the effective date of new IFRS relevant to Trinity Biotech as issued by the IASB and as adopted by the EU. In relation to prior periods presented, none of the differences are relevant in the context of Trinity Biotech and the consolidated financial statements comply with IFRS both as issued by the IASB and as adopted by the EU.
Basis of preparation	iii) Basis of preparation The consolidated financial statements have been prepared in United States Dollars (US$), rounded to the nearest thousand, under the historical cost basis of accounting, except for derivative financial instruments, certain balances arising on acquisition of subsidiary entities and share-based payments which are initially recorded at fair value. Derivative financial instruments are also subsequently revalued and carried at fair value. The preparation of financial statements in conformity with IFRS requires management to make judgements, estimates and assumptions that affect the application of policies and amounts reported in the financial statements and accompanying notes. The estimates and associated assumptions are based on historical experience and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis of making the judgements about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates. The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised if the revision affects only that period or in the period of the revision and future periods if the revision affects both current and future periods. Judgements made by management that have a significant effect on the financial statements and estimates with a significant risk of material adjustment in the next year are discussed in Note 29. The directors have considered the Group’s current financial position and cash flow projections, taking into account all known events and developments. The directors believe that the Group will be able to continue its operations for at least the next 12 months from the date of this report and that it is appropriate to continue to prepare the consolidated financial statements on a going concern basis. At December 31, 2022, the Group had net current assets of US$29.3 million. At the date of this report, the Group’s liquidity position has substantially improved following the sale of its Fitzgerald life sciences business for cash proceeds of approximately US$30 million (subject to customary adjustments). This transaction substantially improves the Group’s capital structure by reducing gross debt by approximately US$10 million; with the balance of the proceeds (net of costs) providing significant capital for growth, transformation, and potentially further debt reduction. There are no material debt maturities until 2026. The accounting policies set out below have been applied consistently to all periods presented in these consolidated financial statements. The accounting policies have been applied consistently by all Group entities.
Basis of consolidation	iv) Basis of consolidation Subsidiaries Subsidiaries are entities controlled by the Company. Control exists when the Company has the power, directly or indirectly, to govern the financial and reporting policies of an entity so as to obtain benefits from its activities. In assessing control, potential voting rights that presently are exercisable or convertible are taken into account. The financial statements of subsidiaries are included in the consolidated financial statements from the date that control commences until the date that control ceases. Transactions eliminated on consolidation Intra-group balances and any unrealised gains or losses or income and expenses arising from intra-group transactions are eliminated in preparing the consolidated financial statements.
Property, plant and equipment	v) Property, plant and equipment Owned assets Items of property, plant and equipment are stated at cost less any accumulated depreciation and any impairment losses (see Note 1(viii)). The cost of self-constructed assets includes the cost of materials, direct labour and attributable overheads. It is not Group policy to revalue any items of property, plant and equipment. Depreciation is charged to the statement of operations on a straight-line basis to write-off the cost of the assets over their expected useful lives as follows: • Leasehold improvements 5-15 years • Buildings 50 years • Office equipment and fittings 10 years • Computer equipment 3-5 years • Plant and equipment 5-15 years Land is not depreciated. The residual values, if not insignificant, useful lives and depreciation methods of property, plant and equipment are reviewed and adjusted if appropriate on a prospective basis, at each balance sheet date. There were no changes to useful lives in the year. The Group considers whether a contract is or contains a lease. A lease is defined as ‘a contract, or part of a contract, that conveys the right to use an asset (the underlying asset) for a period of time in exchange for consideration’. To apply this definition the Group assesses whether the contract meets three key evaluations which are whether: • the contract contains an identified asset, which is either explicitly identified in the contract or implicitly specified by being identified at the time the asset is made available to the Group • the Group has the right to obtain substantially all of the economic benefits from use of the identified asset throughout the period of use, considering its rights within the defined scope of the contract • the Group has the right to direct the use of the identified asset throughout the period of use. The Group assess whether it has the right to direct ‘how and for what purpose’ the asset is used throughout the period of use. At lease commencement date, the Group recognises a right-of-use asset and a lease liability on the balance sheet. The right-of-use asset is measured at cost, which is made up of the initial measurement of the lease liability, any initial direct costs incurred by the Group, an estimate of any costs to dismantle and remove the asset at the end of the lease, and any lease payments made in advance of the lease commencement date (net of any incentives received). The Group depreciates the right-of-use assets on a straight-line basis from the lease commencement date to the earlier of the end of the useful life of the right-of-use asset or the end of the lease term. The Group also assesses the right-of-use asset for impairment when such indicators exist. At the commencement date, the Group measures the lease liability at the present value of the lease payments unpaid at that date, discounted using the interest rate implicit in the lease if that rate is readily available or the Group’s incremental borrowing rate. Lease payments included in the measurement of the lease liability are made up of fixed payments (including in substance fixed), variable payments based on an index or rate, amounts expected to be payable under a residual value guarantee and payments arising from options reasonably certain to be exercised. Subsequent to initial measurement, the liability will be reduced for payments made and increased for interest. It is remeasured to reflect any reassessment or modification, or if there are changes in in-substance fixed payments. When the lease liability is remeasured, the corresponding adjustment is reflected in the right-of-use asset, or profit and loss if the right-of-use asset is already reduced to zero. The Group has elected to account for short-term leases and leases of low-value assets using the practical expedients. Instead of recognising a right-of-use asset and lease liability, the payments in relation to these are recognised as an expense in profit or loss on a straight-line basis over the lease term. On the statement of financial position, right-of-use assets have been included in property, plant and equipment and lease liabilities have been included in separate lines within the current liabilities and non-current liabilities sections. Leased assets - as lessor The Group’s accounting policy under IFRS 16 has not changed from the comparative period. As a lessor, the Group classifies its leases as either operating or finance leases. A lease is classified as a finance lease if it transfers substantially all the risks and rewards incidental to ownership of the underlying asset, and classified as an operating lease if it does not.
Goodwill	vi) Goodwill In respect of business combinations that have occurred since January 1, 2004 (being the transition date to IFRS), goodwill represents the difference between the cost of the acquisition and the fair value of the net identifiable assets acquired. In respect of acquisitions prior to this date, goodwill is included on the basis of its deemed cost, which represents the amount recorded under the old basis of accounting, Irish GAAP, (“Previous GAAP”). Save for retrospective restatement of deferred tax as an adjustment to retained earnings in accordance with IAS 12, Income Taxes, To the extent that the Group’s interest in the net fair value of the identifiable assets, liabilities and contingent liabilities acquired exceeds the cost of a business combination, the identification and measurement of the related assets, liabilities and contingent liabilities are revisited accompanied by a reassessment of the cost of the transaction, and any remaining balance is immediately recognised in the statement of operations. At the acquisition date, any goodwill is allocated to each of the cash-generating units expected to benefit from the combination’s synergies. Following initial recognition, goodwill is stated at cost less any accumulated impairment losses (see Note 1(viii)).
Intangibles, including research and development (other than goodwill)	vii) Intangibles, including research and development (other than goodwill) An intangible asset, which is an identifiable non-monetary asset without physical substance, is recognised to the extent that it is probable that the expected future economic benefits attributable to the asset will flow to the Group and that its cost can be measured reliably. The asset is deemed to be identifiable when it is separable (that is, capable of being divided from the entity and sold, transferred, licenced, rented or exchanged, either individually or together with a related contract, asset or liability) or when it arises from contractual or other legal rights, regardless of whether those rights are transferable or separable from the Group or from other rights and obligations. Intangible assets acquired as part of a business combination are capitalised separately from goodwill if the intangible asset meets the definition of an asset and the fair value can be reliably measured on initial recognition. Subsequent to initial recognition, these intangible assets are carried at cost less any accumulated amortisation and any accumulated impairment losses (Note 1(viii)). Intangible assets with definite useful lives are reviewed for indicators of impairment annually while intangible assets with indefinite useful lives and those not yet brought into use are tested for impairment at least annually, either individually or at the cash-generating unit level. Expenditure on development activities, whereby research findings are applied to a plan or design for the production of new or substantially improved products and processes, is capitalised if the product or process is technically and commercially feasible and the Group has sufficient resources to complete the development. The expenditure capitalised includes the cost of materials, direct labour and attributable overheads and third party costs. Subsequent expenditure on capitalised intangible assets is capitalised only when it increases the future economic benefits embodied in the specific asset to which it relates. The technical feasibility of a new product is determined by a specific feasibility study undertaken at the first stage of any development project. The majority of our new product developments involve the transfer of existing product know-how to a new application. Since the technology is already proven in an existing product which is being used by customers, this facilitates the proving of the technical feasibility of that same technology in a new product. The results of the feasibility study are reviewed by a design review committee comprising senior managers. The feasibility study occurs in the initial research phase of a project and costs in this phase are not capitalised. The commercial feasibility of a new product is determined by preparing a discounted cash flow projection. This projection compares the discounted sales revenues for future periods with the relevant costs. As part of preparing the cash flow projection, the size of the relevant market is determined, feedback is sought from customers and the strength of the proposed new product is assessed against competitors’ offerings. Once the technical and commercial feasibility has been established and the project has been approved for commencement, the project moves into the development phase. All other development expenditure is expensed as incurred. Subsequent to initial recognition, the capitalised development expenditure is carried at cost less any accumulated amortisation and any accumulated impairment losses (Note 1(viii)). Expenditure on research activities, undertaken with the prospect of gaining new scientific or technical knowledge and understanding, is recognised in the statement of operations as an expense as incurred. Expenditure on internally generated goodwill and brands is recognised in the statement of operations as an expense as incurred. Amortisation Amortisation is charged to the statement of operations on a straight-line basis over the estimated useful lives of intangible assets, unless such lives are indefinite. Intangible assets are amortised from the date they are available for use in its intended market. The estimated useful lives are as follows: • Capitalised development costs 15 years • Patents and licences 6-15 years • Other (including acquired customer and supplier lists) 6-15 years The Group uses a useful economic life of 15 years for capitalised development costs. This is a conservative estimate of the likely life of the products. The Group is confident that products have a minimum of 15 years life given the inertia that characterizes the medical diagnostics industry and the barriers to enter into the industry. The following factors have been considered in estimating the useful life of developed products: (a) once a diagnostic test becomes established, customers are reluctant to change to new technology until it is fully proven, thus resulting in relatively long product life cycles. There is also reluctance in customers to change to a new product as it can be costly both in terms of the initial changeover cost and as new technology is typically more expensive. (b) demand for the diagnostic tests is enduring and robust within a wide geographic base. The diseases that the products diagnose are widely prevalent (HIV, Diabetes and Chlamydia being just three examples) in many countries. There is a general consensus that these diseases will continue to be widely prevalent in the future. (c) there are significant barriers to new entrants in this industry. Patents and/or licences are in place for several of our products, though this is not the only barrier to entry. There is a significant cost and time to develop new products, it is necessary to obtain regulatory approval and tests are protected by proprietary know-how, manufacturing techniques and trade secrets. Certain trade names acquired are deemed to have an indefinite useful life as there is no foreseeable limit to the period over which these assets are expected to generate cash inflows for the Group. Where amortisation is charged on assets with finite lives, this expense is taken to the statement of operations through the ‘selling, general and administrative expenses’ line. Useful lives are examined on an annual basis and adjustments, where applicable, are made on a prospective basis.
Impairment	viii) Impairment The carrying amount of the Group’s assets, other than inventories, accounts receivable, cash and cash equivalents, short-term investments and deferred tax assets, are reviewed at each balance sheet date to determine whether there is any indication of impairment. If any such indication exists, the asset’s recoverable amount (being the greater of fair value less costs to sell and value in use) is assessed at each balance sheet date. Fair value less costs to sell is defined as the amount obtainable from the sale of an asset or cash-generating unit in an arm’s length transaction between knowledgeable and willing parties, less the costs that would be incurred on disposal. Value in use is defined as the present value of the future cash flows expected to be derived through the continued use of an asset or cash-generating unit. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset for which the future cash flow estimates have not yet been adjusted. The estimates of future cash flows exclude cash inflows or outflows attributable to financing activities. For an asset that does not generate largely independent cash flows, the recoverable amount is determined by reference to the cash-generating unit to which the asset belongs. For goodwill, assets that have an indefinite useful life and intangible assets that are not yet available for use, the recoverable amount is estimated at each balance sheet date at the cash-generating unit level. The goodwill and indefinite-lived assets were reviewed for impairment at December 31, 2021 and December 31, 2022. See Note 12. In-process research and development (IPR&D) is tested for impairment on an annual basis, in the periodically and always at year end, or more frequently if impairment indicators are present, using projected discounted cash flow models. If IPR&D becomes impaired or is abandoned, the carrying value of the IPR&D is written down to its revised fair value with the related impairment charge recognised in the period in which the impairment occurs. If the fair value of the asset becomes impaired as the result of unfavorable data from any ongoing or future clinical trial, changes in assumptions that negatively impact projected cash flows, or because of any other information regarding the prospects of successfully developing or commercializing our programs, we could incur significant charges in the period in which the impairment occurs. The valuation techniques utilized in performing impairment tests incorporate significant assumptions and judgments to estimate the fair value, as described above. The use of different valuation techniques or different assumptions could result in materially different fair value estimates. An impairment loss is recognised whenever the carrying amount of an asset or its cash-generating unit exceeds its recoverable amount. Impairment losses are recognised in the statement of operations. Impairment losses recognised in respect of cash-generating units are allocated first to reduce the carrying amount of any goodwill allocated to cash-generating units and then to reduce the carrying amount of other assets in the cash-generating units on a pro-rata basis. An impairment loss is reversed only to the extent that the asset’s carrying amount does not exceed the carrying amount that would have been determined, net of depreciation or amortisation, if no impairment loss had been recognised. An impairment loss in respect of goodwill is not reversed. Following recognition of any impairment loss (and on recognition of an impairment loss reversal), the depreciation or amortisation charge applicable to the asset or cash-generating unit is adjusted prospectively with the objective of systematically allocating the revised carrying amount, net of any residual value, over the remaining useful life.
Inventories	ix) Inventories Inventories are stated at the lower of cost and net realisable value. Cost is based on the first-in, first-out principle and includes all expenditure which has been incurred in bringing the products to their present location and condition and includes an appropriate allocation of manufacturing overhead based on the normal level of operating capacity. Net realisable value is the estimated selling price of inventory on hand in the ordinary course of business less all further costs to completion and costs expected to be incurred in selling these products. The Group provides for inventory, based on estimates of the expected realisability. The estimated realisability is evaluated on a case-by-case basis and any inventory that is approaching its “use-by” date and for which no further re-processing can be performed is written off. Any reversal of an inventory provision is recognised in the statement of operations in the year in which the reversal occurs.
Trade and other receivables	x) Trade and other receivables Trade receivables are amounts due from customers for products sold or services provided in the ordinary course of business. Trade and other receivables are stated at their amortised cost less impairment losses incurred. Cost approximates fair value given the short-term nature of these assets. The Group records the loss allowance as lifetime expected credit losses. These are the expected shortfalls in contractual cash flows, considering the potential for default at any point during the life of the financial instrument. Expected credit losses are recorded on all of trade receivables based on an assessment of the probability of default or delinquency in payments and the probability that debtor will enter into financial difficulties or bankruptcy.
Trade and other payables	xi) Trade and other payables Trade payables are obligations to pay for goods or services that have been acquired in the ordinary course of business. Trade and other payables are stated at cost. Cost approximates fair value given the short term nature of these liabilities.
Cash and cash equivalents	xii) Cash and cash equivalents Cash and cash equivalents comprise cash balances and short-term deposits which are readily available at year-end. Deposits with maturities less than six months as at the year-end date are recognised as cash and cash equivalents and are carried at fair value when there is no expected loss in value on early termination. The Group has no short-term bank overdraft facilities. Where restrictions are imposed by third parties, such as lending institutions, on cash balances held by the Group these are treated as financial assets in the financial statements.
Short-term investments	xiii) Short-term investments Short-term investments comprise short-term bank deposits which have maturities greater than six months as at the year-end date. Short-term deposits made for varying periods depending on the immediate cash requirements of the Group and earn interest at the respective deposit rates in place. Where restrictions are imposed by third parties, such as lending institutions, on short-term deposits held by the Group these are treated as financial assets in the financial statements.
Share-based payments	xiv) Share-based payments For equity-settled share-based payments (share options), the Group measures the services received and the corresponding increase in equity at fair value at the measurement date (which is the grant date) using a trinomial model. Given that the share options granted do not vest until the completion of a specified period of service, the fair value, which is assessed at the grant date, is recognised on the basis that the services to be rendered by employees as consideration for the granting of share options will be received over the vesting period. Certain share options have been granted for which there is a condition that the options only become exercisable into ADSs when the market price of an ADS reaches a certain level. This is deemed to be a non-vesting condition. The term ‘non-vesting condition’ is not explicitly defined in IFRS 2, Share based Payment, but is inferred to be any condition that does not meet the definition of a vesting condition. The only condition for these options to vest is that the option holder continues service and there were no other conditions which would be considered non-vesting conditions. Non-vesting conditions are reflected in measuring the grant-date fair value of the share-based payment and there is no true-up in the measurement of the share-based payment for differences between the expected and the actual outcome of non-vesting conditions. If all service conditions are met, then the share-based payment cost will be recognized even if the option holder does not receive the share-based payment due to a failure to meet the non-vesting condition. The expense in the consolidated statement of operations in relation to share options represents the product of the total number of options anticipated to vest and the fair value of those options; this amount is allocated to accounting periods on a straight-line basis over the vesting period. Share based payments, to the extent they relate to direct labour involved in development activities, are capitalised. The proceeds received net of any directly attributable transaction costs are credited to share capital (nominal value) and share premium when the options are exercised. The Group does not operate any cash-settled share-based payment schemes or share-based payment transactions with cash alternatives as defined in IFRS 2.
Government grants and financial support	xv) Government grants and financial support The Group received government-backed Covid-19 financial supports in the form of forgivable loans. Under IAS 20, Accounting for Government Grants, a forgivable loan from government is treated as a government grant when there is reasonable assurance that the terms for forgiveness of the loan will be met. Where a loan was received in the financial year but not yet forgiven within the financial year, the loan is treated as a current liability. The Group has opted to present government grant income for loans that have been forgiven as Other operating income in the consolidated statement of operations. Grants that compensate the Group for expenses incurred such as research and development, employment and training are recognised as income in the statement of operations on a systematic basis in the same periods in which the expenses are incurred. Grants that compensate the Group for the cost of an asset are recognised in the statement of operations as other operating income on a systematic basis over the useful life of the asset.
Revenue recognition	xvi) Revenue recognition Goods sold and services rendered The Group recognises revenue when it transfers control over a good or service to a customer. Revenue is recognised to the extent that it is probable that economic benefit will flow to the Group and the revenue can be measured. No revenue is recognised if there is uncertainty regarding recovery of the consideration due at the outset of the transaction. Revenue, including any amounts invoiced for shipping and handling costs, represents the value of goods and services supplied to external customers, net of discounts and rebates and excluding sales taxes. Revenue from products is generally recorded as of the date of shipment, consistent with typical ex-works shipment terms. Where the shipment terms do not permit revenue to be recognised as of the date of shipment, revenue is recognised when the Group has satisfied all of its performance obligations to the customer in accordance with the shipping terms. Some contracts oblige the Group to ship product to the customer ahead of the agreed payment schedule. For these shipments, a contract asset is recognised when control over the goods has transferred to the customer. The financing component is insignificant as invoicing for these shipments occurs within a short period of time after shipment has occurred and standard 30 day credit terms typically apply. The Group operates a licenced referenced laboratory in the US, which provides testing services to institutional customers and insurance companies. In the US, there are rules requiring all insurance companies to be billed the same amount per test. However, the amount that each insurance company pays for a particular test varies according to their own internal policies and this can typically be considerably less than the amount invoiced. We recognise lab services revenue for insurance companies by taking the invoiced amount and reducing it by an estimated percentage based on historical payment data. We review the percentage reduction annually based on the latest data. As a practical expedient, and in accordance with IFRS, we apply a portfolio approach to the insurance companies as they have similar characteristics. We judge that the effect on the financial statements of using a portfolio approach for the insurance companies will not differ materially from applying IFRS 15 to the individual contracts within that portfolio. Revenue from services rendered is recognised in the statement of operations in proportion to the stage of completion of the transaction at the balance sheet date. The Group leases instruments to customers typically as part of a bundled package. Where a contract has multiple performance obligations and its duration is greater than one year, the transaction price is allocated to the performance obligations in the contract by reference to their relative standalone selling prices. For contracts where control of the instrument is transferred to the customer, the fair value of the instrument is recognised as revenue at the commencement of the lease and is matched by the related cost of sale. Fair value is determined on the basis of standalone selling price. In the case where control of the instrument does not transfer to the customer, revenue is recognised on the basis of customer usage of the instrument. See also Item 18, Note 1(v). In obtaining these contracts, the Group incurs a number of incremental costs, such as sales bonus paid to sales staff commissions paid to distributors and royalty payments. As the amortisation period of these costs, if capitalised, would be less than one year, the Group makes use of the practical expedient in IFRS 15.94 and expenses them as they incur. A receivable is recognised when the goods are delivered as this is the point in time that the consideration is unconditional because only the passage of time is required before the payment is due. The Group’s obligation to provide a refund for faulty products under the standard warranty terms is recognised as a provision, see Item 18, Note 21 for details. Other operating income Other operating income includes income for the provision of canteen services. This income has not been treated as revenue since the canteen activities are incidental to the main revenue-generating activities of the Group. Other operating income also includes government-backed Covid-19 financial supports and government grant income. The accounting policy for this income is described in Note 1 (xv).
Employee benefits	xvii) Employee benefits Defined contribution plans The Group operates defined contribution schemes in various locations where its subsidiaries are based. Contributions to the defined contribution schemes are recognised in the statement of operations in the period in which the related service is received from the employee. Other long-term benefits Where employees participate in the Group’s other long-term benefit schemes (such as permanent health insurance schemes under which the scheme insures the employees), or where the Group contributes to insurance schemes for employees, the Group pays an annual fee to a service provider, and accordingly the Group expenses such payments as incurred. Termination benefits Termination benefits are recognised as an expense when the Group is demonstrably committed, without realistic possibility of withdrawal, to a formal detailed plan to either terminate employment before normal retirement date, or to provide termination benefits as a result of an offer made to encourage voluntary redundancy.
Foreign currency	xviii) Foreign currency A majority of the revenue of the Group is generated in US Dollars. The Group’s management has determined that the US Dollar is the primary currency of the economic environment in which the Company and its subsidiaries (with the exception of the Group’s subsidiaries in Brazil, Canada and Sweden) principally operate. Thus, the functional currency of the Company and its subsidiaries (other than the Brazilian, Canadian and Swedish subsidiaries) is the US Dollar. The functional currency of the Brazilian entity is the Brazilian Real, the functional currency of the Canadian subsidiary, Nova Century Scientific Inc, is the Canadian Dollar and the functional currency of the Swedish subsidiary is the Swedish Kroner. The presentation currency of the Company and Group is the US Dollar. Monetary assets and liabilities denominated in foreign currencies are translated at the rates of exchange ruling at the balance sheet date. The resulting gains and losses are included in the consolidated statement of operations. Non-monetary assets and liabilities that are measured in terms of historical cost in a foreign currency are translated using the exchange rate at the date of the transaction. Results and cash flows of subsidiary undertakings, which have a functional currency other than the US Dollar, are translated into US Dollars at average exchange rates for the year, and the related balance sheets have been translated at the rates of exchange ruling on the balance sheet date. Any exchange differences arising from the translations are recognised in the currency translation reserve via the statement of changes in equity. Where Euro, Brazilian Real, Canadian Dollar or Swedish Kroner amounts have been referenced in this document, their corresponding US Dollar equivalent has also been included and these equivalents have been calculated with reference to the foreign exchange rates prevailing at December 31, 2022.
Hedging	xix) Hedging The activities of the Group expose it primarily to changes in foreign exchange rates and interest rates. The Group uses derivative financial instruments, from time to time, such as forward foreign exchange contracts to hedge these exposures. The Group enters into forward contracts to sell US Dollars forward for Euro. The principal exchange risk identified by the Group is with respect to fluctuations in the Euro as a substantial portion of its expenses are denominated in Euro but its revenues are primarily denominated in US Dollars. Trinity Biotech monitors its exposure to foreign currency movements and may use these forward contracts as cash flow hedging instruments whose objective is to cover a portion of this Euro expense. At the inception of a hedging transaction entailing the use of derivatives, the Group documents the relationship between the hedged item and the hedging instrument together with its risk management objective and the strategy underlying the proposed transaction. The Group also documents its quarterly assessment of the effectiveness of the hedge in offsetting movements in the cash flows of the hedged items. Derivative financial instruments are recognised at fair value. Where derivatives do not fulfil the criteria for hedge accounting, they are classified as held-for-trading and changes in fair values are reported in the statement of operations. The fair value of forward exchange contracts is calculated by reference to current forward exchange rates for contracts with similar maturity profiles and equates to the current market price at the balance sheet date. The portion of the gain or loss on a hedging instrument that is deemed to be an effective cash flow hedge is recognised directly in the hedging reserve in equity and the ineffective portion is recognised in the statement of operations. As the forward contracts are exercised the net cumulative gain or loss recognised in the hedging reserve is transferred to the statement of operations and reflected in the same line as the hedged item.
Senior secured term loan	xxi) Senior secured term loan The senior secured term loan is initially recorded at the fair value of the consideration received net of: a) directly attributable transaction costs, b) the fair value at the date of issue of the warrants issued to the lender (see Note 1xxii) and c) the fair value of the option to prepay the loan at the date of issue (see Note 1xxii). Subsequent to initial recognition, the term loan is measured at amortised cost employing the effective interest methodology. Borrowing costs, including any penalties for early settlement of the loan, are recognised as an expense in the period in which they are incurred.
Warrants and loan prepayment option	xxii) Warrants and loan prepayment option The company issued warrants to Perceptive (“the warrants”) which are exercisable into ADSs of the Company at a fixed exercise price. The Warrants are exercisable, in whole or part, until the seventh anniversary of the date of drawdown of the funding. The warrants were issued to Perceptive in consideration of them entering into the term loan on the same date and Perceptive paid no other consideration to the company for the warrants issued. A warrant contract might be accounted for as an equity instrument or a financial liability under IFRS depending on the terms of a warrant. A warrant contract that will or might be settled by an entity by delivering a fixed number of its own equity instruments, in exchange for a fixed amount of cash or another financial asset, is an equity instrument. As Perceptive has the option to choose a cashless exercise option, the Company will have to deliver a variable number of ADS, since the number of shares will vary depending on the ADS traded price. Even though the cashless exercise option is economically comparable to the cash exercise option, the fact that the company will issue a variable number of shares under the cashless exercise option results in one settlement alternative violating the ‘fixed for fixed’ requirement. The warrant contract therefore meets the definition of a financial liability and given the value of the warrant changes in response to the price of the Company’s ADS, with no initial investment and settlement occurring in the future it meets the definition of a derivative liability under IFRS 9. The warrant is issued in a separate contract, is transferable independently of the term loan and can be exercised while the term loan remains outstanding. Therefore, the warrant is a separate instrument to the term loan. The warrant contracts are initially recognised as a derivative liability at fair value and subsequently measured at fair value at each reporting period with any changes recognised in the consolidated statement of operations. The Company has the option to prepay the senior secured term loan in whole or in part for an amount equal to the principal, accrued interest and prepayment premium. In accordance with IFRS 9, this option is separated from the term loan and is initially recognised as a derivative asset at fair value and subsequently measured at fair value at each reporting period with any changes recognised in the consolidated statement of operations.
Convertible Note	xxiii) Convertible Note The convertible note is accounted for as a compound financial instrument containing both an equity and liability element. The convertible note has a contractual obligation to deliver cash on redemption equal to the principal amount plus accrued interest and therefore has a liability component in line with the definition of a financial liability in IAS 32. The convertible loan note also has a conversion feature where it mandatorily converts into ADS if the volume weighted average price of the Company’s ADSs is at a certain price for any five consecutive NASDAQ trading days or any other time at the discretion of the Noteholder. Where a derivative that will or may be settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity's own equity instruments, the conversion feature represents an equity component of the convertible note. The equity component is measured as the residual amount that results from deducting the fair value of the liability component from the initial carrying amount of the instrument as a whole. There is no remeasurement of the equity element following initial recognition. The debt component is accounted for at amortised cost employing the effective interest methodology.
Segment reporting	xxiv) Segment reporting Operating segments are reported in a manner consistent with the internal reporting provided to the chief operating decision-maker. The chief operating decision-maker, who is responsible for allocating resources and assessing performance of the operating segments, has been identified as the Board of Directors.
Tax (current and deferred)	xxv) Tax (current and deferred) Income tax on the profit or loss for the year comprises current and deferred tax. Income tax is recognised in the consolidated statement of operations except to the extent that it relates to items recognised directly in equity, in which case it is recognised in equity. Current tax represents the expected tax payable or recoverable on the taxable profit for the year using tax rates enacted or substantively enacted at the balance sheet date in the countries where the company and its subsidiaries operate and generate income and taking into account any adjustments stemming from prior years. Deferred tax is provided on the basis of the balance sheet liability method on all temporary differences at the balance sheet date which is defined as the difference between the tax bases of assets and liabilities and their carrying amounts in the financial statements. Deferred tax assets and liabilities are not subject to discounting and are measured at the tax rates that are anticipated to apply in the period in which the asset is realised or the liability is settled based on tax rates and tax laws that have been enacted or substantively enacted at the balance sheet date. Deferred tax assets are recognised when it is probable that future taxable profits will be available to utilize the associated losses or temporary differences. The amount of deferred tax provided is based on the expected manner of realisation or settlement of the carrying amount of assets and liabilities. Deferred tax assets and liabilities are recognised for all temporary differences (that is, differences between the carrying amount of the asset or liability and its tax base) with the exception of the following: i. Where the deferred tax liability arises from goodwill not deductible for tax purposes or the initial recognition of an asset or a liability in a transaction that is not a business combination and affects neither the accounting profit nor the taxable profit or loss at the time of the transaction; and ii. Where, in respect of temporary differences associated with investments in subsidiary undertakings, the timing of the reversal of the temporary difference is subject to control and it is probable that the temporary difference will not reverse in the foreseeable future. Where goodwill is tax deductible, a deferred tax liability is not recognised on initial recognition of goodwill. It is recognised subsequently for the taxable temporary difference which arises when the goodwill is amortised for tax with no corresponding adjustment to the carrying value of the goodwill. The carrying amounts of deferred tax assets are subject to review at each balance sheet date and are derecognised to the extent that future taxable profits are considered to be inadequate to allow all or part of any deferred tax asset to be utilised.
Provisions	xxvi) Provisions A provision is recognised in the balance sheet when the Group has a present legal or constructive obligation as a result of a past event, and it is probable that an outflow of economic benefits will be required to settle the obligation.
Cost of sales	xxvii) Cost of sales Cost of sales comprises product cost including manufacturing and payroll costs, quality control, shipping, handling, and packaging costs and the cost of services provided.
Finance income and costs	xxviii) Finance income and costs Financing expenses comprise interest costs payable on senior secured term loan, convertible note, leases and exchangeable notes along with non-recurring financing expenses such as penalty for early settlement of term loan and loss on disposal of exchangeable notes. Interest payable on finance leases is allocated to each period during the lease term so as to produce a constant periodic rate of interest on the remaining balance of the liability. Financing expenses also includes the financing element of long term liabilities which have been discounted. Finance income includes interest income on deposits and is recognised in the consolidated statement of operations as it accrues, using the effective interest method. Finance income also includes fair value adjustments for derivative assets and liabilities related to the senior secured term loan and to embedded derivatives associated with exchangeable notes.
Treasury shares	xxvix) Treasury shares When the Group purchases its
Equity	xxx) Equity Share capital represents the nominal (par) value of shares that have been issued. Share premium includes any premiums received on issue of share capital. Any transaction costs associated with the issuing of shares are deducted from share premium, net of any related income tax benefits.
Profit or loss from discontinued operations	xxxi) Profit or loss from discontinued operations A discontinued operation is a component of the Group that either has been disposed of or is classified as held for sale. Profit or loss from discontinued operations comprises the post-tax profit or loss of discontinued operations and the post-tax gain or loss resulting from the measurement and disposal of assets classified as held for sale.
Fair values	xxxii) Fair values For financial reporting purposes, fair value measurements are categorized into Level 1, 2 or 3 based on the degree to which inputs to the fair value measurements are observable and the significance of the inputs to the fair value measurement in its entirety, which are described as follows: Level 1: quoted prices (unadjusted) in active markets for identical assets or liabilities Level 2: valuation techniques for which the lowest level of inputs which have a significant effect on the recorded fair value are observable, either directly or indirectly Level 3: valuation techniques for which the lowest level of inputs that have a significant effect on the recorded fair value are not based on observable market data
New IFRS Standards adopted as of January 1, 2022	xxxiii) New IFRS Standards adopted as of January 1, 2022 The following standard amendments became effective for the Group as of January 1, 2022: • Amendments to IFRS 3 Business Combinations – Reference to the Conceptual Framework • Amendments to IAS 16 Property, Plant and Equipment – Proceeds before Intended Use • Amendments to IAS 37 Provisions, Contingent Liabilities and Contingent Assets – Onerous Contracts – Costs of Fulfilling a Contract The standard amendments did not result in a material impact on the Group’s results.
Standards, amendments and interpretations to existing IFRS Standards that are not yet effective	xxxiv) Standards, amendments and interpretations to existing IFRS Standards that are not yet effective  At the date of authorisation of these financial statements, several new, but not yet effective, Standards and amendments to existing Standards, and interpretations have been published by the IASB or IFRIC. None of these Standards or amendments to existing Standards have been adopted early by the Group and no interpretations have been issued that are applicable and need to be taken into consideration by the Group at either reporting date. Management anticipates that all relevant pronouncements will be adopted for the first period beginning on or after the effective date of the pronouncement. New Standards, amendments and Interpretations not adopted in the current year have not been disclosed as they are not expected to have a material impact on the Group’s consolidated financial statements.

BASIS OF PREPARATION AND SIGN_3

BASIS OF PREPARATION AND SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Dec. 31, 2022
Disclosure of basis of preparation and significant accounting policies [Abstract]
Schedule of Estimated Useful Lives of Owned Assets	• Leasehold improvements 5-15 years • Buildings 50 years • Office equipment and fittings 10 years • Computer equipment 3-5 years • Plant and equipment 5-15 years
Schedule of Estimated Useful Lives of Intangible Assets	• Capitalised development costs 15 years • Patents and licences 6-15 years • Other (including acquired customer and supplier lists) 6-15 years

SEGMENT INFORMATION (Tables)

SEGMENT INFORMATION (Tables)	12 Months Ended
	Dec. 31, 2022
Disclosure of operating segments [abstract]
Schedule of Revenue by Geographical Area Based on Location of Assets	Revenue Americas Rest of World Ireland Eliminations Total Year ended December 31, 2022 US$‘000 US$‘000 US$’000 US$‘000 Revenue from external customers 50,508 24,271 - 74,779 Inter-segment revenue 26,110 828 (26,938 ) - Total revenue 76,618 25,099 (26,938 ) 74,779 Revenue Americas Rest of World Ireland Eliminations Total Year ended December 31, 2021 US$‘000 US$‘000 US$’000 US$‘000 Revenue from external customers 67,249 25,716 - 92,965 Inter-segment revenue 49,059 2,517 (51,576 ) - Total revenue 116,308 28,233 (51,576 ) 92,965 Revenue Americas Rest of World Ireland Eliminations Total Year ended December 31, 2020 US$‘000 US$‘000 US$’000 US$‘000 Revenue from external customers 77,688 24,292 - 101,980 Inter-segment revenue 59,304 1,095 (60,399 ) - Total revenue 136,992 25,387 (60,399 ) 101,980
Schedule of Revenue by Customers' Geographical Area	Revenue December 31, 2022 US$‘000 December 31, 2021 US$‘000 December 31, 2020 US$‘000 Americas 40,176 57,799 70,408 Asia / Africa 25,022 25,504 22,567 Europe (including Ireland) * 9,581 9,662 9,005 74,779 92,965 101,980 * Revenue from customers in Ireland is not disclosed separately due to the immateriality of these revenues.
Schedule of Revenue by Major Product Group	Revenue December 31, 2022 US$‘000 December 31, 2021 US$‘000 December 31, 2020 US$‘000 Clinical laboratory goods 58,294 74,700 84,280 Clinical laboratory services 7,272 7,928 8,485 Point-of-Care 9,213 10,337 9,215 74,779 92,965 101,980
Schedule of Amount Relating From Revenue	Revenue December 31, 2022 US$‘000 December 31, US$‘000 December 31, US$‘000 Revenue from contracts with customers (a) 74,779 92,965 101,980 74,779 92,965 101,980
Schedule of Revenue Derives From Transfer of Goods and Services	Timing of revenue recognition Americas Rest of World Ireland Rest of World Other Total Year ended December 31, 2022 US$‘000 US$‘000 US$‘000 US$‘000 At a point in time 50,174 24,271 - 74,445 Over time 334 - - 334 Total 50,508 24,271 - 74,779 Timing of revenue recognition Americas Rest of World Ireland Rest of World Other Total Year ended December 31, 2021 US$‘000 US$‘000 US$‘000 US$‘000 At a point in time 66,806 25,716 - 92,522 Over time 443 - - 443 Total 67,249 25,716 - 92,965 Timing of revenue recognition Americas Rest of World Ireland Rest of World Other Total Year ended December 31, 2020 US$‘000 US$‘000 US$‘000 US$‘000 At a point in time 77,060 24,292 - 101,352 Over time 628 - - 628 Total 77,688 24,292 - 101,980 Timing of revenue recognition Americas Asia / Africa Europe Total Year ended December 31, 2022 US$‘000 US$‘000 US$‘000 US$‘000 At a point in time 39,842 25,022 9,581 74,445 Over time 334 - - 334 Total 40,176 25,022 9,581 74,779 Timing of revenue recognition Americas Asia / Africa Europe Total Year ended December 31, 2021 US$‘000 US$‘000 US$‘000 US$‘000 At a point in time 57,356 25,504 9,662 92,522 Over time 443 - - 443 Total 57,799 25,504 9,662 92,965 Timing of revenue recognition Americas Asia / Africa Europe Total Year ended December 31, 2020 US$‘000 US$‘000 US$‘000 US$‘000 At a point in time 69,780 22,567 9,005 101,352 Over time 628 - - 628 Total 70,408 22,567 9,005 101,980
Schedule of Segment Results by Geographical Area	Rest of World Americas Ireland Other Total Year ended December 31, 2022 US$‘000 US$‘000 US$‘000 US$‘000 Result before impairment and unallocated expenses (5,891 ) (2,516 ) (33 ) (8,440 ) Impairment charges (2,331 ) (3,508 ) - (5,839 ) Result after impairment (8,222 ) (6,024 ) (33 ) (14,279 ) Unallocated expenses * (2,473 ) Operating loss (16,752 ) Net financing expense (Note 6) (24,442 ) Loss before tax (41,194 ) Income tax credit (Note 7) 192 Loss for the year on continuing operations (41,002 ) Loss for the year on discontinued operations (Note 8) (7 ) Loss for the year (41,009 ) Rest of World Americas Ireland Other Total Year ended December 31, 2021 US$‘000 US$‘000 US$‘000 US$‘000 Result before impairment and unallocated expenses 9,276 5,084 (12 ) 14,348 Impairment charges (6,088 ) (856 ) - (6,944 ) Result after impairment 3,188 4,228 (12 ) 7,404 Unallocated expenses * (779 ) Operating profit 6,625 Net financing expense (Note 6) (5,874 ) Profit before tax 751 Income tax credit (Note 7) 178 Profit for the year on continuing operations 929 Loss for the year on discontinued operations (Note 8) (54 ) Profit for the year 875 Rest of World Americas Ireland Other Total Year ended December 31, 2020 US$‘000 US$‘000 US$‘000 US$‘000 Result before impairment and unallocated expenses 14,495 4,264 (71 ) 18,688 Impairment (17,779 ) - - (17,779 ) Result after impairment (3,284 ) 4,264 (71 ) 909 Unallocated expenses * (827 ) Operating profit 82 Net financing expense (Note 6) (6,715 ) Loss before tax (6,633 ) Income tax credit (Note 7) 620 Loss for the year on continuing operations (6,013 ) Loss for the year on discontinued operations (Note 8) (375 ) Loss for the year (6,388 ) * Unallocated expenses represent head office general and administration costs of the Group, which cannot be allocated to the results of any specific geographical area.
Schedule of Segment Assets and Segment Liabilities by Geographical Area	Rest of World Americas Ireland Other Total As at December 31, 2022 US$‘000 US$‘000 US$‘000 US$‘000 Assets and liabilities Segment assets 41,779 37,695 - 79,474 Unallocated assets: Income tax assets (current and deferred) 6,052 Cash and cash equivalents and short-term investments 6,578 Total assets as reported in the Group balance sheet 92,104 Segment liabilities 58,307 30,845 42 89,194 Unallocated liabilities: Income tax liabilities (current and deferred) 5,086 Total liabilities as reported in the Group balance sheet 94,280 Rest of World Americas Ireland Other Total As at December 31, 2021 US$‘000 US$‘000 US$‘000 US$‘000 Assets and liabilities Segment assets 45,891 41,453 1 87,345 Unallocated assets: Income tax assets (current and deferred) 5,640 Cash and cash equivalents and short-term investments 25,910 Total assets as reported in the Group balance sheet 118,895 Segment liabilities 12,382 101,927 25 114,334 Unallocated liabilities: Income tax liabilities (current and deferred) 4,880 Total liabilities as reported in the Group balance sheet 119,214
Schedule of Long-Lived Assets	December 31, 2022 US$‘000 December 31, 2021 US$‘000 Rest of World – Ireland 21,180 22,617 Americas 19,910 19,489 41,090 42,106
Schedule of Depreciation and Amortisation by Geographical Area	December 31, 2022 US$‘000 December 31, 2021 US$‘000 December 31, 2020 US$‘000 Depreciation: Rest of World – Ireland 128 204 127 Americas 1,282 1,662 1,587 1,410 1,866 1,714 Amortisation: Rest of World – Ireland 123 69 32 Americas 800 848 1,371 923 917 1,403
Schedule of Interest Income and Interest Expense by Geographical Area	December 31, 2022 US$‘000 December 31, 2021 December 31, 2020 Rest of World – Ireland 632 1,072 722 Americas 1,123 28 70 1,755 1,100 792
Schedule of Taxation Expense by Geographical Area	December 31, 2022 US$‘000 December 31, 2021 US$‘000 December 31, 2020 US$‘000 Rest of World – Ireland 284 540 293 Rest of World – Other (4 ) (2 ) (8 ) Americas (88 ) (360 ) 335 192 178 620
Schedule of Capital Expenditure by Geographical Area	December 31 2022 US$‘000 December 31, 2021 US$‘000 Rest of World – Ireland 2,443 3,826 Rest of World – Other - - Americas 4,370 4,776 6,813 8,602

EMPLOYMENT (Tables)

EMPLOYMENT (Tables)	12 Months Ended
	Dec. 31, 2022
Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [abstract]
Schedule of Persons Employed by the Group in the Financial Year	December 31, 2022 December 31, 2021 December 31, 2020 Research and development 30 41 52 Administration and sales 119 134 148 Manufacturing and quality 249 302 343 398 477 543
Schedule of Employment Costs	December 31, 2022 US$‘000 December 31, 2021 US$‘000 December 31, 2020 US$‘000 Wages and salaries 23,608 26,561 26,187 Social welfare costs 2,036 2,403 2,195 Pension costs 352 352 447 Share-based payments 1,755 1,100 792 Restructuring Cost 274 270 388 Recognition of contingent asset (Note 24) - - (1,316 ) 28,025 30,686 28,693

OTHER OPERATING INCOME (Tables)

OTHER OPERATING INCOME (Tables)	12 Months Ended
	Dec. 31, 2022
Disclosure of other operating income [Abstract]
Schedule of Other Operating Income	December 31, 2022 US$‘000 December 31, 2021 US$‘000 December 31, 2020 US$‘000 Government supports - COVID-19 7 4,668 1,840 Government grants 333 - - Other income - - 17 Rental income from premises 3 4 3 343 4,672 1,860

IMPAIRMENT CHARGES (Tables)

IMPAIRMENT CHARGES (Tables)	12 Months Ended
	Dec. 31, 2022
Disclosure of impairment charges and inventory provisioning [Abstract]
Schedule of Impairment Charges and Inventory Provisioning	December 31, December 31, December 31, 2022 2021 2020 US$’000 US$’000 US$’000 Selling, general & administration expenses Impairment of PP&E (Note 11) 733 2,508 1,795 Impairment of goodwill and other intangible assets (Note 12) 4,624 3,853 15,422 Impairment of prepayments (Note 16) 482 583 562 Total impairment loss 5,839 6,944 17,779

FINANCIAL INCOME AND EXPENSES (

FINANCIAL INCOME AND EXPENSES (Tables)	12 Months Ended
	Dec. 31, 2022
Disclosure Of Financing Income Expenses Net Abstract
Schedule of Financial Income and Expenses	December 31, 2022 US$‘000 December 31, 2021 US$‘000 December 31, 2020 US$‘000 Financial income: Non-cash financial income 303 1,220 - Interest income - 3 36 303 1,223 36 Financial expense: Interest on leases (Note 27) (657 ) (815 ) (896 ) Loss on disposal of exchangeable notes (Note 22, 27) (9,678 ) - - Penalty for early partial settlement of senior secured term loan (Note 22) (3,450 ) - - Cash interest payable on senior secure term loan (7,039 ) - - Cash interest payable on convertible note (199 ) - - Cash interest on exchangeable notes (296 ) (3,996 ) (3,996 ) Loan origination costs - (1,638 ) - Non-cash interest on exchangeable notes (84 ) (648 ) (643 ) Non-cash interest on senior secured term loan (2,772 ) - - Non-cash interest on convertible note (495 ) - - Non-cash financial expense (74 ) - (1,216 ) Other (1 ) - - (24,745 ) (7,097 ) (6,751 ) Net Financing Expense (24,442 ) (5,874 ) (6,715 )

INCOME TAX CREDIT (Tables)

INCOME TAX CREDIT (Tables)	12 Months Ended
	Dec. 31, 2022
Disclosure of income tax credit [Abstract]
Schedule of Charge for Tax	December 31, US$‘000 December 31, US$‘000 December 31, US$‘000 Current tax (credit)/expense Irish Corporation tax (331 ) (511 ) (480 ) Foreign taxes (a) (5 ) 296 179 Adjustment in respect of prior years 61 - (152 ) Total current tax credit (275 ) (215 ) (453 ) Deferred tax credit Origination and reversal of temporary differences (see Note 13) 321 620 48 Origination and reversal of net operating losses (see Note 13) (238 ) (583 ) (215 ) Total deferred tax charge/(credit) 83 37 (167 ) Total income tax credit on continuing operations in statement of operations (192 ) (178 ) (620 ) Tax charge on discontinued operations (see Note 8) - 12 438 Total tax credit (192 ) (166 ) (182 ) (a) In 2022, the foreign taxes relate primarily to USA and Canada. (b) In 2022, there was a deferred tax charge of US$109,000 (2021: charge of US$118,000) (2020: credit of US$444,000) recognised in respect of Ireland and a deferred tax credit of US$26,000 (2021: credit of US$81,000) (2020: credit of US$397,000) recognised in respect of overseas tax jurisdictions.
Schedule of Overseas Tax Jurisdictions	Effective tax rate December 31, December 31, December 31, (Loss)/profit before taxation – continuing operations (US$‘000) (41,194 ) 751 (6,633 ) As a percentage of (loss)/profit before tax: Current tax % (0.67 )% (28.63 ) % (6.83 )% Total (current and deferred) % (0.47 )% (23.70 ) % (9.35 )%
Schedule of Statutory Tax Rate	December 31, 2022 December 31, 2021 December 31, 2020 Irish corporation tax (12.5 )% 12.5 % (12.5 )% Effect of current year net operating losses and temporary differences for which no deferred tax asset was recognised (a) 11.66 % 49.63 % 24.13 % Effect of tax rates on overseas earnings (7.76 )% (0.22 )% (9.92 )% Effect of Irish income taxable at higher tax rate 4.17 % 98.68 % 5.92 % Adjustments in respect of prior years 0.15 % (0.01 )% (10.66 )% R&D tax credits (0.81 )% (79.22 )% (11.00 )% Other items (b) 4.62 % (105.06 )% 4.68 % Effective tax rate (0.47 )% (23.70 )% (9.35 )% (a) No deferred tax asset was recognised because there was no reversing deferred tax liability in the same jurisdiction reversing in the same period and insufficient future projected taxable income in the same jurisdiction. (b) Other items comprise items not chargeable to tax and expenses not deductible for tax purposes. This was a significant number in 2021 because the US$4.7 million income from the Paycheck Protection Program loans was not chargeable for tax purposes. There is no Paycheck Protection Program income in 2022. In 2022, other items mainly relate to the loss on disposal of the exchangeable notes.
Schedule of Unrecognised Deferred Tax Assets	December 31, 2022 US$‘000 December 31, 2021 US$‘000 December 31, 2020 US$‘000 Rest of World – Ireland (19,768 ) 1,862 296 Rest of World – Other (33 ) 3,939 3,304 Americas (21,393 ) (5,050 ) (10,233 ) (41,194 ) 751 (6,633 )
Schedule of (Loss)/Profit Before Taxes	December 31, 2022 US$‘000 December 31, 2021 US$‘000 December 31, 2020 US$‘000 Rest of World – Ireland 62,731 68,132 78,700 Rest of World – Other 448 1,000 2,185 Americas 12,778 4,761 4,313 75,957 73,893 85,198
Schedule of Unutilised Net Operating Losses	December 31, 2022 US$‘000 December 31, 2021 US$‘000 December 31, 2020 US$‘000 Rest of World – Ireland – unused tax losses 7,489 9,272 12,514 Rest of World – Other – unused tax losses 124 279 546 Americas – unused tax losses 3,163 5,891 1,466 Americas – unused tax credits 4,658 3,368 2,862 Unrecognised deferred tax asset 15,434 18,810 17,388

LOSS FOR THE YEAR ON DISCONTI_2

LOSS FOR THE YEAR ON DISCONTINUED OPERATION (Tables)	12 Months Ended
	Dec. 31, 2022
Disclosure of loss on discontinued operations [Abstract]
Schedule of Loss on Remeasurement of Assets and Liabilities	December 31, 2022 US$‘000 December 31, 2021 US$‘000 December 31, 2020 US$‘000 Administrative expenses (7 ) - - Closure provision - (42 ) 127 Foreign currency translation reserve - - (64 ) Tax expense - (12 ) (438 ) Total loss (7 ) (54 ) (375 ) Loss for the year from discontinued operations (7 ) (54 ) (375 )
Schedule of Earnings Per ADS for Discontinued Operations	December 31, 2022 December 31, 2021 December 31, 2020 Basic loss per ADS (US Dollars) – discontinued operations 0.00 0.00 (0.02 ) Diluted loss per ADS (US Dollars) – discontinued operations 0.00 0.00 (0.02 ) Basic loss per ‘A’ share (US Dollars) – discontinued operations 0.00 0.00 0.00 Diluted loss per ‘A’ share (US Dollars) – discontinued operations 0.00 0.00 0.00
Schedule of Cash Flows Attributable to Discontinued Operations	December 31, 2022 December 31, 2021 December 31, US$000 US$000 US$000 Cash flows from operating activities (10 ) (40 ) (22 )

(LOSS)_PROFIT BEFORE TAX (Table

(LOSS)/PROFIT BEFORE TAX (Tables)	12 Months Ended
	Dec. 31, 2022
Disclosure of loss profit before tax [Abstract]
Schedule of Loss/profit Before Tax	December 31, US$‘000 December 31, US$‘000 December 31, US$‘000 Directors’ emoluments (including non- executive directors): Remuneration 1,639 1,391 2,020 Pension 24 24 41 Share based payments 1,707 986 678 Auditor’s remuneration Audit fees 888 580 558 Tax fees 89 77 146 Depreciation (Note 11) 1 1,410 1,827 1,674 Amortisation (Note 12) 923 917 1,403 Loss/(profit) on the disposal of property, plant and equipment 2 (1 ) 30 Selling, General and Administrative Expenses – Closure Costs - - 2,425 Net foreign exchange differences (1,210 ) (789 ) 583 1

(LOSS)_EARNINGS PER SHARE (Tab

(LOSS)/EARNINGS PER SHARE (Tables)	12 Months Ended
	Dec. 31, 2022
Earnings per share [abstract]
Schedule of Basic Earnings Per Ordinary Share	December 31, 2022 December 31, 2021 December 31, 2020 ‘A’ ordinary shares 134,939,327 83,606,810 83,606,810 Basic (loss)/earnings per share denominator 134,939,327 83,606,810 83,606,810 Reconciliation to weighted average (loss)/earnings per share denominator: Number of ‘A’ ordinary shares at January 1 (Note 18) 96,162,410 96,162,410 96,162,410 Weighted average number of ‘A’ ordinary shares issued during the year 51,332,517 - - Weighted average number of treasury shares (12,555,600 ) (12,555,600 ) (12,555,600 ) Basic (loss)/earnings per share denominator 134,939,327 83,606,810 83,606,810
Schedule of Diluted Earnings Per Ordinary Share	December 31, 2022 December 31, 2021 December 31, 2020 Potentially Dilutive Instruments: Issuable on exercise of options (Note 19) 44,814,672 18,727,990 19,485,990 Issuable on exercise of warrants to Perceptive (Note 22) 10,000,000 - - Issuable on conversion of Exchangeable notes (Note 22) 38,391 18,263,254 18,263,254 Issuable on conversion of Convertible notes (Note 22) 24,691,358 - - Total number of potentially dilutive instruments excluded from the weighted average number of ‘A’ ordinary shares in calculating dilutive (loss)/earnings per ‘A’ ordinary share 79,544,421 36,991,244 37,749,244
Schedule of Basic Earning per ADS	December 31, 2022 December 31, 2021 December 31, 2020 ADS 33,734,832 20,901,703 20,901,703 Basic (loss)/earnings per ADS denominator 33,734,832 20,901,703 20,901,703 Reconciliation to weighted average (loss)/earnings per ADS denominator: Number of ADS at January 1 (Note 18) 24,040,602 24,040,602 24,040,602 Weighted average number of shares issued during the year* 12,833,129 - - Weighted average number of treasury shares (3,138,899 ) (3,138,899 ) (3,138,899 ) Basic (loss)/earnings per ADS denominator 33,734,832 20,901,703 20,901,703
Schedule of Diluted Earning per ADS	December 31, 2022 December 31, 2021 December 31, 2020 Potentially Dilutive Instruments: Issuable on exercise of options (Note 19) 11,203,668 4,681,998 4,871,498 Issuable on exercise of warrants to Perceptive (Note 22) 2,500,000 - - Issuable on conversion of Exchangeable notes (Note 22) 9,598 4,565,814 4,565,814 Issuable on conversion of Convertible notes (Note 22) 6,172,840 - - Total number of potentially dilutive instruments excluded from the weighted average number of ADS in calculating dilutive (loss)/earnings per ADS 19,886,106 9,247,812 9,437,312

PROPERTY, PLANT AND EQUIPMENT (

PROPERTY, PLANT AND EQUIPMENT (Tables)	12 Months Ended
	Dec. 31, 2022
Disclosure of detailed information about property, plant and equipment [abstract]
Schedule of Property, Plant and Equipment	Land & Buildings US$‘000 Leasehold Improvements US$‘000 Computer & Office Equipment US$‘000 Plant & Equipment US$‘000 Total US$‘000 Cost At January 1, 2021 24,287 2,670 4,309 33,839 65,105 Additions 46 126 144 1,392 1,708 Disposals or retirements - (186 ) (255 ) (2,410 ) (2,851 ) Exchange adjustments 1 (18 ) 2 (484 ) (499 ) At December 31, 2021 24,334 2,592 4,200 32,337 63,463 At January 1, 2022 24,334 2,592 4,200 32,337 63,463 Additions 379 93 362 1,100 1,934 Disposals or retirements - - (25 ) (42 ) (67 ) Reallocations/ reclassifications - - (2 ) 2 - Exchange adjustments (31 ) 16 5 286 276 At December 31, 2022 24,682 2,701 4,540 33,683 65,606 Accumulated amortisation and Impairment losses At January 1, 2021 (19,629 ) (1,884 ) (3,946 ) (31,099 ) (56,558 ) Charge for the year (628 ) (149 ) (115 ) (974 ) (1,866 ) Disposals or retirements - 186 255 2,410 2,851 Impairment losses (1,196 ) (279 ) (98 ) (935 ) (2,508 ) Exchange adjustments 21 (5 ) (46 ) 566 536 At December 31, 2021 (21,432 ) (2,131 ) (3,950 ) (30,032 ) (57,545 ) At January 1, 2022 (21,432 ) (2,131 ) (3,950 ) (30,032 ) (57,545 ) Charge for the year (414 ) (133 ) (214 ) (649 ) (1,410 ) Disposals or retirements - - 22 43 65 Impairment losses (48 ) (4 ) (31 ) (650 ) (733 ) Exchange adjustments 9 (16 ) (5 ) (289 ) (301 ) At December 31, 2022 (21,885 ) (2,284 ) (4,178 ) (31,577 ) (59,924 ) Carrying amounts At December 31, 2022 2,797 417 362 2,106 5,682 At December 31, 2021 2,902 461 250 2,305 5,918
Schedule Of Additional Information On Right Of Use Assets	Additional information on the right-of-use assets by class of assets is as follows: Carrying amount Depreciation Charge Impairment Charge At December 31, 2022 Year ended December 31, 2022 Year ended December 31, 2022 US$000 US$000 US$000 Buildings 2,482 (398 ) (48 ) Computer equipment 217 (40 ) - Plant and Equipment, vehicles - (17 ) (200 ) 2,699 (455 ) (248 ) Carrying amount Depreciation Charge Impairment Charge At December 31, 2021 Year ended December 31, 2021 Year ended December 31, 2021 US$000 US$000 US$000 Buildings 2,549 (609 ) (1,089 ) Computer equipment 23 (5 ) - Plant and Equipment, vehicles - - - 2,572 (614 ) (1,089 )
Schedule of income from sub-letting right-of-use buildings	Right-of-Use assets at 31 December 2022 No. of Right-of-Use leased assets Range of remaining term in years Average remaining lease term (years) No. of Leases with extension options No. of Leases with options to purchase No. of leases with variable payments linked to index No. of leases with termination options Building 9 1 to 11 5 2 - - - Vehicle 20 0.4 to 3 2 - 20 - 20 I.T. and office equipment 5 4 4 - - - - Right-of-Use assets at 31 December 2021 No. of Right-of-Use leased assets Range of remaining term in years Average remaining lease term (years) No. of Leases with extension options No. of Leases with options to purchase No. of leases with variable payments linked to index No. of leases with termination options Building 11 1 to 12 3 1 - 2 - Vehicle 16 1 to 3 2 - 16 - 16 I.T. and office equipment 2 1 to 5 4 - - - -

GOODWILL AND INTANGIBLE ASSETS

GOODWILL AND INTANGIBLE ASSETS (Tables)	12 Months Ended
	Dec. 31, 2022
Disclosure Of Goodwill And Intangible Assets [Abstract]
Schedule of Goodwill and Intangible Assets	Goodwill US$‘000 Development costs US$‘000 Patents and licenses US$‘000 Other US$‘000 Total US$‘000 Cost At January 1, 2021 79,182 128,977 8,947 33,311 250,417 Additions - 6,771 102 21 6,894 Disposals or retirements - (14,576 ) (342 ) (134 ) (15,052 ) Exchange adjustments - 1 - - 1 At December 31, 2021 79,182 121,173 8,707 33,198 242,260 At January 1, 2022 79,182 121,173 8,707 33,198 242,260 Additions - 4,475 22 382 4,879 Exchange adjustments - (64 ) - - (64 ) At December 31, 2022 79,182 125,584 8,729 33,580 247,075 Accumulated amortisation and Impairment losses At January 1, 2021 (66,591 ) (115,533 ) (8,790 ) (25,643 ) (216,557 ) Charge for the year - (482 ) (7 ) (428 ) (917 ) Disposals or retirements - 14,573 342 132 15,047 Impairment losses (54 ) (2,053 ) (106 ) (1,640 ) (3,853 ) Exchange adjustments - 1 - - 1 At December 31, 2021 (66,645 ) (103,494 ) (8,561 ) (27,579 ) (206,279 ) At January 1, 2022 (66,645 ) (103,494 ) (8,561 ) (27,579 ) (206,279 ) Charge for the year (479 ) (9 ) (435 ) (923 ) Impairment losses - (4,623 ) - (1 ) (4,624 ) Exchange adjustments - 20 - - 20 At December 31, 2022 (66,645 ) (108,576 ) (8,570 ) (28,015 ) (211,806 ) Carrying amounts At December 31, 2022 12,537 17,008 159 5,565 35,269 At December 31, 2021 12,537 17,679 146 5,619 35,981
Schedule of Principal Development Projects	Product Name 2022 US$’000 2021 US$’000 Premier Instruments for A1c and haemoglobinopathies testing 1,904 2,538 COVID-19 tests 1,378 1,320 Mid-tier haemoglobins instrument 484 303 HIV screening rapid test 379 1,488 Tri-stat point-of-care instrument 163 245 Uni-gold raw material stabilisation 42 144 Autoimmune Smart Reader 82 550 Other projects 43 183 Total capitalised development costs 4,475 6,771
Schedule of Specific Asset Impairment Charges	Asset name Entity 2022 US$’000 Rapid COVID-19 antigen test Trinity Biotech Manufacturing Ltd 2,214 Autoimmune smart reader Trinity Biotech Manufacturing Ltd 1,265 Tri-stat instrument Primus Corp. 1,024 COVID-19 ELISA test Trinity Biotech Manufacturing Ltd 120 Total 4,623
Schedule of Impairment Loss Recorded on Discontinued Assets	December 31, 2022 December 31, 2021 US$’000 US$’000 Trinity Biotech Manufacturing Limited 3,599 856 Primus Corp 1,024 - Trinity Biotech Do Brasil 454 956 Clark Laboratories Inc. 407 - Biopool US Inc. 355 153 Immco Diagnostics Inc - 4,979 Total impairment loss 5,839 6,944
Schedule of Impairment Loss for Each Class of Asset	December 31, 2022 December 31, 2021 US$’000 US$’000 Goodwill and other intangible assets 4,624 3,853 Property, plant and equipment (see Note 11) 733 2,508 Prepayments (see Note 16) 482 583 Total impairment loss 5,839 6,944
Schedule of Significant Goodwill	Fitzgerald Industries December 31, 2022 December 31, 2021 Carrying amount of goodwill (US$’000) 12,591 12,591 Discount rate applied (real pre-tax) 15.77 % 19.66 % Excess value-in-use over carrying amount (US$’000) 7,432 3,496 % EBITDA would need to decrease for an impairment to arise 31.28 % 18.15 % Long-term growth rate 2.0 % 2.0 %
Schedule of Internal and External Factors Based on Historical Experience	Intangible Assets with Indefinite Useful lives (included in other intangibles) December 31, 2022 US$‘000 December 31, 2021 US$‘000 Fitzgerald Industries International CGU Fitzgerald trade name 970 970 RDI trade name 560 560 Primus Corporation CGU Primus trade name 365 365 Immco Diagnostic CGU Immco Diagnostic trade name 2,069 2,069 Total 3,964 3,964

DEFERRED TAX ASSETS AND LIABI_2

DEFERRED TAX ASSETS AND LIABILITIES (Tables)	12 Months Ended
	Dec. 31, 2022
Disclosure Of Deferred Tax Assets And Liabilities [Abstract]
Schedule of Deferred Tax Assets and Liabilities	Assets Liabilities Net 2022 US$’000 2021 US$’000 2022 2021 2022 2021 Property, plant and equipment 229 477 (5 ) (11 ) 224 466 Intangible assets - - (3,950 ) (3,969 ) (3,950 ) (3,969 ) Inventories 423 620 - - 423 620 Provisions 2,194 1,871 - - 2,194 1,871 Tax value of loss carry-forwards 1,254 1,016 - - 1,254 1,016 Other items 118 117 (1,103 ) (878 ) (985 ) (761 ) Deferred tax assets/(liabilities) 4,218 4,101 (5,058 ) (4,858 ) (840 ) (757 )
Schedule of Unrecognised Deferred Tax Liabilities	Balance January, 1 2022 Recognised in income Balance December 31, 2022 US$’000 US$’000 US$’000 Property, plant and equipment 466 (242 ) 224 Intangible assets (3,969 ) 19 (3,950 ) Inventories 620 (197 ) 423 Provisions 1,871 323 2,194 Tax value of loss carry-forwards 1,016 238 1,254 Other items (761 ) (224 ) (985 ) (757 ) (83 ) (840 ) Balance January, 1 2021 Recognised in income Balance December 31, 2021 US$’000 US$’000 US$’000 Property, plant and equipment 724 (258 ) 466 Intangible assets (4,072 ) 103 (3,969 ) Inventories 750 (130 ) 620 Provisions 2,159 (288 ) 1,871 Tax value of loss carry-forwards 433 583 1,016 Other items (714 ) (47 ) (761 ) (720 ) (37 ) (757 )
Schedule of Deferred Tax Assets Not Recognised	December 31, 2022 December 31, 2021 US$’000 US$’000 Capital losses 8,293 8,293 Net operating losses 75,957 73,893 US alternative minimum tax credits 1,906 1,704 Other temporary timing differences 38,960 21,301 US state credit carryforwards 2,753 1,664 127,869 106,855

OTHER NON-CURRENT ASSETS (Table

OTHER NON-CURRENT ASSETS (Tables)	12 Months Ended
	Dec. 31, 2022
Disclosure Of Other Assets Abstract
Schedule of Other Non-Current Assets	December 31, 2022 US$‘000 December 31, 2021 US$‘000 Finance lease receivables (see Note 16) 84 151 Other assets 55 56 139 207

INVENTORIES (Tables)

INVENTORIES (Tables)	12 Months Ended
	Dec. 31, 2022
Classes of current inventories [abstract]
Schedule of Inventories	December 31, US$‘000 December 31, US$‘000 Raw materials and consumables 12,094 13,650 Work-in-progress 3,948 5,546 Finished goods 6,461 9,927 22,503 29,123
Schedule of Movement on Inventory Provision	December 31, 2022 US$‘000 December 31, 2021 US$‘000 December 31, 2020 US$‘000 Opening provision at January 1 12,063 9,781 6,716 Charged during the year 7,391 5,589 5,179 Utilised during the year (3,180 ) (3,307 ) (1,994 ) Released during the year - - (120 ) Closing provision at December 31 16,274 12,063 9,781

TRADE AND OTHER RECEIVABLES (Ta

TRADE AND OTHER RECEIVABLES (Tables)	12 Months Ended
	Dec. 31, 2022
Trade and other receivables [abstract]
Schedule of Trade and Other Receivables	December 31, 2022 US$‘000 December 31, 2021 US$‘000 Trade receivables, net of impairment losses 12,620 13,290 Prepayments 1,932 1,945 Contract assets 739 739 Value added tax 43 - Finance lease receivables 86 142 Grant receivable 333 - 15,753 16,116
Schedule of Future Minimum Finance Lease Receivables	Long-term contract receivable (i) Finance lease commitments – Group as lessor The Group leases instruments as part of its business. Future minimum receivables with non-cancellable terms are as follows: December 31, 2022 US$‘000 Gross Unearned Minimum Less than one year 180 6 86 Between one and five years (Note 14) 173 6 84 353 12 170 December 31, 2021 US$‘000 Gross Unearned Minimum Less than one year 292 11 142 Between one and five years (Note 14) 310 11 151 602 22 293
Schedule of Future Minimum Rentals Receivable Under Non-Cancellable Operating Leases	December 31, 2022 US$‘000 Instruments Total Less than one year 1,589 1,589 1,589 1,589 December 31, 2021 Instruments Total Less than one year 3,953 3,953 Between one and five years 171 171 4,124 4,124

CASH AND CASH EQUIVALENTS (Tabl

CASH AND CASH EQUIVALENTS (Tables)	12 Months Ended
	Dec. 31, 2022
Cash and cash equivalents [abstract]
Schedule of Cash and Cash Equivalents	December 31, US$’000 December 31, US$’000 Cash at bank and in hand 6,578 22,790 Short-term deposits - 3,120 Cash and cash equivalents 6,578 25,910

CAPITAL AND RESERVES (Tables)

CAPITAL AND RESERVES (Tables)	12 Months Ended
	Dec. 31, 2022
Disclosure of classes of share capital [abstract]
Schedule of Share Capital	December 31, 2022 December 31, 2021 Class ‘A’ ‘000s Class ‘A’ ‘000s In thousands of shares In issue at January 1 96,162 96,162 Issued for cash (a) 47,492 - Issued as consideration for Exchangeable Notes purchase (b) 21,332 - At period end 164,986 96,162 December 31, 2022 December 31, 2021 ADS ADS In thousands of ADSs Balance at January 1 24,041 24,041 Issued for cash 11,873 - Issued as consideration for Exchangeable Notes purchase 5,333 - At period end 41,247 24,041 The amounts in the tables above are inclusive of Treasury Shares. The number of Treasury Shares is as follows: December 31, 2022 December 31, 2021 Class ‘A’ ‘000s Class ‘A’ ‘000s In thousands of shares Balance at January 1 12,556 12,556 Purchased during period - - At period end 12,556 12,556 December 31, 2022 December 31, 2021 Class ‘A’ ‘000s Class ‘A’ ‘000s In thousands of ADSs Balance at January 1 3,139 3,139 Purchased during period - - At period end 3,139 3,139

SHARE OPTIONS (Tables)

SHARE OPTIONS (Tables)	12 Months Ended
	Dec. 31, 2022
Disclosure Of Share Options And Share Warrants [Abstract]
Schedule of Grants of Share Options and Warrants	Share Weighted- US$ Range US$ Options ‘A’ Ordinary Shares Per ‘A’ Ordinary Share Per ‘A’ Ordinary Outstanding January 1, 2020 12,303,990 1.31 0.46 –4.36 Granted 9,100,000 0.38 0.19 –1.10 Exercised - - - Expired / Forfeited (1,918,000 ) 2.14 0.19-4.21 Outstanding at end of year 19,485,990 0.79 0.19-4.36 Exercisable at end of year 7,959,323 1.27 0.66-4.36 Outstanding January 1, 2021 19,485,990 0.79 0.19-4.36 Granted - - - Exercised - - - Expired / Forfeited (758,000 ) 1.07 0.19-4.21 Outstanding at end of year 18,727,990 0.78 0.19-4.36 Exercisable at end of year 13,401,322 0.93 0.19-4.36 Outstanding January 1, 2022 18,727,990 0.78 0.19-4.36 Granted 29,400,000 0.27 0.27-0.29 Exercised (2,733,328 ) 0.19 0.19-0.19 Expired / Forfeited (579,990 ) 1.87 0.69-4.36 Outstanding at end of year 44,814,672 0.47 0.19-2.43 Exercisable at end of year 14,138,004 0.89 0.19-2.43 Share Options ‘ADS’ Weighted- exercise price US$ Range US$ Equivalent Per ‘ADS’ Per ‘ADS’ Outstanding January 1, 2020 3,075,998 5.24 1.83 - 17.45 Granted 2,275,000 1.52 0.77 - 4.41 Exercised - - - Expired / Forfeited (479,500 ) 8.56 0.77 - 16.84 Outstanding at end of year 4,871,498 3.15 0.77-17.45 Exercisable at end of year 1,989,831 5.08 2.64 -17.45 Outstanding January 1, 2021 4,871,498 3.15 0.77-17.45 Granted - - - Exercised - - - Expired / Forfeited (189,500 ) 4.28 0.76 - 16.84 Outstanding at end of year 4,681,998 3.12 0.76 - 17.44 Exercisable at end of year 3,350,331 3.72 0.76 –17.44 Outstanding January 1, 2022 4,681,998 3.12 0.76 - 17.44 Granted 7,350,000 1.09 1.07-1.14 Exercised (683,332 ) 0.77 0.77-0.77 Expired / Forfeited (144,998 ) 7.48 2.76 - 17.44 Outstanding at end of year 11,203,668 1.88 0.77-9.73 Exercisable at end of year 3,534,501 3.56 0.77-9.73
Schedule of Range of Prices of Stock Options	Outstanding Exercisable Exercise price range No. of Weighted– Weighted- No. of Weighted– Weighted- US$0.19-US$0.99 39,546,672 0.35 6.10 8,930,004 0.59 4.05 US$1.00-US$1.74 4,988,000 1.34 1.78 4,928,000 1.34 1.74 US$1.75- US$2.43 280,000 2.43 0.15 280,000 2.43 0.15 44,814,672 14,138,004 Outstanding Exercisable Exercise price range No. of Weighted– Weighted- No. of Weighted– Weighted- US$0.77-US$3.96 9,886,668 1.39 6.10 2,232,501 2.37 4.05 US$4.00-US$6.94 1,247,000 5.37 1.78 1,232,000 5.38 1.74 US$6.95- US$9.73 70,000 9.73 0.15 70,000 9.73 0.15 11,203,668 3,534,501 Outstanding Exercisable Exercise price range No. of Weighted– Weighted- No. of Weighted– Weighted- US$0.19-US$0.99 13,000,006 0.48 3.54 7,960,004 0.55 2.92 US$1.00-US$2.05 5,228,000 1.34 0.79 4,941,334 1.35 0.99 US$2.06- US$2.99 439,984 2.53 0.03 439,984 2.53 0.04 US$3.00 -US$4.36 60,000 4.17 0.00 60,000 4.17 0.00 18,727,990 13,401,322 Outstanding Exercisable Exercise price range No. of Weighted– Weighted- No. of Weighted– Weighted- US$0.77-US$3.96 3,250,002 1.94 3.54 1,990,001 2.19 2.92 US$4.00-US$8.20 1,307,000 5.36 0.79 1,235,334 5.40 0.99 US$8.24- US$11.96 109,996 10.13 0.03 109,996 10.13 0.04 US$12.00 -US$17.45 15,000 16.67 0.00 15,000 16.67 0.00 4,681,998 3,350,331
Schedule of Fair Value of the Options Vesting Period	December 31, 2022 US$‘000 December 31, 2021 US$‘000 December 31, 2020 US$‘000 Share-based payments – cost of sales - 5 12 Share-based payments – selling, general and administrative 1,755 1,095 780 Total – continuing operations 1,755 1,100 792 Share-based payments – discontinued operations - - - Total 1,755 1,100 792
Schedule of Assumption Determining Fair Value of Share Options	Key management personnel Other employees Key management personnel Other employees Key management personnel Other employees 2022 2022 2021 2021 2020 2020 Weighted average fair value at measurement date per ‘A’ share / (per ADS) US$0.19 / (US$0.77 ) - / - - / - - / - US$0.20 / (US$0.80 ) US$0.27 / (US$1.08 ) Total ‘A’ share options granted / (ADS’s equivalent) 29,400,000 / (7,350,000 ) - / - - / - - / - 8,480,000 / (2,120,000 ) 620,000 / (155,000 ) Weighted average share price per ‘A’ share / (per ADS) US$0.27 / (US$1.09 ) - / - - / - - / - US$0.38 / (US$1.52 ) US$0.48 / (US$1.96 ) Weighted average exercise price per ‘A’ share / (per ADS) US$0.27 / (US$1.09 ) - / - - / - - / - US$0.38 / (US$1.52 ) US$0.48 / (US$1.96 ) Weighted average expected volatility 76.79 % - % - % - % 66.98 % 65.89 % Weighted average expected life 6.82 - - - 4.34 4.35 Weighted average risk-free interest rate 3.59 % - % - % - % 0.44 % 0.42 %

TRADE AND OTHER PAYABLES (Table

TRADE AND OTHER PAYABLES (Tables)	12 Months Ended
	Dec. 31, 2022
Trade and other current payables [abstract]
Schedule of Trade and Other Payables	December 31, 2022 US$’000 December 31, 2021 US$’000 Trade payables 6,205 6,763 Accruals and other liabilities 8,585 7,595 Payroll taxes 368 398 Employee related social insurance 103 130 Deferred income 114 141 Deferred government grants - 69 Other payables - 31 15,375 15,127

PROVISIONS (Tables)

PROVISIONS (Tables)	12 Months Ended
	Dec. 31, 2022
Provisions [abstract]
Schedule of Provisions	December 31, 2022 US$’000 December 31, 2021 US$’000 Product warranty provision 50 50 50 50

INTEREST-BEARING LOANS AND BO_2

INTEREST-BEARING LOANS AND BORROWINGS (Tables)	12 Months Ended
	Dec. 31, 2022
Disclosure Of Interest-bearing Loans And Borrowings [Abstract]
Schedule of Borrowings	December 31, 2022 US$’000 December 31, 2021 US$’000 Current liabilities Exchangeable senior notes 210 83,312 Total 210 83,312 December 31, US$’000 December 31, US$’000 Non-Current liabilities Senior secured term loan 44,301 - Derivative financial liability 1,569 - Convertible Note 13,746 - Total non-current liabilities 59,616 - December 31, 2022 US$’000 December 31, 2021 US$’000 Non-Current assets Derivative financial asset 128 - Total non-current assets 128 -
Schedule of Exchangeable Notes Balance	December 31, 2022 US$000 December 31, 2021 US$000 Balance at January 1 (83,312 ) (82,664 ) Accretion interest (83 ) (648 ) Repaid to Note holders 86,730 0 Shares issued to Note holders as consideration 6,133 0 Loss on disposal (9,678 ) 0 Liability (210 ) (83,312 )
Schedule of Term Loan And The 7-Year Convertible Notes	Senior secured term loan US$000 7-year Convertible Note US$000 Balance at January 1, 2022 - - Principal amount loaned (81,250 ) (20,000 ) Loan origination costs 3,551 40 Derivative financial liability at date of issue 1,872 - Derivative financial asset at date of issue (202 ) - Equity component at date of issue - 6,709 Accretion interest (2,772 ) (495 ) Cash repayment of principal 34,500 - Non-current liability at December 31, 2022 (44,301 ) (13,746 )
Schedule of Derivative Financial Liability	US$000 Balance at January 1, 2022 - Derivative financial liability at date of issue of Term Loan (1,872 ) Fair value adjustments in the period 303 Non-current liability at December 31, 2022 (1,569 )
Schedule of Derivative Financial Asset	US$000 Balance at January 1, 2022 - Derivative financial asset at date of issue of Term Loan 202 Fair value adjustments in the period (74 ) Non-current asset at December 31, 2022 128

LEASE LIABILITIES (Tables)

LEASE LIABILITIES (Tables)	12 Months Ended
	Dec. 31, 2022
Disclosure of finance lease liabilities [Abstract]
Schedule of Carrying Values of Finance Lease Liabilities	December 31, 2022 US$’000 December 31, 2021 US$’000 Current liabilities Lease liabilities related to Right of Use assets 1,631 1,878 Sale and leaseback liabilities 45 102 1,676 1,980 Non-Current liabilities Lease liabilities related to Right of Use assets 12,267 13,790 Sale and leaseback liabilities - 75 12,267 13,865
Schedule of Finance Lease Liabilities Payable	December 31, 2022 December 31, 2022 Lease liabilities related to Right of Use assets Sale and leaseback Liabilities Minimum lease payments Interest Principal Minimum lease payments Interest Principal Less than one year 2,249 618 1,631 46 1 45 In more than one year, but not more than two 2,240 561 1,679 - - - In more than two years but not more than five 5,739 1,217 4,522 - - - more than five years 6,968 902 6,066 - - - 17,196 3,298 13,898 46 1 45 December 31, 2021 US$’000 December 31, 2021 US$’000 Lease liabilities related to Right of Use assets Sale and leaseback Liabilities Minimum lease payments Interest Principal Minimum lease payments Interest Principal Less than one year 2,575 697 1,878 109 7 102 In more than one year, but not more than two 2,175 621 1,554 77 2 75 In more than two years but not more than five 5,985 1,469 4,516 - - - more than five years 8,992 1,272 7,720 - - - 19,727 4,059 15,668 186 9 177
Schedule of Outstanding Interest Bearing Loans and Borrowings	Facility Currency Nominal interest Year of maturity Fair Value Carrying Value Sale and leaseback liabilities USD 5.51 % 2023 45 45 The terms and conditions of outstanding interest bearing loans and borrowings at December 31, 2021 are as follows: Facility Currency Nominal interest Year of maturity Fair Value Carrying Value Sale and leaseback liabilities Euro 4.53 % 2023 65 65 Sale and leaseback liabilities USD 5.51 % 2023 111 111 Total 176 176

RELATED PARTY TRANSACTIONS (Tab

RELATED PARTY TRANSACTIONS (Tables)	12 Months Ended
	Dec. 31, 2022
Disclosure of transactions between related parties [abstract]
Schedule of Compensation	December 31, 2022 December 31, 2021 US$’000 US$’000 Short-term employee benefits 1,074 1,065 Performance related bonus 512 227 Post-employment benefits 24 24 Share-based compensation benefits as calculated under IFRS 2 1,690 965 3,300 2,281
Schedule of Company's Shares and Share Option Plan	‘A’ Ordinary Shares Share options At January 1, 2022 9,077,713 16,738,000 Shares of retired director (626,600 ) - Options of retired director - (2,924,000 ) Shares purchased during the year 2,666,664 (2,666,664 ) Shares sold during the year - - Granted - 29,400,000 Expired / forfeited - - At December 31, 2022 11,117,777 40,547,336 ‘A’ Ordinary Shares Share options At January 1, 2021 9,077,713 17,394,000 Shares of retired director - - Options of retired director - (656,000 ) Shares purchased during the year - - Shares sold during the year - - Granted - - Expired / forfeited - - At December 31, 2021 9,077,713 16,738,000

CAPITAL AND FINANCIAL RISK MA_2

CAPITAL AND FINANCIAL RISK MANAGEMENT (Tables)	12 Months Ended
	Dec. 31, 2022
Disclosure of detailed information about financial instruments [abstract]
Schedule of Fair Values of Financial Assets/Liabilities	Level 1 Level 2 Total carrying amount Fair Value Note US$’000 US$’000 US$’000 US$’000 December 31, 2022 Loans and receivables at amortised cost Trade receivables 16 12,620 - 12,620 12,620 Cash and cash equivalents 17 6,578 - 6,578 6,578 Finance lease receivable 14, 16 170 - 170 170 19,368 - 19,368 19,368 Liabilities at amortised cost Senior secured term loan 22 - (44,301 ) (44,301 ) (44,301 ) Convertible note 22 - (13,746 ) (13,746 ) (13,746 ) Exchangeable note 22 (210 ) - (210 ) (210 ) Lease liabilities 23 (13,943 ) - (13,943 ) (13,943 ) Trade and other payables (excluding deferred income) 20 (15,261 ) - (15,261 ) (15,261 ) Provisions 21 (50 ) - (50 ) (50 ) (29,464 ) (58,047 ) (87,511 ) (87,511 ) Fair value through profit and loss (FVPL) Derivative liability - warrants 22 - (1,569 ) (1,569 ) (1,569 ) Derivative asset – prepayment option 22 - 128 128 128 - (1,441 ) (1,441 ) (1,441 ) (10,096 ) (59,488 ) (69,584 ) (69,584 ) Level 1 Level 2 Total carrying amount Fair Value Note US$’000 US$’000 US$’000 US$’000 December 31, 2021 Loans and receivables at amortised cost Trade receivables 16 13,290 - 13,290 13,290 Cash and cash equivalents 17 25,910 - 25,910 25,910 Finance lease receivable 14, 16 293 - 293 293 39,493 - 39,493 39,493 Liabilities at amortised cost Exchangeable note¹ 22 - (83,312 ) (83,312 ) (83,312 ) Lease liabilities 23 (15,845 ) - (15,845 ) (15,845 ) Trade and other payables (excluding deferred income) 20 (14,986 ) - (14,986 ) (14,986 ) Provisions 21 (50 ) - (50 ) (50 ) (30,881 ) (83,312 ) (114,193 ) (114,193 ) Fair value through profit and loss (FVPL) Exchangeable note bond call option 22 - - - - Exchangeable note equity conversion option 22 - - - - - - - - 8,612 (83,312 ) (74,700 ) (74,700 )
Schedule of Interest Rate Risk Effective and Repricing Analysis	As at December 31, 2022 Note Effective interest Total US$’000 6 mths or less US$’000 6 –12 mths US$’000 1-2 years US$’000 2-5 years US$’000 > 5 years US$’000 Cash and cash equivalents 17 0.00 % 6,578 6,578 - - - - Lease receivable 14,16 4.0 % 170 46 41 49 34 - Exchangeable note 22 4.8 % (210 ) - - - - (210 ) Senior secured term loan 1 22 15.4 % (44,301 ) - - - (44,301 ) - Convertible note 2 22 1.5 % (13,746 ) - - - - (13,746 ) Lease payable on Right of Use assets 23 5.0 % (13,898 ) (812 ) (819 ) (1,679 ) (4,522 ) (6,066 ) Lease payable on sale & leaseback transactions 23 5.0 % (45 ) (35 ) (10 ) - - - Total (65,452 ) 5,777 (788 ) (1,630 ) (48,789 ) (20,022 ) ¹ The senior secured term loan is a variable instrument which bears interest at an annual rate equal to 11.25% plus the greater of (a) one-month Term SOFR Reference Rate and (b) one percent per annum. 2 3 As at December 31, 2021 Note Effective interest Total US$’000 6 mths or less US$’000 6 -12 mths US$’000 1-2 years US$’000 2-5 years US$’000 > 5 years US$’000 Cash and cash equivalents 17 0.01 % 25,910 25,910 - - - - Lease receivable 14,16 4.0 % 293 81 61 89 62 - Exchangeable note¹ 22 4.8 % (83,312 ) - - - - (83,312 ) Other borrowings 0 % (31 ) - (31 ) - - - Lease payable on Right of Use assets 23 5.0 % (15,668 ) (973 ) (905 ) (1,554 ) (4,516 ) (7,720 ) Lease payable on sale & leaseback transactions 23 5.0 % (177 ) (51 ) (51 ) (75 ) - - Total (72,985 ) 24,967 (926 ) (1,540 ) (4,454 ) (91,032 ) ¹ The maturity of the Exchangeable Notes is based on the contractual maturity date of April 1, 2045.
Schedule of Interest Rate Profile of Financial Assets/Liabilities	December 31, 2022 US$‘000 December 31, 2021 US$‘000 Variable rate instruments Cash at bank and in hand 6,578 22,790 Short-term deposits - 3,120 Variable rate financial liabilities (senior secured term loan) (44,301 ) - (37,723 ) 25,910 Fixed rate instruments Fixed rate financial liabilities (exchangeable note) (210 ) (83,312 ) Fixed rate financial liabilities (convertible note) (13,746 ) - Fixed rate financial liabilities (borrowings) - (31 ) Fixed rate financial liabilities (lease payables) (13,943 ) (15,844 ) Financial assets (short-term deposits and short-term investments) - 3,121 Financial assets (lease receivables) 170 293 (27,729 ) (95,773 )
Schedule of Liquidity Risk Estimated Interest Payments of Maturities	As at December 31, 2022 US$’000 Carrying US$’000 Contractual US$’000 6 mths or US$’000 6 mths – 12 mths US$’000 1-2 years US$’000 2-5 years US$’000 >5 years US$’000 Financial liabilities Trade & other payables 15,261 15,261 15,261 - - - - Lease payable on Right of Use assets 13,898 17,196 1,120 1,130 2,240 5,739 6,967 Lease payable on sale & leaseback transactions 45 46 36 10 - - - Senior secured term loan 44,301 69,519 4,194 3,595 7,190 54,540 - Convertible note 13,746 21,900 150 150 300 900 20,400 Exchangeable notes 210 397 4 4 8 24 357 87,461 124,319 20,765 4,889 9,738 61,203 27,724 The contractual cash flows of interest on the senior secured term loan is estimated based on the prevailing interest rate at December 31, 2022 As at December 31, 2021 US$’000 Carrying US$’000 Contractual US$’000 6 mths or US$’000 6 mths – 12 mths US$’000 1-2 years US$’000 2-5 years US$’000 >5 years US$’000 Financial liabilities Trade & other payables 15,127 15,127 15,127 - - - - Lease payable on Right of Use assets 15,668 15,668 973 905 1,554 4,516 7,720 Lease payable on sale & leaseback transactions 177 177 51 51 75 - - Other borrowings 31 31 - 31 - - - Exchangeable notes ¹ 83,312 99,900 - - - - 99,900 Exchangeable note interest 999 93,906 1,998 1,998 3,996 11,988 73,926 115,314 224,809 18,149 2,985 5,625 16,504 181,546
Schedule of Foreign Currency Risk Short Term Financial Assets and Liabilities	EUR GBP SEK CAD BRL Other As at December 31, 2022 US$‘000 US$‘000 US$‘000 US$‘000 US$‘000 US$‘000 Cash 700 199 5 2,061 756 - Trade and other receivable 1,001 27 - 950 1,443 - Trade and other payables (3,481 ) (5 ) (6 ) (473 ) (662 ) - Lease liabilities (9,024 ) - - - (277 ) - Total exposure (10,804 ) 221 (1 ) 2,538 1,260 - EUR GBP SEK CAD BRL Other As at December 31, 2021 US$‘000 US$‘000 US$‘000 US$‘000 US$‘000 US$‘000 Cash 327 115 5 4,617 1,370 - Trade and other receivable 464 58 - 488 1,538 - Trade and other payables (2,456 ) (28 ) (11 ) (166 ) (629 ) - Lease liabilities (10,629 ) - - - (139 ) - Total exposure (12,294 ) 145 (6 ) 4,939 2,140 -
Schedule of Sensitivity Analysis	A 10% strengthening of the US Dollar against the Euro at December 31, 2022 would have increased profit and other equity by the amounts shown below. This analysis assumes that all other variables, in particular interest rates, remain constant. Profit or Loss US$’000 December 31, 2022 Euro 982 December 31, 2021 Euro 780 A 10% weakening of the US Dollar against the Euro at December 31, 2022 would have decreased profit and other equity by the amounts shown below. This analysis assumes that all other variables, in particular interest rates, remain constant. Profit or Loss US$000 December 31, 2022 Euro (1,200 ) December 31, 2021 Euro (953 )
Schedule of Maximum Credit Exposure of Financial Assets	Carrying Value 2022 Carrying Value 2021 Third party trade receivables (Note 16) 12,620 13,290 Finance lease income receivable (Note 16) 170 293 Cash and cash equivalents (Note 17) 6,578 25,910 19,368 39,493
Schedule of Exposure of Trade Receivables by Geographic Location	Carrying Value 2022 Carrying Value 2021 United States 6,061 5,822 Euro-zone countries 1,183 1,072 United Kingdom 67 118 Other regions 5,479 6,571 12,790 13,583
Schedule of Exposure of Trade Receivables by Customer	Carrying Value 2022 Carrying Value 2021 End-user customers 7,365 6,923 Distributors 4,630 6,220 Non-governmental organisations 795 440 12,790 13,583
Schedule of Ageing of Trade Receivables	Gross Impairment Expected Credit Loss Rate Gross Impairment Expected Credit Loss Rate 2022 2022 2022 2021 2021 2021 US$’000 US$’000 % US$’000 US$’000 % Not past due 8,341 - - % 8,461 - - % Past due 0-30 days 1,622 - - % 2,423 1 0.1 % Past due 31-120 days 1,564 23 1.5 % 1,981 97 4.9 % Greater than 120 days 3,783 2,668 70.5 % 3,011 2,888 73.0 % 15,310 2,691 - 15,876 2,986 -
Schedule of Movement in Allowance for Impairment of Trade Receivables	2022 2021 US$’000 US$’000 Balance at January 1 2,986 3,922 Charged to costs and expenses 1,240 76 Amounts written off during the year (1,535 ) (1,012 ) Balance at December 31 2,691 2,986

RECONCILIATION OF LIABILITIES_2

RECONCILIATION OF LIABILITIES ARISING FROM FINANCING ACTIVITIES (Tables)	12 Months Ended
	Dec. 31, 2022
Disclosure of reconciliation of liabilities arising from financing activities [abstract]
Schedule of Liabilities Arising from Financing Activities	Note Borrowings & derivative financial instruments Lease liabilities Balance at January 1, 2022 20,22,23 83,343 15,845 Cash-flows: Principal amount loaned – term loan 81,250 Principal amount loaned – convertible note 20,000 - Loan origination costs paid (3,591 ) - Interest paid for term loan (6,424 ) - Interest paid for convertible note (199 ) Interest paid for exchangeable notes (1,293 ) Repayment of exchangeable notes (86,730 ) Repayment of term loan (34,500 ) Repayment of CEBA loan (23 ) (2,761 ) Penalty paid for early settlement of term loan (3,450 ) - Non-cash: Interest charged 7,914 - Penalty for early settlement charged 3,450 - Shares issued as consideration for purchase of Exchangeable Notes (6,133 ) - Equity component of convertible note at date of issue (6,709 ) - Derivative financial asset at date of issue 202 - Loss on disposal of Exchangeable Notes 9,678 - Additions (related to Right of Use assets) - 830 Exchange adjustment - (628 ) Loan forgiven (7 ) - Accretion interest 3,351 657 Fair value of derivative liability - warrants (303 ) - Balance at December 31, 2022 22,23 59,826 13,943 Note Borrowings & derivative financial instruments Lease liabilities Balance at January 1, 2021 20, 22,23 84,065 18,741 Cash-flows: Interest paid (3,996 ) (11 ) Repayment - (2,939 ) Non-cash: - Interest charged 3,996 - Additions (related to Right of Use assets) - 71 Exchange adjustment - (820 ) Accretion interest 648 803 Fair value 6 (1,370 ) - Balance at December 31, 2021 22,23 83,343 15,845

GROUP UNDERTAKINGS (Tables)

GROUP UNDERTAKINGS (Tables)	12 Months Ended
	Dec. 31, 2022
Disclosure of group undertakings [Abstract]
Schedule of subsidiary undertakings	Name and registered office Principal activity Principal Country of Group % holding Trinity Biotech Manufacturing Limited IDA Business Park, Bray County Wicklow, Ireland Manufacture and sale Ireland 100% Trinity Research Limited IDA Business Park, Bray County Wicklow, Ireland Research and Ireland 100% Benen Trading Limited IDA Business Park, Bray County Wicklow, Ireland Trading Ireland 100% Trinity Biotech Manufacturing Services Limited IDA Business Park, Bray County Wicklow, Ireland Dormant Ireland 100% Trinity Biotech Luxembourg Sarl 1, rue Bender, L-1229 Luxembourg Investment and Luxembourg 100% Trinity Biotech Inc Girts Road, Jamestown, NY 14702, USA Holding Company U.S.A. 100% Clark Laboratories Inc Trading as Trinity Biotech (USA) Girts Road, Jamestown NY14702, USA Manufacture and sale U.S.A. 100% Mardx Diagnostics Inc 5919 Farnsworth Court Carlsbad CA 92008, USA Dormant U.S.A. 100% Fitzgerald Industries International, Inc 2711 Centerville Road, Suite 400 Wilmington, New Castle Delaware, 19808, USA Management services U.S.A. 100% Biopool US Inc (trading as Trinity Biotech Distribution) Girts Road, Jamestown NY14702, USA Sale of diagnostic test U.S.A. 100% Primus Corporation 4231 E 75 th Kansas City, MO 64132, USA Manufacture and sale U.S.A. 100% Name and registered office Principal activity Principal Country of Group % holding Phoenix Bio-tech Corp. 1166 South Service Road West Oakville, ON L6L 5T7 Canada. Dormant Canada 100% Fiomi Diagnostics Holding AB Dag Hammarskjöldsv 52A SE-752 37 Uppsala Sweden Holding Company Sweden 100% Fiomi Diagnostics AB Dag Hammarskjöldsv 52A SE-752 37 Uppsala Sweden Discontinued operation Sweden 100% Trinity Biotech Do Brasil Comercio e Importacao Ltda Rua Silva Bueno 1.660 – Cj. 101/102 Ipiranga Sao Paulo Brazil Sale of diagnostic test Brazil 100% Trinity Biotech (UK) Ltd Mills and Reeve LLP Botanic House 100 Hills Road Cambridge, CB2 1PH United Kingdom Sales & marketing UK 100% Immco Diagnostics Inc 60 Pineview Drive Buffalo NY 14228, USA Manufacture and sale of U.S.A. 100% Nova Century Scientific Inc 5022 South Service Road Burlington Ontario Canada Manufacture and sale of Canada 100% Trinity Biotech Investment Ltd PO Box 309 Ugland House Grand Cayman KY1-1104 Cayman Islands Investment and Cayman Islands 100%

BASIS OF PREPARATION AND SIGN_4

BASIS OF PREPARATION AND SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details) $ in Millions	12 Months Ended
	Dec. 31, 2022 USD ($)
Basis Of Preparation And Significant Accounting Policies [Line Items]
Net current assets	$ 29.3
Proceeds from sale of business	30
Reduction Of Gross Debt	$ 10
Capitalised development expenditure [member]
Basis Of Preparation And Significant Accounting Policies [Line Items]
Estimated useful lives of intangible assets (In years)	15 years

BASIS OF PREPARATION AND SIGN_5

BASIS OF PREPARATION AND SIGNIFICANT ACCOUNTING POLICIES (Schedule of Owned Assets) (Details)	12 Months Ended
	Dec. 31, 2022
Leasehold improvements [member]
Disclosure of detailed information about property, plant and equipment [line items]
Estimated useful lives of intangible assets (In years)	5-15
Buildings [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Estimated useful lives of intangible assets (In years)	50
Office equipment and fittings [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Estimated useful lives of intangible assets (In years)	10
Computer equipment [member]
Disclosure of detailed information about property, plant and equipment [line items]
Estimated useful lives of intangible assets (In years)	3-5
Plant and equipment [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Estimated useful lives of intangible assets (In years)	5-15

BASIS OF PREPARATION AND SIGN_6

BASIS OF PREPARATION AND SIGNIFICANT ACCOUNTING POLICIES (Schedule of Amortisation) (Details)	12 Months Ended
	Dec. 31, 2022
Capitalised development expenditure [member]
Disclosure of intangible assets with indefinite useful life [line items]
Estimated useful lives of intangible assets (In years)	15 years
Patents and licences [Member]
Disclosure of intangible assets with indefinite useful life [line items]
Estimated useful lives of intangible assets (In years)	6-15
Other (including acquired customer and supplier lists) [Member]
Disclosure of intangible assets with indefinite useful life [line items]
Estimated useful lives of intangible assets (In years)	6-15

SEGMENT INFORMATION (Schedule o

SEGMENT INFORMATION (Schedule of Revenue by Geographical Area Based on Location of Assets) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disclosure of disaggregation of revenue from contracts with customers [line items]
Revenue from external customers	$ 74,779	$ 92,965	$ 101,980
Inter-segment revenue	0	0	0
Total revenue	74,779	92,965	101,980
Americas [Member]
Disclosure of disaggregation of revenue from contracts with customers [line items]
Revenue from external customers	50,508	67,249	77,688
Inter-segment revenue	26,110	49,059	59,304
Total revenue	76,618	116,308	136,992
Ireland [Member]
Disclosure of disaggregation of revenue from contracts with customers [line items]
Revenue from external customers	24,271	25,716	24,292
Inter-segment revenue	828	2,517	1,095
Total revenue	25,099	28,233	25,387
Eliminations [Member]
Disclosure of disaggregation of revenue from contracts with customers [line items]
Revenue from external customers	0	0	0
Inter-segment revenue	(26,938)	(51,576)	(60,399)
Total revenue	$ (26,938)	$ (51,576)	$ (60,399)

SEGMENT INFORMATION (Schedule_2

SEGMENT INFORMATION (Schedule of Revenue by Customers Geographical Area) (Details) - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disclosure of disaggregation of revenue from contracts with customers [line items]
Revenue from external customers		$ 74,779	$ 92,965	$ 101,980
Americas [Member]
Disclosure of disaggregation of revenue from contracts with customers [line items]
Revenue from external customers		40,176	57,799	70,408
Asia / Africa [Member]
Disclosure of disaggregation of revenue from contracts with customers [line items]
Revenue from external customers		25,022	25,504	22,567
Europe (including Ireland) [Member]
Disclosure of disaggregation of revenue from contracts with customers [line items]
Revenue from external customers	[1]	$ 9,581	$ 9,662	$ 9,005
[1]Revenue from customers in Ireland is not disclosed separately due to the immateriality of these revenues.

SEGMENT INFORMATION (Schedule_3

SEGMENT INFORMATION (Schedule of Revenue by Major Product Group) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disclosure of products and services [line items]
Revenue	$ 74,779	$ 92,965	$ 101,980
Clinical Laboratory Member
Disclosure of products and services [line items]
Revenue	58,294	74,700	84,280
Clinical laboratory services [Member]
Disclosure of products and services [line items]
Revenue	7,272	7,928	8,485
Point-of-Care [Member]
Disclosure of products and services [line items]
Revenue	$ 9,213	$ 10,337	$ 9,215

SEGMENT INFORMATION (Schedule_4

SEGMENT INFORMATION (Schedule of Amount Relating From Revenue) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disclosure of operating segments [abstract]
Revenue from contracts with customers (a)	$ 74,779	$ 92,965	$ 101,980
Revenue from other sources	0	0	0
Total revenue	$ 74,779	$ 92,965	$ 101,980

SEGMENT INFORMATION (Schedule_5

SEGMENT INFORMATION (Schedule of Revenue Derives From Transfer of Goods and Services) (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Timing of revenue recognition
At a point in time	$ 74,445	$ 92,522	$ 101,352
Over time	334	443	628
Total	74,779	92,965	101,980
America [Member]
Timing of revenue recognition
At a point in time	50,174	66,806	77,060
Over time	334	443	628
Total	50,508	67,249	77,688
Ireland [Member]
Timing of revenue recognition
At a point in time	24,271	25,716	24,292
Over time	0	0	0
Total	24,271	25,716	24,292
Other Countries [Member]
Timing of revenue recognition
At a point in time	0	0	0
Over time	0	0	0
Total	0	0	0
Customer [Member]
Timing of revenue recognition
At a point in time	74,445	92,522	101,352
Over time	334	443	628
Total	74,779	92,965	101,980
Customer [Member] | America [Member]
Timing of revenue recognition
At a point in time	39,842	57,356	69,780
Over time	334	443	628
Total	40,176	57,799	70,408
Customer [Member] | Asia Or Africa Member
Timing of revenue recognition
At a point in time	25,022	25,504	22,567
Over time	0	0	0
Total	25,022	25,504	22,567
Customer [Member] | Europe [Member]
Timing of revenue recognition
At a point in time	9,581	9,662	9,005
Over time	0	0	0
Total	$ 9,581	$ 9,662	$ 9,005

SEGMENT INFORMATION (Schedule_6

SEGMENT INFORMATION (Schedule of Segment Results by Geographical Area) (Details) - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disclosure of disaggregation of revenue from contracts with customers [line items]
Result before impairment and unallocated expenses		$ (8,440)	$ 14,348	$ 18,688
Impairment charges		(5,839)	(6,944)	(17,779)
Result after impairment		(14,279)	7,404	909
Unallocated expenses	[1]	(2,473)	(779)	(827)
Operating loss		(16,752)	6,625	82
Net financing expense (Note 6)		(24,442)	(5,874)	(6,715)
Profit/Loss before taxes		(41,194)	751	(6,633)
Income tax credit (Note 7)		192	178	620
Profit/Loss for the year on continuing operations		(41,002)	929	(6,013)
Profit/loss for the year on discontinued operations (Note 8)		(7)	(54)	(375)
(Loss)/profit for the year		(41,009)	875	(6,388)
America [Member]
Disclosure of disaggregation of revenue from contracts with customers [line items]
Result before impairment and unallocated expenses		(5,891)	9,276	14,495
Impairment charges		(2,331)	(6,088)	(17,779)
Result after impairment		(8,222)	3,188	3,284
Profit/Loss before taxes		(21,393)	(5,050)	(10,233)
Ireland [Member]
Disclosure of disaggregation of revenue from contracts with customers [line items]
Result before impairment and unallocated expenses		(2,516)	5,084	4,264
Impairment charges		(3,508)	(856)	0
Result after impairment		(6,024)	4,228	4,264
Profit/Loss before taxes		(19,768)	1,862	296
Other Countries [Member]
Disclosure of disaggregation of revenue from contracts with customers [line items]
Result before impairment and unallocated expenses		(33)	(12)	(71)
Impairment charges		0	0	0
Result after impairment		$ (33)	$ (12)	$ (71)
[1]Unallocated expenses represent head office general and administration costs of the Group, which cannot be allocated to the results of any specific geographical area.

SEGMENT INFORMATION (Schedule_7

SEGMENT INFORMATION (Schedule of Segment Assets and Segment Liabilities by Geographical Area) (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Assets and liabilities
Segment assets	$ 79,474	$ 87,345
Unallocated Assets By Segment Abstract
Income tax assets (current and deferred)	6,052	5,640
Cash and cash equivalents and short-term investments	6,578	25,910	$ 27,327	$ 16,400
Total assets as reported in the Group balance sheet	92,104	118,895
Segment liabilities	89,194	114,334
Unallocated liabilities:
Income tax liabilities (current and deferred)	5,086	4,880
Total liabilities as reported in the Group balance sheet	94,280	119,214
America [Member]
Assets and liabilities
Segment assets	41,779	45,891
Unallocated Assets By Segment Abstract
Segment liabilities	58,307	12,382
Ireland [Member]
Assets and liabilities
Segment assets	37,695	41,453
Unallocated Assets By Segment Abstract
Segment liabilities	30,845	101,927
Other Countries [Member]
Assets and liabilities
Segment assets	0	1
Unallocated Assets By Segment Abstract
Segment liabilities	$ 42	$ 25

SEGMENT INFORMATION (Schedule_8

SEGMENT INFORMATION (Schedule of Long Lived Assets) (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Disclosure of disaggregation of revenue from contracts with customers [line items]
Long lived asstes	$ 41,090	$ 42,106
Ireland [Member]
Disclosure of disaggregation of revenue from contracts with customers [line items]
Long lived asstes	21,180	22,617
America [Member]
Disclosure of disaggregation of revenue from contracts with customers [line items]
Long lived asstes	$ 19,910	$ 19,489

SEGMENT INFORMATION (Schedule_9

SEGMENT INFORMATION (Schedule of Depreciation and Amortisation by Geographical Area) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disclosure of disaggregation of revenue from contracts with customers [line items]
Depreciation	$ 1,410	$ 1,866	$ 1,714
Amortisation	923	917	1,403
Ireland [Member]
Disclosure of disaggregation of revenue from contracts with customers [line items]
Depreciation	128	204	127
Amortisation	123	69	32
America [Member]
Disclosure of disaggregation of revenue from contracts with customers [line items]
Depreciation	1,282	1,662	1,587
Amortisation	$ 800	$ 848	$ 1,371

SEGMENT INFORMATION (Schedul_10

SEGMENT INFORMATION (Schedule of Share Based Payment Expense by Geographical Area) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disclosure of disaggregation of revenue from contracts with customers [line items]
Total Share-based payments	$ 1,755	$ 1,100	$ 792
Ireland [Member]
Disclosure of disaggregation of revenue from contracts with customers [line items]
Total Share-based payments	632	1,072	722
America [Member]
Disclosure of disaggregation of revenue from contracts with customers [line items]
Total Share-based payments	$ 1,123	$ 28	$ 70

SEGMENT INFORMATION (Schedul_11

SEGMENT INFORMATION (Schedule of Taxation Expense by Geographical Area) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disclosure of disaggregation of revenue from contracts with customers [line items]
Taxation expense	$ 192	$ 178	$ 620
Ireland [Member]
Disclosure of disaggregation of revenue from contracts with customers [line items]
Taxation expense	284	540	293
Other Countries [Member]
Disclosure of disaggregation of revenue from contracts with customers [line items]
Taxation expense	(4)	(2)	(8)
America [Member]
Disclosure of disaggregation of revenue from contracts with customers [line items]
Taxation expense	$ (88)	$ (360)	$ 335

SEGMENT INFORMATION (Schedul_12

SEGMENT INFORMATION (Schedule of Capital Expenditure by Geographical Area) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Disclosure of disaggregation of revenue from contracts with customers [line items]
Capital expenditure	$ 6,813	$ 8,602
Ireland [Member]
Disclosure of disaggregation of revenue from contracts with customers [line items]
Capital expenditure	2,443	3,826
Other Countries [Member]
Disclosure of disaggregation of revenue from contracts with customers [line items]
Capital expenditure	0	0
America [Member]
Disclosure of disaggregation of revenue from contracts with customers [line items]
Capital expenditure	$ 4,370	$ 4,776

EMPLOYMENT (Narrative) (Details

EMPLOYMENT (Narrative) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [abstract]
Total personnel expenses, inclusive of amounts capitalised for wages and salaries, social welfare costs and pension costs	$ 28,848,000	$ 33,366,000	$ 33,347,000
Total share based payments, inclusive of amounts capitalised	1,755,000	1,111,000	816,000
Employees contribution	352,000	352,000	447,000
Pension accrual	$ 44,000	$ 47,000	$ 47,000

EMPLOYMENT (Schedule of Average

EMPLOYMENT (Schedule of Average Number of Persons Employed) (Details)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disclosure of defined benefit plans [line items]
Number of persons employed	398	477	543
Research and development [Member]
Disclosure of defined benefit plans [line items]
Number of persons employed	30	41	52
Administration and sales [Member]
Disclosure of defined benefit plans [line items]
Number of persons employed	119	134	148
Manufacturing and quality [Member]
Disclosure of defined benefit plans [line items]
Number of persons employed	249	302	343

EMPLOYMENT (Schedule of Employm

EMPLOYMENT (Schedule of Employment Costs) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [abstract]
Wages and salaries	$ 23,608	$ 26,561	$ 26,187
Social welfare costs	2,036	2,403	2,195
Pension costs	352	352	447
Share-based payments	1,755	1,100	792
Restructuring Cost	274	270	388
Recognition of contingent asset	0	0	(1,316)
Employment Costs	$ 28,025	$ 30,686	$ 28,693

OTHER OPERATING INCOME (Narrati

OTHER OPERATING INCOME (Narrative) (Details)	12 Months Ended
	Dec. 31, 2022 CAD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)
Other Operating Income [Line Items]
Amount received from Provider Relief Fund				$ 225,000
Paycheck Protection Program Loan [Member]
Other Operating Income [Line Items]
Forgiveness amount	$ 10,000	$ 7,000	$ 4,668,000	$ 1,615,000

OTHER OPERATING INCOME (Schedul

OTHER OPERATING INCOME (Schedule of Other Operating Income) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disclosure of other operating income [Abstract]
Government supports - COVID-19	$ 7	$ 4,668	$ 1,840
Government grants	333	0	0
Other income	0	0	17
Rental income from premises	3	4	3
Other operating income	$ 343	$ 4,672	$ 1,860

IMPAIRMENT CHARGES (Schedule of

IMPAIRMENT CHARGES (Schedule of Statement of Operation) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disclosure of impairment charges and inventory provisioning [Abstract]
Impairment of PP&E (Note 11)	$ 733,000	$ 2,508,000	$ 1,795,000
Impairment of goodwill and other intangible assets (Note 14)	4,624,000	3,853,000	15,422,000
Impairment of prepayments (Note 16)	482,000	583,000	562,000
Total impairment loss	$ 5,839,000	$ 6,944,000	$ 17,779,000

FINANCIAL INCOME AND EXPENSES_2

FINANCIAL INCOME AND EXPENSES (Schedule of Financial Income (Expenses), Net) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Financial income:
Non-cash financial income	$ 303	$ 1,220	$ 0
Interest income	0	3	36
Financial income	303	1,223	36
Financial expense:
Interest on leases	(657)	(815)	(896)
Loss on disposal of exchangeable notes	(9,678)	0	0
Penalty for early settlement of term loan	(3,450)	0	0
Cash interest payable on senior secure term loan	(7,039)	0	0
Cash interest payable on convertible note	(199)	0	0
Cash interest on exchangeable notes	(296)	(3,996)	(3,996)
Loan origination costs	0	(1,638)	0
Non-cash interest on exchangeable notes	(84)	(648)	(643)
Non-cash interest on senior secured term loan	(2,772)	0	0
Non-cash interest on convertible note	(495)	0	0
Non-cash financial expense	(74)	0	(1,216)
Other	(1)	0	0
Financial expenses	(24,745)	(7,097)	(6,751)
Net Financing Expense	$ (24,442)	$ (5,874)	$ (6,715)

INCOME TAX CREDIT (Narrative) (

INCOME TAX CREDIT (Narrative) (Details) - USD ($)		12 Months Ended
		Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disclosure of disaggregation of revenue from contracts with customers [line items]
Total deferred tax (credit)/expense	[1]	$ 83,000	$ 37,000	$ (167,000)
Income from the Paycheck Protection Program loans			$ 4,700,000
Corporation tax rate		12.50%	(12.50%)	12.50%
Ireland [Member]
Disclosure of disaggregation of revenue from contracts with customers [line items]
Total deferred tax (credit)/expense		$ 109,000	$ 118,000	$ 444,000
Other Countries [Member]
Disclosure of disaggregation of revenue from contracts with customers [line items]
Total deferred tax (credit)/expense		$ 26,000	$ 81,000	$ 397,000
[1]In 2022, there was a deferred tax charge of US$109,000 (2021: charge of US$118,000) (2020: credit of US$444,000) recognised in respect of Ireland and a deferred tax credit of US$26,000 (2021: credit of US$81,000) (2020: credit of US$397,000) recognised in respect of overseas tax jurisdictions.

INCOME TAX CREDIT (Schedule of

INCOME TAX CREDIT (Schedule of Charge for Tax) (Details) - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Current tax (credit)/ expense
Irish Corporation tax		$ (331)	$ (511)	$ (480)
Foreign taxes	[1]	(5)	296	179
Adjustment in respect of prior years		61	0	(152)
Total current tax credit		(275)	(215)	(453)
Deferred tax credit
Origination and reversal of temporary differences (see Note 15)	[2]	321	620	48
Origination and reversal of net operating losses (see Note 15)	[2]	(238)	(583)	(215)
Total deferred tax credit	[2]	83	37	(167)
Total income tax credit on continuing operations in statement of operations		(192)	(178)	(620)
Tax charge on discontinued operations (see Note 10)		0	12	438
Total tax credit		$ (192)	$ (166)	$ (182)
[1]In 2022, the foreign taxes relate primarily to USA and Canada.[2]In 2022, there was a deferred tax charge of US$109,000 (2021: charge of US$118,000) (2020: credit of US$444,000) recognised in respect of Ireland and a deferred tax credit of US$26,000 (2021: credit of US$81,000) (2020: credit of US$397,000) recognised in respect of overseas tax jurisdictions.

INCOME TAX CREDIT (Schedule o_2

INCOME TAX CREDIT (Schedule of Overseas Tax Jurisdictions) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Effective tax rate
(Loss)/profit before taxation – continuing operations	$ (41,194)	$ 751	$ (6,633)
As a percentage of (loss)/profit before tax
Current tax %	(0.67%)	(28.63%)	(6.83%)
Total (current and deferred) %	(0.47%)	(23.70%)	(9.35%)

INCOME TAX CREDIT (Schedule o_3

INCOME TAX CREDIT (Schedule of Statutory Tax Rate) (Details)		12 Months Ended
		Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disclosure of income tax credit [Abstract]
Irish corporation tax		(12.50%)	12.50%	(12.50%)
Effect of current year net operating losses and temporary differences for which no deferred tax asset was recognised	[1]	11.66%	49.63%	24.13%
Effect of tax rates on overseas earnings		(7.76%)	(0.22%)	(9.92%)
Effect of Irish income taxable at higher tax rate		4.17%	98.68%	5.92%
Adjustments in respect of prior years		0.15%	(0.01%)	(10.66%)
R&D tax credits		(0.81%)	(79.22%)	(11.00%)
Other items	[2]	4.62%	(105.06%)	4.68%
Effective tax rate		(0.47%)	(23.70%)	(9.35%)
[1]No deferred tax asset was recognised because there was no reversing deferred tax liability in the same jurisdiction. reversing in the same period and insufficient future projected taxable income in the same jurisdiction.[2]Other items comprise items not chargeable to tax/expenses not deductible for tax purposes. This was a significant number in 2021 because the US$4.7 million income from the Paycheck Protection Program loans was not chargeable for tax purposes. There is no Paycheck Protection Program income in 2022.

INCOME TAX CREDIT (Schedule o_4

INCOME TAX CREDIT (Schedule of Loss Profit Before Taxes) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disclosure of disaggregation of revenue from contracts with customers [line items]
Profit/Loss before taxes	$ (41,194)	$ 751	$ (6,633)
Ireland [Member]
Disclosure of disaggregation of revenue from contracts with customers [line items]
Profit/Loss before taxes	(19,768)	1,862	296
Other regions [Member]
Disclosure of disaggregation of revenue from contracts with customers [line items]
Profit/Loss before taxes	33	3,939	3,304
America [Member]
Disclosure of disaggregation of revenue from contracts with customers [line items]
Profit/Loss before taxes	$ (21,393)	$ (5,050)	$ (10,233)

INCOME TAX CREDIT (Schedule o_5

INCOME TAX CREDIT (Schedule of Net Operating Losses) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disclosure of disaggregation of revenue from contracts with customers [line items]
Unutilised net operating losses	$ 75,957	$ 73,893	$ 85,198
Ireland [Member]
Disclosure of disaggregation of revenue from contracts with customers [line items]
Unutilised net operating losses	62,731	68,132	78,700
Other regions [Member]
Disclosure of disaggregation of revenue from contracts with customers [line items]
Unutilised net operating losses	448	1,000	2,185
America [Member]
Disclosure of disaggregation of revenue from contracts with customers [line items]
Unutilised net operating losses	$ 12,778	$ 4,761	$ 4,313

INCOME TAX CREDIT (Schedule o_6

INCOME TAX CREDIT (Schedule of Unrecognised Deferred Tax Assets) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disclosure of disaggregation of revenue from contracts with customers [line items]
Unrecognised deferred tax asset	$ 15,434	$ 18,810	$ 17,388
Ireland [Member]
Disclosure of disaggregation of revenue from contracts with customers [line items]
Unrecognised deferred tax asset	7,489	9,272	12,514
Other regions [Member]
Disclosure of disaggregation of revenue from contracts with customers [line items]
Unrecognised deferred tax asset	124	279	546
Americas – unused tax losses [Member]
Disclosure of disaggregation of revenue from contracts with customers [line items]
Unrecognised deferred tax asset	3,163	5,891	1,466
USA Tax Credits [Member]
Disclosure of disaggregation of revenue from contracts with customers [line items]
Unrecognised deferred tax asset	$ 4,658	$ 3,368	$ 2,862

LOSS FOR THE YEAR ON DISCONTI_3

LOSS FOR THE YEAR ON DISCONTINUED OPERATION (Narrative) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disclosure of classes of share capital [line items]
Loss for the year from discontinued operations	$ (7,000)	$ (54,000)	$ (375,000)
Basic (loss)/earnings per ADS denominator	134,939,327	83,606,810	83,606,810
Tax credit recovered	$ 0	$ 12,000	$ 438,000
Sweden [Member]
Disclosure of classes of share capital [line items]
Administrative expenses	7,000	0	0
Loss for the year from discontinued operations	(7,000)	(54,000)	(375,000)
Closure costs	0	(42,000)	127,000
Tax expense	$ 0	$ (12,000)	$ (438,000)
Class A Ordinary shares [Member]
Disclosure of classes of share capital [line items]
Basic (loss)/earnings per ADS denominator	134,939,327	83,606,810	83,606,810
Diluted earnings per share denominator	134,939,327	83,606,810	83,606,810
Basic (loss)/earnings per ordinary share for discontinued operations	$ (7,000)	$ (54,000)	$ (375,000)
Diluted (loss)/earnings per ordinary share for discontinued operations	$ (7,000)	$ (54,000)	$ (375,000)
American depositary share [Member]
Disclosure of classes of share capital [line items]
Basic (loss)/earnings per ADS denominator	33,734,832	20,901,703	20,901,703
Diluted earnings per share denominator	33,734,832	20,901,703	20,901,703
Basic (loss)/earnings per ordinary share for discontinued operations	$ (7,000)	$ (54,000)	$ (375,000)
Diluted (loss)/earnings per ordinary share for discontinued operations	$ (7,000)	$ (54,000)	$ (375,000)

LOSS FOR THE YEAR ON DISCONTI_4

LOSS FOR THE YEAR ON DISCONTINUED OPERATION (Schedule of Operating Profit/(Loss) for Cardiac) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
loss on re-measurement re-measurement of assets and liabilities:
Loss for the year from discontinued operations	$ (7,000)	$ (54,000)	$ (375,000)
Sweden [Member]
loss on re-measurement re-measurement of assets and liabilities:
Administrative expenses	(7,000)	0	0
Closure provision	0	(42,000)	127,000
Foreign currency translation reserve	0	0	(64,000)
Tax expense	0	(12,000)	(438,000)
Total loss	(7,000)	(54,000)	(375,000)
Loss for the year from discontinued operations	$ (7,000)	$ (54,000)	$ (375,000)

LOSS FOR THE YEAR ON DISCONTI_5

LOSS FOR THE YEAR ON DISCONTINUED OPERATION (Schedule of Earnings Per ADS) (Details) - $ / shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
American depositary share [Member]
Disclosure of classes of share capital [line items]
Basic loss per ADS (US Dollars) – discontinued operations	$ 0	$ 0	$ (0.02)
Diluted loss per ADS (US Dollars) – discontinued operations	0	0	(0.02)
Class A Ordinary shares [Member]
Disclosure of classes of share capital [line items]
Basic loss per ADS (US Dollars) – discontinued operations	0	0	0
Diluted loss per ADS (US Dollars) – discontinued operations	$ 0	$ 0	$ 0

LOSS FOR THE YEAR ON DISCONTI_6

LOSS FOR THE YEAR ON DISCONTINUED OPERATION (Schedule of Cash Flows Attributable) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disclosure of loss on discontinued operations [Abstract]
Cash flows from operating activities	$ (10)	$ (40)	$ (22)

(LOSS)_PROFIT BEFORE TAX (Narra

(LOSS)/PROFIT BEFORE TAX (Narrative) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disclosure of loss profit before tax [Abstract]
Depreciation on capitalised Intangible projects		$ 38,000	$ 40,000
Selling, General and Administrative Expenses – Closure Costs	$ 0	$ 0	$ 2,425,000

(LOSS)_PROFIT BEFORE TAX (Sched

(LOSS)/PROFIT BEFORE TAX (Schedule of Amount Charged to Statement of Operation) (Details) - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Directors' emoluments (including non- executive directors):
Remuneration		$ 1,639	$ 1,391	$ 2,020
Pension		24	24	41
Share based payments		1,707	986	678
Auditor's remuneration
Audit fees		888	580	558
Tax fees		89	77	146
Depreciation	[1]	1,410	1,827	1,674
Amortisation		923	917	1,403
Loss/(profit) on the disposal of property, plant and equipment		2	(1)	30
Selling, General and Administrative Expenses – Closure Costs		0	0	2,425
Net foreign exchange differences		$ (1,210)	$ (789)	$ 583
[1]In 2022, no depreciation was capitalised to research and development projects (2021: US$38,000) (2020: US$40,000).

(LOSS)_EARNINGS PER SHARE (Nar

(LOSS)/EARNINGS PER SHARE (Narrative) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disclosure of classes of share capital [line items]
(Loss)/profit for the year	$ (41,009,000)	$ 875,000	$ (6,388,000)
Weighted average number of shares	134,939,327	83,606,810	83,606,810
Issuable on exercise of warrants to Perceptive	10,000,000	0	0
Class A Ordinary shares [Member]
Disclosure of classes of share capital [line items]
(Loss)/profit for the year	$ 41,009,000	$ 875,000	$ (6,388,000)
Basic earnings per ordinary share for continuing operations	$ 41,002,000	$ 929,000	$ (6,013,000)
Weighted average number of shares	134,939,327	83,606,810	83,606,810
Number of shares issued	164,986,000	96,162,000	96,162,000
Number of ordinary shares issuable on exercise of options	16,800,000
Number of options granted	3,000,000
Number of options issuable	1,400,000
Number of options lapsed unexercised	280,000
Number of shares issued on the exercise of options	400,000
Issuable on exercise of warrants to Perceptive	10,000,000
American depositary share [Member]
Disclosure of classes of share capital [line items]
(Loss)/profit for the year	$ 41,009,000	$ 875,000	$ (6,388,000)
Basic earnings per ordinary share for continuing operations	$ 41,002,000	$ 929,000	$ (6,013,000)
Weighted average number of shares	33,734,832	20,901,703	20,901,703
Number of shares issued	41,247,000	24,041,000	24,041,000
Number of ordinary shares issuable on exercise of options	4,200,000
Number of options granted	750,000
Number of options issuable	350,000
Number of options lapsed unexercised	70,000
Number of shares issued on the exercise of options	100,000
Issuable on exercise of warrants to Perceptive	2,500,000	0	0
Minimum [Member] | Class A Ordinary shares [Member]
Disclosure of classes of share capital [line items]
Number of shares issuable on exercise of warrants to perceptive exercise price per share	$ 0.325
Minimum [Member] | American depositary share [Member]
Disclosure of classes of share capital [line items]
Number of shares issuable on exercise of warrants to perceptive exercise price per share	1.3
Maximum [Member] | Class A Ordinary shares [Member]
Disclosure of classes of share capital [line items]
Number of shares issuable on exercise of warrants to perceptive exercise price per share	0.268
Maximum [Member] | American depositary share [Member]
Disclosure of classes of share capital [line items]
Number of shares issuable on exercise of warrants to perceptive exercise price per share	$ 1.071

(LOSS)_EARNINGS PER SHARE (Sch

(LOSS)/EARNINGS PER SHARE (Schedule of Basic Earnings Per Ordinary Share) (Details) - shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disclosure of classes of share capital [line items]
Basic (loss)/earnings per share denominator	134,939,327	83,606,810	83,606,810
Reconciliation to weighted average (loss)/earnings per share denominator:
Basic (loss)/earnings per share denominator	134,939,327	83,606,810	83,606,810
Class A Ordinary shares [Member]
Disclosure of classes of share capital [line items]
Basic (loss)/earnings per share denominator	134,939,327	83,606,810	83,606,810
Reconciliation to weighted average (loss)/earnings per share denominator:
Number of ‘A’ ordinary shares at January 1	96,162,410	96,162,410	96,162,410
Weighted average number of ‘A’ ordinary shares issued during the year	51,332,517	0	0
Weighted average number of treasury shares	(12,555,600)	(12,555,600)	(12,555,600)
Basic (loss)/earnings per share denominator	134,939,327	83,606,810	83,606,810

(LOSS)_EARNINGS PER SHARE (S_2

(LOSS)/EARNINGS PER SHARE (Schedule of Diluted Earnings Per Ordinary Share) (Details) - shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Potentially Dilutive Instruments
Issuable on exercise of options	44,814,672	18,727,990	19,485,990
Issuable on exercise of warrants to Perceptive	10,000,000	0	0
Issuable on conversion of Exchangeable notes	38,391	18,263,254	18,263,254
Issuable on conversion of Convertible notes	24,691,358	0	0
Total number of potentially dilutive instruments excluded from the weighted average number of ‘A’ ordinary shares in calculating dilutive (loss)/earnings per ‘A’ ordinary share	79,544,421	36,991,244	37,749,244

(LOSS)_EARNINGS PER SHARE (S_3

(LOSS)/EARNINGS PER SHARE (Schedule of Earnings Per ADS) (Details) - shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disclosure of classes of share capital [line items]
Basic (loss)/earnings per ADS denominator	134,939,327	83,606,810	83,606,810
Reconciliation to weighted average (loss)/earnings per ADS denominator:
Basic (loss)/earnings per share denominator	134,939,327	83,606,810	83,606,810
American depositary share [Member]
Disclosure of classes of share capital [line items]
ADS	33,734,832	20,901,703	20,901,703
Basic (loss)/earnings per ADS denominator	33,734,832	20,901,703	20,901,703
Reconciliation to weighted average (loss)/earnings per ADS denominator:
Number of ADS at January 1 (Note 18)	24,040,602	24,040,602	24,040,602
Weighted average number of shares issued during the year	12,833,129	0	0
Weighted average number of treasury shares	(3,138,899)	(3,138,899)	(3,138,899)
Basic (loss)/earnings per share denominator	33,734,832	20,901,703	20,901,703

(LOSS)_EARNINGS PER SHARE (S_4

(LOSS)/EARNINGS PER SHARE (Schedule of Diluted Earnings Per ADS Share Calculation) (Details) - shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Potentially Dilutive Instruments
Issuable on exercise of options	44,814,672	18,727,990	19,485,990
Issuable on exercise of warrants to Perceptive	10,000,000	0	0
Issuable on conversion of Exchangeable notes	38,391	18,263,254	18,263,254
Issuable on conversion of Convertible notes	24,691,358	0	0
Total number of potentially dilutive instruments excluded from the weighted average number of ‘A’ ordinary shares in calculating dilutive (loss)/earnings per ‘A’ ordinary share	79,544,421	36,991,244	37,749,244
American depositary share [Member]
Potentially Dilutive Instruments
Issuable on exercise of options	11,203,668	4,681,998	4,871,498
Issuable on exercise of warrants to Perceptive	2,500,000	0	0
Issuable on conversion of Exchangeable notes	9,598	4,565,814	4,565,814
Issuable on conversion of Convertible notes	6,172,840	0	0
Total number of potentially dilutive instruments excluded from the weighted average number of ‘A’ ordinary shares in calculating dilutive (loss)/earnings per ‘A’ ordinary share	19,886,106	9,247,812	9,437,312

PROPERTY, PLANT AND EQUIPMENT_2

PROPERTY, PLANT AND EQUIPMENT (Narrative) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disclosure of detailed information about property, plant and equipment [line items]
Impairment loss	$ 733,000	$ 2,508,000	$ 1,795,000
Net book value of assets held under operating lease
Depreciation charged on assets under operating lease	34,000	27,000
Property, plant and equipment under construction	0	0
Buildings [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Income from sub-letting right-of-use	$ 3,000	$ 3,000

PROPERTY, PLANT AND EQUIPMENT_3

PROPERTY, PLANT AND EQUIPMENT (Schedule of Composition of Property and Equipment Related to Accumulated Depreciation) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disclosure of detailed information about property, plant and equipment [line items]
Balance at beginning year	$ 5,918,000
Impairment loss	(733,000)	$ (2,508,000)	$ (1,795,000)
Balance at end of year	5,682,000	5,918,000
Cost [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Balance at beginning year	63,463,000	65,105,000
Additions	1,934,000	1,708,000
Disposals or retirements	(67,000)	(2,851,000)
Reallocations / reclassifications	0
Exchange adjustments	276,000	(499,000)
Balance at end of year	65,606,000	63,463,000	65,105,000
Cost [Member] | Land and buildings [member]
Disclosure of detailed information about property, plant and equipment [line items]
Balance at beginning year	24,334,000	24,287,000
Additions	379,000	46,000
Disposals or retirements	0	0
Reallocations / reclassifications	0
Exchange adjustments	(31,000)	1,000
Balance at end of year	24,682,000	24,334,000	24,287,000
Cost [Member] | Leasehold improvements [member]
Disclosure of detailed information about property, plant and equipment [line items]
Balance at beginning year	2,592,000	2,670,000
Additions	93,000	126,000
Disposals or retirements	0	(186,000)
Reallocations / reclassifications	0
Exchange adjustments	16,000	(18,000)
Balance at end of year	2,701,000	2,592,000	2,670,000
Cost [Member] | Computer equipment [member]
Disclosure of detailed information about property, plant and equipment [line items]
Balance at beginning year	4,200,000	4,309,000
Additions	362,000	144,000
Disposals or retirements	(25,000)	(255,000)
Reallocations / reclassifications	(2,000)
Exchange adjustments	5,000	2,000
Balance at end of year	4,540,000	4,200,000	4,309,000
Cost [Member] | Plant and equipment [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Balance at beginning year	32,337,000	33,839,000
Additions	1,100,000	1,392,000
Disposals or retirements	(42,000)	(2,410,000)
Reallocations / reclassifications	2,000
Exchange adjustments	286,000	(484,000)
Balance at end of year	33,683,000	32,337,000	33,839,000
Accumulated depreciation and impairment losses [member]
Disclosure of detailed information about property, plant and equipment [line items]
Balance at beginning year	(57,545,000)	(56,558,000)
Charge for the year	(1,410,000)	(1,866,000)
Disposals or retirements	65,000	2,851,000
Impairment loss	(733,000)	(2,508,000)
Exchange adjustments	(301,000)	536,000
Balance at end of year	(59,924,000)	(57,545,000)	(56,558,000)
Accumulated depreciation and impairment losses [member] | Land and buildings [member]
Disclosure of detailed information about property, plant and equipment [line items]
Balance at beginning year	(21,432,000)	(19,629,000)
Charge for the year	(414,000)	(628,000)
Disposals or retirements	0	0
Impairment loss	(48,000)	(1,196,000)
Exchange adjustments	9,000	21,000
Balance at end of year	(21,885,000)	(21,432,000)	(19,629,000)
Accumulated depreciation and impairment losses [member] | Leasehold improvements [member]
Disclosure of detailed information about property, plant and equipment [line items]
Balance at beginning year	(2,131,000)	(1,884,000)
Charge for the year	(133,000)	(149,000)
Disposals or retirements	0	186,000
Impairment loss	(4,000)	(279,000)
Exchange adjustments	(16,000)	(5,000)
Balance at end of year	(2,284,000)	(2,131,000)	(1,884,000)
Accumulated depreciation and impairment losses [member] | Computer equipment [member]
Disclosure of detailed information about property, plant and equipment [line items]
Balance at beginning year	(3,950,000)	(3,946,000)
Charge for the year	(214,000)	(115,000)
Disposals or retirements	22,000	255,000
Impairment loss	(31,000)	(98,000)
Exchange adjustments	(5,000)	(46,000)
Balance at end of year	(4,178,000)	(3,950,000)	(3,946,000)
Accumulated depreciation and impairment losses [member] | Plant and equipment [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Balance at beginning year	(30,032,000)	(31,099,000)
Charge for the year	(649,000)	(974,000)
Disposals or retirements	43,000	2,410,000
Impairment loss	(650,000)	(935,000)
Exchange adjustments	(289,000)	566,000
Balance at end of year	(31,577,000)	(30,032,000)	$ (31,099,000)
Carrying amounts [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Balance at beginning year	5,918,000
Balance at end of year	5,682,000	5,918,000
Carrying amounts [Member] | Land and buildings [member]
Disclosure of detailed information about property, plant and equipment [line items]
Balance at beginning year	2,902,000
Balance at end of year	2,797,000	2,902,000
Carrying amounts [Member] | Leasehold improvements [member]
Disclosure of detailed information about property, plant and equipment [line items]
Balance at beginning year	461,000
Balance at end of year	417,000	461,000
Carrying amounts [Member] | Computer equipment [member]
Disclosure of detailed information about property, plant and equipment [line items]
Balance at beginning year	250,000
Balance at end of year	362,000	250,000
Carrying amounts [Member] | Plant and equipment [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Balance at beginning year	2,305,000
Balance at end of year	$ 2,106,000	$ 2,305,000

PROPERTY, PLANT AND EQUIPMENT_4

PROPERTY, PLANT AND EQUIPMENT (Schedule of Additional Information on Right-of-use Assets) (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Disclosure of detailed information about property, plant and equipment [line items]
Right-of-use assets	$ 2,699	$ 2,572
Depreciation Member
Disclosure of detailed information about property, plant and equipment [line items]
Right-of-use assets	(455)	(614)
Accumulated impairment Charge [member]
Disclosure of detailed information about property, plant and equipment [line items]
Right-of-use assets	(248)	(1,089)
Buildings [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Right-of-use assets	2,482	2,549
Buildings [Member] | Depreciation Member
Disclosure of detailed information about property, plant and equipment [line items]
Right-of-use assets	(398)	(609)
Buildings [Member] | Accumulated impairment Charge [member]
Disclosure of detailed information about property, plant and equipment [line items]
Right-of-use assets	(48)	(1,089)
Computer equipment [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Right-of-use assets	217	23
Computer equipment [Member] | Depreciation Member
Disclosure of detailed information about property, plant and equipment [line items]
Right-of-use assets	(40)	(5)
Computer equipment [Member] | Accumulated impairment Charge [member]
Disclosure of detailed information about property, plant and equipment [line items]
Right-of-use assets	0	0
Plant and equipment [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Right-of-use assets	0	0
Plant and equipment [Member] | Depreciation Member
Disclosure of detailed information about property, plant and equipment [line items]
Right-of-use assets	(17)	0
Plant and equipment [Member] | Accumulated impairment Charge [member]
Disclosure of detailed information about property, plant and equipment [line items]
Right-of-use assets	$ (200)	$ 0

PROPERTY, PLANT AND EQUIPMENT_5

PROPERTY, PLANT AND EQUIPMENT (Schedule of Income from Sub-letting Right-of-use Buildings) (Details)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Buildings [Member]
Disclosure of quantitative information about right-of-use assets [line items]
Number Of Right Of Use Leased Assets	9	11
Average remaining lease term (years)	5 years	3 years
No. of Leases with extension options	2	1
No. of Leases with options to purchase	0	0
No. of leases with variable payments linked to index	0	2
No. of leases with termination options	0	0
Buildings [Member] | Bottom of range [member]
Disclosure of quantitative information about right-of-use assets [line items]
Range of remaining term in years	1 year	1 year
Buildings [Member] | Top of range [member]
Disclosure of quantitative information about right-of-use assets [line items]
Range of remaining term in years	11 years	12 years
Vehicles [Member]
Disclosure of quantitative information about right-of-use assets [line items]
Number Of Right Of Use Leased Assets	20	16
Average remaining lease term (years)	2 years	2 years
No. of Leases with extension options	0	0
No. of Leases with options to purchase	20	16
No. of leases with variable payments linked to index	0	0
No. of leases with termination options	20	16
Vehicles [Member] | Bottom of range [member]
Disclosure of quantitative information about right-of-use assets [line items]
Range of remaining term in years	4 months 24 days	1 year
Vehicles [Member] | Top of range [member]
Disclosure of quantitative information about right-of-use assets [line items]
Range of remaining term in years	3 years	3 years
I.T. and office equipment [Member]
Disclosure of quantitative information about right-of-use assets [line items]
Number Of Right Of Use Leased Assets	5	2
Range of remaining term in years	4 years
Average remaining lease term (years)	4 years	4 years
No. of Leases with extension options	0	0
No. of Leases with options to purchase	0	0
No. of leases with variable payments linked to index	0	0
No. of leases with termination options	0	0
I.T. and office equipment [Member] | Bottom of range [member]
Disclosure of quantitative information about right-of-use assets [line items]
Range of remaining term in years		1 year
I.T. and office equipment [Member] | Top of range [member]
Disclosure of quantitative information about right-of-use assets [line items]
Range of remaining term in years		5 years

GOODWILL AND INTANGIBLE ASSET_2

GOODWILL AND INTANGIBLE ASSETS (Narrative) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Development costs not amortised	$ 6,982,000	$ 7,994,000	$ 6,980,000
Description of project completion period	January 1, 2023 to December 31, 2025
Additional project cost	$ 1,100,000
Intangible assets under development written down	2,214,000
Intangible assets under development impairment charge	120,000
Assets under development carrying value	$ 1,265,000
Long Term Growth Rate	2%	2%
Variation in discount rate	10%
Actuarial assumption of discount rate percentage	10%
Impairment loss	$ 4,624,000	$ 3,853,000	$ 15,422,000
Impairment loss recognised in other comprehensive income, intangible assets other than goodwill	5,839,000	$ 6,944,000
Tri-stat [Member]
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Assets under development carrying value	$ 1,024,000
Top of range [member]
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Cash flow projections	0%
Pre tax discount rates	24%	25%
Bottom of range [member]
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Cash flow projections	5%
Pre tax discount rates	16%	16%
Immco Diagnostics Inc [Member]
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Impairment loss		$ 869,000
Impairment loss recognised in other comprehensive income, intangible assets other than goodwill		4,979,000
Trinity Biotech Manufacturing Limited [Member]
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Impairment loss recognised in other comprehensive income, intangible assets other than goodwill	$ 3,599,000	$ 856,000

GOODWILL AND INTANGIBLE ASSET_3

GOODWILL AND INTANGIBLE ASSETS (Schedule of Goodwill and Intangible Assets) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disclosure of detailed information about intangible assets [line items]
Balance at beginning year	$ 35,981
Impairment losses	4,624	$ 3,853	$ 15,422
Exchange adjustments	(64)
Balance at end of year	35,269	35,981
Cost [Member]
Disclosure of detailed information about intangible assets [line items]
Balance at beginning year	242,260	250,417
Additions	4,879	6,894
Disposals or retirements		(15,052)
Exchange adjustments		1
Balance at end of year	247,075	242,260	250,417
Carrying amounts [Member]
Disclosure of detailed information about intangible assets [line items]
Balance at beginning year	35,981
Balance at end of year	35,269	35,981
Accumulated depreciation and impairment losses [member]
Disclosure of detailed information about intangible assets [line items]
Balance at beginning year	(206,279)	(216,557)
Disposals or retirements		15,047
Charge for the year	(923)	(917)
Impairment losses	(4,624)	(3,853)
Exchange adjustments	20	1
Balance at end of year	(211,806)	(206,279)	(216,557)
Goodwill [member] | Cost [Member]
Disclosure of detailed information about intangible assets [line items]
Balance at beginning year	79,182	79,182
Additions	0	0
Disposals or retirements		0
Exchange adjustments	0	0
Balance at end of year	79,182	79,182	79,182
Goodwill [member] | Carrying amounts [Member]
Disclosure of detailed information about intangible assets [line items]
Balance at beginning year	12,537
Balance at end of year	12,537	12,537
Goodwill [member] | Accumulated depreciation and impairment losses [member]
Disclosure of detailed information about intangible assets [line items]
Balance at beginning year	(66,645)	(66,591)
Disposals or retirements		0
Charge for the year		0
Impairment losses	0	(54)
Exchange adjustments	0	0
Balance at end of year	(66,645)	(66,645)	(66,591)
Development cost [Member] | Cost [Member]
Disclosure of detailed information about intangible assets [line items]
Balance at beginning year	121,173	128,977
Additions	4,475	6,771
Disposals or retirements		(14,576)
Exchange adjustments	(64)	1
Balance at end of year	125,584	121,173	128,977
Development cost [Member] | Carrying amounts [Member]
Disclosure of detailed information about intangible assets [line items]
Balance at beginning year	17,679
Balance at end of year	17,008	17,679
Development cost [Member] | Accumulated depreciation and impairment losses [member]
Disclosure of detailed information about intangible assets [line items]
Balance at beginning year	(103,494)	(115,533)
Disposals or retirements		14,573
Charge for the year		(482)
Impairment losses	(4,623)	(2,053)
Exchange adjustments	20	1
Balance at end of year	(108,576)	(103,494)	(115,533)
Patents and licences [Member] | Cost [Member]
Disclosure of detailed information about intangible assets [line items]
Balance at beginning year	8,707	8,947
Additions	22	102
Disposals or retirements		(342)
Exchange adjustments	0	0
Balance at end of year	8,729	8,707	8,947
Patents and licences [Member] | Carrying amounts [Member]
Disclosure of detailed information about intangible assets [line items]
Balance at beginning year	146
Balance at end of year	159	146
Patents and licences [Member] | Accumulated depreciation and impairment losses [member]
Disclosure of detailed information about intangible assets [line items]
Balance at beginning year	(8,561)	(8,790)
Disposals or retirements		342
Charge for the year	(9)	(7)
Impairment losses	0	(106)
Exchange adjustments	0	0
Balance at end of year	(8,570)	(8,561)	(8,790)
Intangible assets [Member] | Cost [Member]
Disclosure of detailed information about intangible assets [line items]
Balance at beginning year	33,198	33,311
Additions	382	21
Disposals or retirements		(134)
Exchange adjustments	0	0
Balance at end of year	33,580	33,198	33,311
Intangible assets [Member] | Carrying amounts [Member]
Disclosure of detailed information about intangible assets [line items]
Balance at beginning year	5,619
Balance at end of year	5,565	5,619
Intangible assets [Member] | Accumulated depreciation and impairment losses [member]
Disclosure of detailed information about intangible assets [line items]
Balance at beginning year	(27,579)	(25,643)
Disposals or retirements		132
Charge for the year	(435)	(428)
Impairment losses	(1)	(1,640)
Exchange adjustments	0	0
Balance at end of year	$ (28,015)	$ (27,579)	$ (25,643)

GOODWILL AND INTANGIBLE ASSET_4

GOODWILL AND INTANGIBLE ASSETS (Schedule of Principal Development Projects) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Disclosure of detailed information about intangible assets [line items]
Capitalised development costs	$ 4,475	$ 6,771
Premier Instruments for A1c and haemoglobinopathies testing [Member]
Disclosure of detailed information about intangible assets [line items]
Capitalised development costs	1,904	2,538
HIV Screening Rapid Test [Member]
Disclosure of detailed information about intangible assets [line items]
Capitalised development costs	379	1,488
COVID tests [Member]
Disclosure of detailed information about intangible assets [line items]
Capitalised development costs	1,378	1,320
Autoimmune Smart Reader [Member]
Disclosure of detailed information about intangible assets [line items]
Capitalised development costs	82	550
Mid-tier haemoglobins instrument [Member]
Disclosure of detailed information about intangible assets [line items]
Capitalised development costs	484	303
Tri-stat point-of-care instrument [Member]
Disclosure of detailed information about intangible assets [line items]
Capitalised development costs	163	245
Uni-Gold Raw Material Stabilisation [Member]
Disclosure of detailed information about intangible assets [line items]
Capitalised development costs	42	144
Other Projects [Member]
Disclosure of detailed information about intangible assets [line items]
Capitalised development costs	$ 43	$ 183

GOODWILL AND INTANGIBLE ASSET_5

GOODWILL AND INTANGIBLE ASSETS (Schedule of Specific asset impairment charges) (Details) $ in Thousands	Dec. 31, 2022 USD ($)
Disclosure of detailed information about intangible assets [line items]
Internally developed intangible assets	$ 4,623
Rapid COVID-19 antigen test [Member]
Disclosure of detailed information about intangible assets [line items]
Internally developed intangible assets	2,214
Autoimmune smart reader [Member]
Disclosure of detailed information about intangible assets [line items]
Internally developed intangible assets	1,265
Tri-stat instrument [Member]
Disclosure of detailed information about intangible assets [line items]
Internally developed intangible assets	1,024
COVID-19 ELISA test [Member]
Disclosure of detailed information about intangible assets [line items]
Internally developed intangible assets	$ 120

GOODWILL AND INTANGIBLE ASSET_6

GOODWILL AND INTANGIBLE ASSETS (Schedule of Impairment Loss) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Disclosure of detailed information about intangible assets [line items]
Impairment loss recognised in other comprehensive income, intangible assets other than goodwill	$ 5,839	$ 6,944
Immco Diagnostics Inc [Member]
Disclosure of detailed information about intangible assets [line items]
Impairment loss recognised in other comprehensive income, intangible assets other than goodwill		4,979
Trinity Biotech Manufacturing Limited [Member]
Disclosure of detailed information about intangible assets [line items]
Impairment loss recognised in other comprehensive income, intangible assets other than goodwill	3,599	856
Trinity Biotech Do Brasil [Member]
Disclosure of detailed information about intangible assets [line items]
Impairment loss recognised in other comprehensive income, intangible assets other than goodwill	454	956
Biopool US Inc [Member]
Disclosure of detailed information about intangible assets [line items]
Impairment loss recognised in other comprehensive income, intangible assets other than goodwill	355	$ 153
Primus Corp [Member]
Disclosure of detailed information about intangible assets [line items]
Impairment loss recognised in other comprehensive income, intangible assets other than goodwill	1,024
Clark Laboratories Inc [Member]
Disclosure of detailed information about intangible assets [line items]
Impairment loss recognised in other comprehensive income, intangible assets other than goodwill	$ 407

GOODWILL AND INTANGIBLE ASSET_7

GOODWILL AND INTANGIBLE ASSETS (Schedule of Breakdown of Impairment Loss) (Details) (USD $) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disclosure Of Goodwill And Intangible Assets [Abstract]
Goodwill and other intangible assets (see Note 14)	$ 4,624,000	$ 3,853,000
Property, plant and equipment (see Note 13)	733,000	2,508,000
Prepayments (see Note 18)	482,000	583,000	$ 562,000
Total impairment loss	$ 5,839,000	$ 6,944,000

GOODWILL AND INTANGIBLE ASSET_8

GOODWILL AND INTANGIBLE ASSETS (Schedule of Significant Goodwill and Intangible Assets) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Carrying amount of goodwill	$ 12,591	$ 12,591
Discount rate applied (real pre-tax)	15.77%	19.66%
Excess value-in-use over carrying amount	$ 7,432	$ 3,496
EBITDA would need to decrease for an impairment to arise	31.28%	18.15%
Long term growth rate on fifth year	2%	2%

GOODWILL AND INTANGIBLE ASSET_9

GOODWILL AND INTANGIBLE ASSETS (Schedule of Intangible Assets with Indefinite Useful lives) (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Intangible assets with indefinite useful lives	$ 3,964	$ 3,964
Fitzgerald Industries International CGU Trade Name [Member]
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Intangible assets with indefinite useful lives	970	970
Fitzgerald Industries International CGU RDI Trade Name [Member]
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Intangible assets with indefinite useful lives	560	560
Primus Corporation CGU Trade Name [Member]
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Intangible assets with indefinite useful lives	365	365
Immco Diagnostic C G U Member
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Intangible assets with indefinite useful lives	$ 2,069	$ 2,069

DEFERRED TAX ASSETS AND LIABI_3

DEFERRED TAX ASSETS AND LIABILITIES (Narrative) (Details)	12 Months Ended
	Dec. 31, 2022 USD ($)
Disclosure Of Deferred Tax Assets And Liabilities [Abstract]
Deferred tax asset increase due to increase in provision	$ 117,000
Deferred tax liability increased	$ 200,000

DEFERRED TAX ASSETS AND LIABI_4

DEFERRED TAX ASSETS AND LIABILITIES (Schedule of Recognised Deferred Tax Assets and Liabilities) (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Deferred tax assets	$ 4,218	$ 4,101
Deferred tax liabilities	(5,058)	(4,858)
Net deferred tax assets/(liabilities)	(840)	(757)	$ (720)
Plant and equipment [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Deferred tax assets	229	477
Deferred tax liabilities	(5)	(11)
Net deferred tax assets/(liabilities)	224	466	724
Intangible assets [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Deferred tax assets	0	0
Deferred tax liabilities	(3,950)	(3,969)
Net deferred tax assets/(liabilities)	(3,950)	(3,969)	(4,072)
Inventory Member
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Deferred tax assets	423	620
Deferred tax liabilities	0	0
Net deferred tax assets/(liabilities)	423	620	750
Provisions [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Deferred tax assets	2,194	1,871
Deferred tax liabilities	0	0
Net deferred tax assets/(liabilities)	2,194	1,871	2,159
Tax value of loss carry-forwards [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Deferred tax assets	1,254	1,016
Deferred tax liabilities	0	0
Net deferred tax assets/(liabilities)	1,254	1,016	433
Other items [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Deferred tax assets	118	117
Deferred tax liabilities	(1,103)	(878)
Net deferred tax assets/(liabilities)	$ (985)	$ (761)	$ (714)

DEFERRED TAX ASSETS AND LIABI_5

DEFERRED TAX ASSETS AND LIABILITIES (Schedule of Unrecognised Deferred Tax Liabilities) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Balance at beginning of year	$ (757)	$ (720)
Recognised in income	(83)	(37)
Balance at end of year	(840)	(757)
Plant and equipment [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Balance at beginning of year	466	724
Recognised in income	(242)	(258)
Balance at end of year	224	466
Intangible assets [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Balance at beginning of year	(3,969)	(4,072)
Recognised in income	19	103
Balance at end of year	(3,950)	(3,969)
Inventories [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Balance at beginning of year	620	750
Recognised in income	(197)	(130)
Balance at end of year	423	620
Provisions [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Balance at beginning of year	1,871	2,159
Recognised in income	323	(288)
Balance at end of year	2,194	1,871
Tax value of loss carry-forwards [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Balance at beginning of year	1,016	433
Recognised in income	238	583
Balance at end of year	1,254	1,016
Other items [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Balance at beginning of year	(761)	(714)
Recognised in income	(224)	(47)
Balance at end of year	$ (985)	$ (761)

DEFERRED TAX ASSETS AND LIABI_6

DEFERRED TAX ASSETS AND LIABILITIES (Schedule of Unrecognised Deferred Tax Assets) (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Disclosure Of Deferred Tax Assets And Liabilities [Abstract]
Capital losses	$ 8,293	$ 8,293
Net operating losses	75,957	73,893
US alternative minimum tax credits	1,906	1,704
Other temporary timing differences	38,960	21,301
US state credit carryforwards	2,753	1,664
Unrecognised deferred tax assets	$ 127,869	$ 106,855

OTHER NON-CURRENT ASSETS (Detai

OTHER NON-CURRENT ASSETS (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Miscellaneous non-current assets [abstract]
Finance lease receivables	$ 84	$ 151
Other assets	55	56
Total other assets	$ 139	$ 207

INVENTORIES (Narrative) (Detail

INVENTORIES (Narrative) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Classes of current inventories [abstract]
Inventories net of provisions	$ 16,274,000	$ 12,063,000	$ 9,781,000
Cost of sales	45,340,000	49,299,000	48,342,000
Inventory provision released during the year	$ 0	$ 0	$ 120,000

INVENTORIES (Schedule of invent

INVENTORIES (Schedule of inventories) (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Classes of current inventories [abstract]
Raw materials and consumables	$ 12,094	$ 13,650
Work-in-progress	3,948	5,546
Finished goods	6,461	9,927
Total inventories	$ 22,503	$ 29,123

INVENTORIES (Schedule of Moveme

INVENTORIES (Schedule of Movement on the Inventory Provision) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disclosure of other provisions [line items]
Released during the year	$ 0	$ 0	$ (120,000)
Provision for inventories [Member]
Disclosure of other provisions [line items]
Opening provision at January 1	12,063,000	9,781,000	6,716,000
Charged during the year	7,391,000	5,589,000	5,179,000
Utilised during the year	(3,180,000)	(3,307,000)	(1,994,000)
Released during the year	0	0	(120,000)
Closing provision at December 31	$ 16,274,000	$ 12,063,000	$ 9,781,000

TRADE AND OTHER RECEIVABLES (Na

TRADE AND OTHER RECEIVABLES (Narrative) (Details) - USD ($)	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disclosure of maturity analysis of operating lease payments [line items]
Trade receivables, net impairment losses provision	$ 2,691,000	$ 2,986,000	$ 3,922,000
Prepayments of impairment	482,000	583,000	$ 562,000
Finance lease receivable	170,000	293,000
Between one and five years [Member]
Disclosure of maturity analysis of operating lease payments [line items]
Finance lease receivable	$ 84,000	$ 151,000

TRADE AND OTHER RECEIVABLES (Sc

TRADE AND OTHER RECEIVABLES (Schedule of Trade and Other Receivables) (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Trade and other current receivables [abstract]
Trade receivables, net of impairment losses	$ 12,620	$ 13,290
Prepayments	1,932	1,945
Contract assets	739	739
Value added tax	43	0
Finance lease receivable	86	142
Grant receivable	333	0
Total and other receivables	$ 15,753	$ 16,116

TRADE AND OTHER RECEIVABLES (_2

TRADE AND OTHER RECEIVABLES (Schedule of Future Minimum Finance Lease Receivables) (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Disclosure of maturity analysis of operating lease payments [line items]
Gross investment	$ 353	$ 602
Unearned income	12	22
Minimum Finance Lease Payments Receivable At Present Value	170	293
Less than one year [Member]
Disclosure of maturity analysis of operating lease payments [line items]
Gross investment	180	292
Unearned income	6	11
Minimum Finance Lease Payments Receivable At Present Value	86	142
Between one and five years [Member]
Disclosure of maturity analysis of operating lease payments [line items]
Gross investment	173	310
Unearned income	6	11
Minimum Finance Lease Payments Receivable At Present Value	$ 84	$ 151

TRADE AND OTHER RECEIVABLES (_3

TRADE AND OTHER RECEIVABLES (Schedule of Future Minimum Rentals Receivable Under Non-Cancellable Operating Leases) (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Disclosure of maturity analysis of operating lease payments [line items]
Future minimum rentals receivable under non-cancellable operating leases	$ 1,589	$ 4,124
Instruments [Member]
Disclosure of maturity analysis of operating lease payments [line items]
Future minimum rentals receivable under non-cancellable operating leases	1,589	4,124
Less than one year [Member]
Disclosure of maturity analysis of operating lease payments [line items]
Future minimum rentals receivable under non-cancellable operating leases	1,589	3,953
Less than one year [Member] | Instruments [Member]
Disclosure of maturity analysis of operating lease payments [line items]
Future minimum rentals receivable under non-cancellable operating leases	$ 1,589	3,953
Between one and five years [Member]
Disclosure of maturity analysis of operating lease payments [line items]
Future minimum rentals receivable under non-cancellable operating leases		171
Between one and five years [Member] | Instruments [Member]
Disclosure of maturity analysis of operating lease payments [line items]
Future minimum rentals receivable under non-cancellable operating leases		$ 171

CASH AND CASH EQUIVALENTS (Sche

CASH AND CASH EQUIVALENTS (Schedule of Cash and Cash Equivalents) (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Cash and cash equivalents [abstract]
Cash	$ 6,578	$ 22,790
Short-term deposits, classified as cash equivalents	0	3,120
Cash and cash equivalents	$ 6,578	$ 25,910

CAPITAL AND RESERVES (Narrative

CAPITAL AND RESERVES (Narrative) (Details)	1 Months Ended	12 Months Ended
	May 31, 2022 USD ($) $ / shares	Dec. 31, 2022 USD ($) Share shares	Dec. 31, 2021 Share shares	Dec. 31, 2020 Share shares
Disclosure of classes of share capital [line items]
Reserve of cash flow hedges		$ 23,000
Value of shares to be issued for hedging reserves		$ 63,000
MiCo Ltd [Member]
Disclosure of classes of share capital [line items]
Amount of investment from MiCo	$ 45,200,000
Equity investment	$ 25,200,000
Maturity of unsecured junior convertible note	seven-year
Unsecured junior convertible note	$ 20,000,000
Maximum weighted average price of ADS | $ / shares	$ 3.24
Equity component of the convertible note	$ 6,700,000
Class A Ordinary shares [Member]
Disclosure of classes of share capital [line items]
Ordinary shares issued | shares		47,492,000	0
Proceeds from issue of ordinary shares		$ 25,707,000
Share issue related cost		$ 606,000
Ordinary shares issued from exercise of employee share options | Share		2,733,328	0	0
Treasury shares purchased | shares			0	0
Shares issued as consideration for Exchangeable Notes purchase | shares		21,332,000	0
Shares issued as consideration for Exchangeable Notes purchase, value		$ 6,133,000
Share Issue Cost For Exchangeable Notes Purchase		$ 213,000
Class A Ordinary shares [Member] | MiCo Ltd [Member]
Disclosure of classes of share capital [line items]
Ordinary shares issued | shares		44,759,000

CAPITAL AND RESERVES (Schedule

CAPITAL AND RESERVES (Schedule of Share Capital) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Disclosure of classes of share capital [line items]
Balance at January 1	$ 24,922
At period end	$ 24,922	$ 24,922
Class A Ordinary shares [Member]
Disclosure of classes of share capital [line items]
Number of shares at January 1	96,162,000	96,162,000
Issued for cash	47,492,000	0
Issued as consideration for Exchangeable Notes purchase	21,332,000	0
At period end	164,986,000	96,162,000
American depositary share [Member]
Disclosure of classes of share capital [line items]
Number of shares at January 1	24,041,000	24,041,000
Issued for cash	11,873,000	0
Issued as consideration for Exchangeable Notes purchase	5,333,000	0
At period end	41,247,000	24,041,000
Class A Treasury shares [Member]
Disclosure of classes of share capital [line items]
Balance at January 1	$ 12,556	$ 12,556
Purchased during period	0	0
At period end	12,556	12,556
American Depositary Share Treasury Shares Member
Disclosure of classes of share capital [line items]
Balance at January 1	3,139	3,139
Purchased during period	0	0
At period end	$ 3,139	$ 3,139

SHARE OPTIONS (Narrative) (Deta

SHARE OPTIONS (Narrative) (Details)	12 Months Ended
	Dec. 31, 2022 USD ($) Share $ / shares	Dec. 31, 2021 USD ($) Share $ / shares	Dec. 31, 2020 USD ($) Share $ / shares	Dec. 31, 2019 Share
Disclosure of classes of share capital [line items]
Weighted-average remaining contractual life of options outstanding	5 years 6 months 29 days	4 years 4 months 6 days
Share based payments continuing operations | $	$ 1,755,000	$ 1,100,000	$ 792,000
Share based payments capitalised in intangible development project assets | $		11,000	24,000
Share based payments charge | $	$ 1,755,000	$ 1,111,000	$ 816,000
Class A Ordinary shares [Member]
Disclosure of classes of share capital [line items]
Number of options | Share	44,814,672	18,727,990	19,485,990	12,303,990
Number of share options exercised | Share	2,733,328	0	0
Average share price, share options exercised	$ 0.28
Opening share price	0.36	$ 0.95	$ 0.27
Closing share price	0.25	0.36	0.95
Average share price	0.3
Weighted average exercise price	0.19	$ 0	$ 0
Class A Ordinary shares [Member] | Bottom of range [member]
Disclosure of classes of share capital [line items]
Weighted average exercise price	0.19
Class A Ordinary shares [Member] | Top of range [member]
Disclosure of classes of share capital [line items]
Weighted average exercise price	$ 0.19
American depositary share [Member]
Disclosure of classes of share capital [line items]
Number of options | Share	11,203,668	4,681,998	4,871,498	3,075,998
Number of share options exercised | Share	683,332	0	0
Average share price, share options exercised	$ 1.13
Opening share price	1.43	$ 3.81	$ 1.07
Closing share price	0.99	1.43	3.81
Average share price	1.22
Weighted average exercise price	0.77	$ 0	$ 0
American depositary share [Member] | Bottom of range [member]
Disclosure of classes of share capital [line items]
Weighted average exercise price	0.77
American depositary share [Member] | Top of range [member]
Disclosure of classes of share capital [line items]
Weighted average exercise price	$ 0.77

SHARE OPTIONS (Schedule of Gran

SHARE OPTIONS (Schedule of Grants of Share Options and Warrants) (Details)	12 Months Ended
	Dec. 31, 2022 Share $ / shares	Dec. 31, 2021 Share $ / shares	Dec. 31, 2020 Share $ / shares
Class A Ordinary shares [Member]
Disclosure of classes of share capital [line items]
Outstanding Beginning Balance | Share	18,727,990	19,485,990	12,303,990
Granted | Share	29,400,000	0	9,100,000
Exercised | Share	(2,733,328)	0	0
Expired/ Forfeited | Share	(579,990)	(758,000)	(1,918,000)
Outstanding at end of year | Share	44,814,672	18,727,990	19,485,990
Exercisable at end of year | Share	14,138,004	13,401,322	7,959,323
Weighted Average exercise price
Outstanding Beginning Balance	$ 0.78	$ 0.79	$ 1.31
Granted	0.27	0	0.38
Weighted average exercise price of share options exercised in share-based payment arrangement	0.19	0	0
Expired/ Forfeited	1.87	1.07	2.14
Outstanding at end of year	0.47	0.78	0.79
Exercisable at end of year	0.89	0.93	1.27
Class A Ordinary shares [Member] | Bottom of range [member]
Weighted Average exercise price
Outstanding Beginning Balance	0.19	0.19	0.46
Granted	0.27		0.19
Weighted average exercise price of share options exercised in share-based payment arrangement	0.19
Expired/ Forfeited	0.69	0.19	0.19
Outstanding at end of year	0.19	0.19	0.19
Exercisable at end of year	0.19	0.19	0.66
Class A Ordinary shares [Member] | Top of range [member]
Weighted Average exercise price
Outstanding Beginning Balance	4.36	4.36	4.36
Granted	0.29		1.1
Weighted average exercise price of share options exercised in share-based payment arrangement	0.19
Expired/ Forfeited	4.36	4.21	4.21
Outstanding at end of year	2.43	4.36	4.36
Exercisable at end of year	$ 2.43	$ 4.36	$ 4.36
American depositary share [Member]
Disclosure of classes of share capital [line items]
Outstanding Beginning Balance | Share	4,681,998	4,871,498	3,075,998
Granted | Share	7,350,000	0	2,275,000
Exercised | Share	(683,332)	0	0
Expired/ Forfeited | Share	(144,998)	(189,500)	(479,500)
Outstanding at end of year | Share	11,203,668	4,681,998	4,871,498
Exercisable at end of year | Share	3,534,501	3,350,331	1,989,831
Weighted Average exercise price
Outstanding Beginning Balance	$ 3.12	$ 3.15	$ 5.24
Granted	1.09	0	1.52
Weighted average exercise price of share options exercised in share-based payment arrangement	0.77	0	0
Expired/ Forfeited	7.48	4.28	8.56
Outstanding at end of year	1.88	3.12	3.15
Exercisable at end of year	3.56	3.72	5.08
American depositary share [Member] | Bottom of range [member]
Weighted Average exercise price
Outstanding Beginning Balance	0.76	0.77	1.83
Granted	1.07		0.77
Weighted average exercise price of share options exercised in share-based payment arrangement	0.77
Expired/ Forfeited	2.76	0.76	0.77
Outstanding at end of year	0.77	0.76	0.77
Exercisable at end of year	0.77	0.76	2.64
American depositary share [Member] | Top of range [member]
Weighted Average exercise price
Outstanding Beginning Balance	17.44	17.45	17.45
Granted	1.14		4.41
Weighted average exercise price of share options exercised in share-based payment arrangement	0.77
Expired/ Forfeited	17.44	16.84	16.84
Outstanding at end of year	9.73	17.44	17.45
Exercisable at end of year	$ 9.73	$ 17.44	$ 17.45

SHARE OPTIONS (Summary of Range

SHARE OPTIONS (Summary of Range of Prices of Stock Options) (Details)	12 Months Ended
	Dec. 31, 2022 USD ($) Share $ / shares shares	Dec. 31, 2021 USD ($) Share $ / shares shares	Dec. 31, 2020 Share $ / shares	Dec. 31, 2019 Share
Outstanding
Weighted average contractual life remaining (years)	5 years 6 months 29 days	4 years 4 months 6 days
Class A Ordinary shares [Member]
Outstanding
Number of options | Share	44,814,672	18,727,990	19,485,990	12,303,990
Exercisable
Number of options | shares	14,138,004	13,401,322
Weighted average exercise price | $ / shares	$ 0.19	$ 0	$ 0
Class A Ordinary shares [Member] | US$0.19-US$0.99 [Member]
Outstanding
Number of options | Share	39,546,672	13,000,006
Weighted average exercise price | $	$ 0.35	$ 0.48
Weighted average contractual life remaining (years)	6 years 1 month 6 days	3 years 6 months 14 days
Exercisable
Number of options | shares	8,930,004	7,960,004
Weighted average exercise price | $ / shares	$ 0.59	$ 0.55
Weighted average contractual life remaining (years)	4 years 18 days	2 years 11 months 1 day
Class A Ordinary shares [Member] | US$1.00-US$1.74 [Member]
Outstanding
Number of options | Share	4,988,000
Weighted average exercise price | $	$ 1.34
Weighted average contractual life remaining (years)	1 year 9 months 10 days
Exercisable
Number of options | shares	4,928,000
Weighted average exercise price | $ / shares	$ 1.34
Weighted average contractual life remaining (years)	1 year 8 months 26 days
Class A Ordinary shares [Member] | US$1.75- US$2.43 [Member]
Outstanding
Number of options | Share	280,000
Weighted average exercise price | $	$ 2.43
Weighted average contractual life remaining (years)	1 month 24 days
Exercisable
Number of options | shares	280,000
Weighted average exercise price | $ / shares	$ 2.43
Weighted average contractual life remaining (years)	1 month 24 days
Class A Ordinary shares [Member] | US$1.00-US$2.05 [Member]
Outstanding
Number of options | Share		5,228,000
Weighted average exercise price | $		$ 1.34
Weighted average contractual life remaining (years)		9 months 14 days
Exercisable
Number of options | shares		4,941,334
Weighted average exercise price | $ / shares		$ 1.35
Weighted average contractual life remaining (years)		11 months 26 days
Class A Ordinary shares [Member] | US$2.06- US$2.99 [Member]
Outstanding
Number of options | Share		439,984
Weighted average exercise price | $		$ 2.53
Weighted average contractual life remaining (years)		10 days
Exercisable
Number of options | shares		439,984
Weighted average exercise price | $ / shares		$ 2.53
Weighted average contractual life remaining (years)		14 days
Class A Ordinary shares [Member] | US$3.00 -US$4.36 [Member]
Outstanding
Number of options | Share		60,000
Weighted average exercise price | $		$ 4.17
Weighted average contractual life remaining (years)		0 years
Exercisable
Number of options | shares		60,000
Weighted average exercise price | $ / shares		$ 4.17
Weighted average contractual life remaining (years)		0 years
American depositary share [Member]
Outstanding
Number of options | Share	11,203,668	4,681,998	4,871,498	3,075,998
Exercisable
Number of options | shares	3,534,501	3,350,331
Weighted average exercise price | $ / shares	$ 0.77	$ 0	$ 0
American depositary share [Member] | US$0.77-US$3.96 [Member]
Outstanding
Number of options | Share	9,886,668	3,250,002
Weighted average exercise price | $	$ 1.39	$ 1.94
Weighted average contractual life remaining (years)	6 years 1 month 6 days	3 years 6 months 14 days
Exercisable
Number of options | shares	2,232,501	1,990,001
Weighted average exercise price | $ / shares	$ 2.37	$ 2.19
Weighted average contractual life remaining (years)	4 years 18 days	2 years 11 months 1 day
American depositary share [Member] | US$4.00-US$6.94 [Member]
Outstanding
Number of options | Share	1,247,000
Weighted average exercise price | $	$ 5.37
Weighted average contractual life remaining (years)	1 year 9 months 10 days
Exercisable
Number of options | shares	1,232,000
Weighted average exercise price | $ / shares	$ 5.38
Weighted average contractual life remaining (years)	1 year 8 months 26 days
American depositary share [Member] | US$6.95- US$9.73 [Member]
Outstanding
Number of options | Share	70,000
Weighted average exercise price | $	$ 9.73
Weighted average contractual life remaining (years)	1 month 24 days
Exercisable
Number of options | shares	70,000
Weighted average exercise price | $ / shares	$ 9.73
Weighted average contractual life remaining (years)	1 month 24 days
American depositary share [Member] | US$4.00-US$8.20 [Member]
Outstanding
Number of options | Share		1,307,000
Weighted average exercise price | $		$ 5.36
Weighted average contractual life remaining (years)		9 months 14 days
Exercisable
Number of options | shares		1,235,334
Weighted average exercise price | $ / shares		$ 5.4
Weighted average contractual life remaining (years)		11 months 26 days
American depositary share [Member] | US$8.24- US$11.96 [Member]
Outstanding
Number of options | Share		109,996
Weighted average exercise price | $		$ 10.13
Weighted average contractual life remaining (years)		10 days
Exercisable
Number of options | shares		109,996
Weighted average exercise price | $ / shares		$ 10.13
Weighted average contractual life remaining (years)		14 days
American depositary share [Member] | US$12.00 -US$17.45 [Member]
Outstanding
Number of options | Share		15,000
Weighted average exercise price | $		$ 16.67
Weighted average contractual life remaining (years)		0 years
Exercisable
Number of options | shares		15,000
Weighted average exercise price | $ / shares		$ 16.67
Weighted average contractual life remaining (years)		0 years

SHARE OPTIONS (Schedule of Fair

SHARE OPTIONS (Schedule of Fair Value of the Options Vesting Period) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disclosure Of Share Options And Share Warrants [Abstract]
Share-based payments - cost of sales	$ 0	$ 5	$ 12
Share-based payments - selling, general and administrative	1,755	1,095	780
Total - continuing operations	1,755	1,100	792
Share-based payments - discontinued operations	0	0	0
Total share-based payments	$ 1,755	$ 1,100	$ 792

SHARE OPTIONS (Schedule of Assu

SHARE OPTIONS (Schedule of Assumption Determining Fair Value of Share Options) (Details)	12 Months Ended
	Dec. 31, 2022 USD ($) Years $ / shares shares	Dec. 31, 2021 USD ($) Years $ / shares shares	Dec. 31, 2020 USD ($) Years $ / shares shares
Key management personnel [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Weighted average expected volatility	76.79%	0%	66.98%
Weighted average expected life | Years	6.82	0	4.34
Weighted average risk free interest rate	3.59%	0%	0.44%
Key management personnel [Member] | Bottom of range [member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Weighted average fair value at measurement date per 'A' share / (per ADS) | $	$ 0.19	$ 0	$ 0.2
Total 'A' share options granted / (ADS's equivalent) | shares	29,400,000	0	8,480,000
Weighted average share price per 'A' share / (per ADS)	$ 0.27	$ 0	$ 0.38
Weighted average exercise price per 'A' share / (per ADS)	$ 0.27	$ 0	$ 0.38
Key management personnel [Member] | Top of range [member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Weighted average fair value at measurement date per 'A' share / (per ADS) | $	$ 0.77	$ 0	$ 0.8
Total 'A' share options granted / (ADS's equivalent) | shares	7,350,000	0	(2,120,000)
Weighted average share price per 'A' share / (per ADS)	$ 1.09	$ 0	$ 1.52
Weighted average exercise price per 'A' share / (per ADS)	$ 1.09	$ 0	$ 1.52
Other employees [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Weighted average expected volatility	0%	0%	65.89%
Weighted average expected life | Years	0	0	4.35
Weighted average risk free interest rate	0%	0%	0.42%
Other employees [Member] | Bottom of range [member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Weighted average fair value at measurement date per 'A' share / (per ADS) | $	$ 0	$ 0	$ 0.27
Total 'A' share options granted / (ADS's equivalent) | shares	0	0	620,000
Weighted average share price per 'A' share / (per ADS)	$ 0	$ 0	$ 0.48
Weighted average exercise price per 'A' share / (per ADS)	$ 0	$ 0	$ 0.48
Other employees [Member] | Top of range [member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Weighted average fair value at measurement date per 'A' share / (per ADS) | $	$ 0	$ 0	$ 1.08
Total 'A' share options granted / (ADS's equivalent) | shares	0	0	(155,000)
Weighted average share price per 'A' share / (per ADS)	$ 0	$ 0	$ 1.96
Weighted average exercise price per 'A' share / (per ADS)	$ 0	$ 0	$ 1.96

TRADE AND OTHER PAYABLES (Narra

TRADE AND OTHER PAYABLES (Narrative) (Details) - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Disclosure of detailed information about business combination [line items]
Accrued liabilities to contracted licence payments	$ 176,000	$ 0

TRADE AND OTHER PAYABLES (Sched

TRADE AND OTHER PAYABLES (Schedule of Trade and Other Payables) (Details) - USD ($)	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Trade and other current payables [abstract]
Trade payables	$ 6,205,000	$ 6,763,000
Accruals and other liabilities	8,585,000	7,595,000
Payroll taxes	368,000	398,000
Employee related social insurance	103,000	130,000
Deferred income	114,000	141,000	$ 4,445,000
Deferred government grants	0	69,000
Other payables	0	31,000
Total trade and other payables	$ 15,375,000	$ 15,127,000

PROVISIONS (Narrative) (Details

PROVISIONS (Narrative) (Details)	12 Months Ended
	Dec. 31, 2022 USD ($)
Provisions [abstract]
Provision for reduced warranty claims	$ 50,000

PROVISIONS (Schedule of Provisi

PROVISIONS (Schedule of Provisions) (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Provisions [abstract]
Product warranty provision	$ 50	$ 50
Provisions	$ 50	$ 50

INTEREST-BEARING LOANS AND BO_3

INTEREST-BEARING LOANS AND BORROWINGS (Narrative) (Details) - USD ($)		1 Months Ended		12 Months Ended
	Dec. 10, 2021	May 31, 2022	Jan. 31, 2022	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Feb. 28, 2023
Disclosure of fair value measurement of liabilities [line items]
Shares consideration				$ 25,336,000	$ 0	$ 0
Loan origination costs				0	1,638,000	$ 0
Equity investment				$ 6,709,000	$ 0
American depositary share [Member]
Disclosure of fair value measurement of liabilities [line items]
Number of shares issued				41,247,000	24,041,000	24,041,000
Class A Ordinary shares [Member]
Disclosure of fair value measurement of liabilities [line items]
Number of shares issued				164,986,000	96,162,000	96,162,000
MiCo Ltd [Member]
Disclosure of fair value measurement of liabilities [line items]
Remaining amount of loan		$ 20,000,000
Loan, maturity		seven-year
Current Liabilities [Member]
Disclosure of fair value measurement of liabilities [line items]
Remaining amount of loan				$ 210,000	$ 83,312,000
Non Current Liabilities [Member]
Disclosure of fair value measurement of liabilities [line items]
Remaining amount of loan				59,616,000	0
Exchangeable Senior Notes [Member]
Disclosure of fair value measurement of liabilities [line items]
Debt retired / repaid		$ 34,500,000	$ 99,700,000
Total exchangeable notes percentage			99.70%
Cash paid to each holder			$ 86,730,000
Cash received per nominal value			$ 0.87
Nominal value per share of the Exchangeable Notes	$ 1		$ 1
Shares consideration			$ 6,100,000
Extinguishment of debt				83,200,000
Loss on disposal				9,700,000
Exchangeable Senior Notes [Member] | American depositary share [Member]
Disclosure of fair value measurement of liabilities [line items]
Shares consideration			$ 0.08
Number of shares issued			5,333,000
Exchangeable Senior Notes [Member] | Class A Ordinary shares [Member]
Disclosure of fair value measurement of liabilities [line items]
Number of shares issued			21,332,000
Exchangeable Senior Notes [Member] | Current Liabilities [Member]
Disclosure of fair value measurement of liabilities [line items]
Debt retired / repaid				86,730,000	0
Loss on disposal				(9,678,000)	0
Remaining amount of loan				210,000	83,312,000	$ 82,664,000
Accretion interest				(83,000)	(648,000)
Senior Secured Term Loan [Member] | Perceptive Credit Holdings Iii, Lp [Member]
Disclosure of fair value measurement of liabilities [line items]
Face amount of loan					$ 81,300
Loan, interest rate basis					accrues interest at an annual rate equal to 11.25% plus the greater of (a) one-month LIBOR (later changed to the Term SOFR Reference Rate effective from October 28, 2022) and (b) one percent per annum, and interest is payable monthly in arrears in cash.
Senior Secured Term Loan [Member] | Perceptive Credit Holdings Iii, Lp [Member] | Warrant reserve [member]
Disclosure of fair value measurement of liabilities [line items]
Number of shares issued					2,500,000
Number of warrants repriced							2,500,000
Exercise price of warrants					$ 1.3		$ 1.071
Payment of penalty					$ 3,500,000
Senior Secured Term Loan [Member] | Non Current Liabilities [Member]
Disclosure of fair value measurement of liabilities [line items]
Debt retired / repaid				34,500,000
Remaining amount of loan				44,301,000	0
Face amount of loan				76,000,000
Principal amount loaned				81,250,000
Loan origination costs				3,551,000
Derivative financial liabilities				1,700,000
Accretion interest				(2,772,000)
Accretion interest accrued				2,800,000
Accretion interest adjustment				2,100,000
Fair value of derivative financial asset				128,000
Fair value of derivative financial liability				1,569,000
Fair value remeasurement for derivative financial balances				200,000
Equity component at date of issue				0
Seven Year Convertible Note [Member] | MiCo Ltd [Member]
Disclosure of fair value measurement of liabilities [line items]
Face amount of loan		45,200,000
Principal amount loaned		20,000,000
Equity investment		$ 25,200,000
Description of conversion		The convertible note has an interest rate of 1.5%. The convertible note mandatorily converts into ADSs if the volume weighted average price of the Company’s ADSs is at or above US$3.24 for any five consecutive NASDAQ trading days.
Seven Year Convertible Note [Member] | Non Current Liabilities [Member]
Disclosure of fair value measurement of liabilities [line items]
Debt retired / repaid				0
Remaining amount of loan				13,746,000	0
Principal amount loaned				20,000,000
Loan origination costs				40,000
Accretion interest				(495,000)
Equity component at date of issue				6,709,000
Convertible Note [Member]
Disclosure of fair value measurement of liabilities [line items]
Remaining amount of loan				13,700,000
Accretion interest				500,000
Equity component at date of issue				6,700
Convertible Note [Member] | Non Current Liabilities [Member]
Disclosure of fair value measurement of liabilities [line items]
Remaining amount of loan				$ 13,746,000	$ 0

INTEREST-BEARING LOANS AND BO_4

INTEREST-BEARING LOANS AND BORROWINGS (Schedule of carrying value of interest-bearing loans, borrowings and related balances (Details) - USD ($)	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Convertible Note [Member]
Disclosure of fair value measurement of liabilities [line items]
Borrowings	$ 13,700,000
Non Current Assets [Member]
Disclosure of fair value measurement of liabilities [line items]
Borrowings	128,000	$ 0
Non Current Assets [Member] | Derivative Financial Asset [Member]
Disclosure of fair value measurement of liabilities [line items]
Borrowings	128,000	0
Current Liabilities [Member]
Disclosure of fair value measurement of liabilities [line items]
Borrowings	210,000	83,312,000
Current Liabilities [Member] | Exchangeable Senior Notes [Member]
Disclosure of fair value measurement of liabilities [line items]
Borrowings	210,000	83,312,000	$ 82,664,000
Non Current Liabilities [Member]
Disclosure of fair value measurement of liabilities [line items]
Borrowings	59,616,000	0
Non Current Liabilities [Member] | Senior Secured Term Loan [Member]
Disclosure of fair value measurement of liabilities [line items]
Borrowings	44,301,000	0
Non Current Liabilities [Member] | Derivative Financial Liability [Member]
Disclosure of fair value measurement of liabilities [line items]
Borrowings	1,569,000	0
Non Current Liabilities [Member] | Convertible Note [Member]
Disclosure of fair value measurement of liabilities [line items]
Borrowings	$ 13,746,000	$ 0

INTEREST-BEARING LOANS AND BO_5

INTEREST-BEARING LOANS AND BORROWINGS (Schedule of movement in the Exchangeable Notes balance) (Details) - USD ($)	1 Months Ended		12 Months Ended
	May 31, 2022	Jan. 31, 2022	Dec. 31, 2022	Dec. 31, 2021
Exchangeable Senior Notes [Member]
Disclosure of fair value measurement of liabilities [line items]
Repaid to Note holders	$ 34,500,000	$ 99,700,000
Loss on disposal			$ 9,700,000
Current Liabilities [Member]
Disclosure of fair value measurement of liabilities [line items]
Balance at January 1		(83,312,000)	(83,312,000)
Balance at end of the period			(210,000)	$ (83,312,000)
Current Liabilities [Member] | Exchangeable Senior Notes [Member]
Disclosure of fair value measurement of liabilities [line items]
Balance at January 1		$ (83,312,000)	(83,312,000)	(82,664,000)
Accretion interest			(83,000)	(648,000)
Repaid to Note holders			86,730,000	0
Shares issued to Note holders as consideration			6,133,000	0
Loss on disposal			(9,678,000)	0
Balance at end of the period			$ (210,000)	$ (83,312,000)

INTEREST-BEARING LOANS AND BO_6

INTEREST-BEARING LOANS AND BORROWINGS (Schedule of movement in the Term Loan and the 7-year convertible notes) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disclosure of fair value measurement of liabilities [line items]
Loan origination costs	$ 0	$ 1,638	$ 0
Non-current liability [Member]
Disclosure of fair value measurement of liabilities [line items]
Balance at beginning of the period	0
Balance at end of the period	(59,616)	0
Non-current liability [Member] | Senior secured term loan [Member]
Disclosure of fair value measurement of liabilities [line items]
Balance at beginning of the period	0
Principal amount loaned	(81,250)
Loan origination costs	3,551
Derivative financial liability at date of issue	1,872
Derivative financial asset at date of issue	(202)
Equity component at date of issue	0
Accretion interest	(2,772)
Cash repayment of principal	34,500
Balance at end of the period	(44,301)	0
Non-current liability [Member] | 7-year Convertible Note [Member]
Disclosure of fair value measurement of liabilities [line items]
Balance at beginning of the period	0
Principal amount loaned	(20,000)
Loan origination costs	40
Derivative financial liability at date of issue	0
Derivative financial asset at date of issue	0
Equity component at date of issue	6,709
Accretion interest	(495)
Cash repayment of principal	0
Balance at end of the period	$ (13,746)	$ 0

INTEREST-BEARING LOANS AND BO_7

INTEREST-BEARING LOANS AND BORROWINGS (Schedule of movement in the derivative financial liability) (Details) - Non-current liability [Member] $ in Thousands	12 Months Ended
	Dec. 31, 2022 USD ($)
Disclosure of fair value measurement of liabilities [line items]
Balance at beginning of the period	$ 0
Balance at end of the period	(59,616)
Derivative Financial Liability [Member]
Disclosure of fair value measurement of liabilities [line items]
Balance at beginning of the period	0
Derivative financial asset at date of issue of Term Loan	(1,872)
Fair value adjustments in the period	303
Balance at end of the period	$ (1,569)

INTEREST-BEARING LOANS AND BO_8

INTEREST-BEARING LOANS AND BORROWINGS (Schedule of movement in the derivative financial asset) (Details) - Non Current Assets [Member] - Derivative Financial Asset [Member] $ in Thousands	12 Months Ended
	Dec. 31, 2022 USD ($)
Disclosure of fair value measurement of liabilities [line items]
Balance at beginning of the period	$ 0
Derivative financial asset at date of issue of Term Loan	202
Fair value adjustments in the period	(74)
Balance at end of the period	$ 128

LEASE LIABILITIES (Schedule of

LEASE LIABILITIES (Schedule of Carrying Values of Finance Lease Liabilities) (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Current liabilities
Lease liabilities related to Right of Use assets	$ 1,631	$ 1,878
Sale and leaseback liabilities	45	102
Current liabilities	1,676	1,980
Non-Current liabilities
Lease liabilities related to Right of Use assets	12,267	13,790
Sale and leaseback liabilities	0	75
Non-current liabilities	$ 12,267	$ 13,865

LEASE LIABILITIES (Schedule o_2

LEASE LIABILITIES (Schedule of Finance Lease Liabilities Payable) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Disclosure of maturity analysis of operating lease payments [line items]
Minimum Finance Lease Payments Payable At Present Value		$ 176
Lease Liabilities Related To Right Of Use Assets Member
Disclosure of maturity analysis of operating lease payments [line items]
Minimum Finance Lease Payments Payable	$ 17,196	19,727
Interest Expense On Lease Liabilities 1	3,298	4,059
Minimum Finance Lease Payments Payable At Present Value	13,898	15,668
Sale and leaseback liabilities [Member]
Disclosure of maturity analysis of operating lease payments [line items]
Minimum Finance Lease Payments Payable	46	186
Interest Expense On Lease Liabilities 1	1	9
Minimum Finance Lease Payments Payable At Present Value	45	177
Less than one year [Member] | Lease Liabilities Related To Right Of Use Assets Member
Disclosure of maturity analysis of operating lease payments [line items]
Minimum Finance Lease Payments Payable	2,249	2,575
Interest Expense On Lease Liabilities 1	618	697
Minimum Finance Lease Payments Payable At Present Value	1,631	1,878
Less than one year [Member] | Sale and leaseback liabilities [Member]
Disclosure of maturity analysis of operating lease payments [line items]
Minimum Finance Lease Payments Payable	46	109
Interest Expense On Lease Liabilities 1	1	7
Minimum Finance Lease Payments Payable At Present Value	45	102
In more than one year, but not more than two [Member] | Lease Liabilities Related To Right Of Use Assets Member
Disclosure of maturity analysis of operating lease payments [line items]
Minimum Finance Lease Payments Payable	2,240	2,175
Interest Expense On Lease Liabilities 1	561	621
Minimum Finance Lease Payments Payable At Present Value	1,679	1,554
In more than one year, but not more than two [Member] | Sale and leaseback liabilities [Member]
Disclosure of maturity analysis of operating lease payments [line items]
Minimum Finance Lease Payments Payable	0	77
Interest Expense On Lease Liabilities 1	0	2
Minimum Finance Lease Payments Payable At Present Value	0	75
In more than two years but not more than five [Member] | Lease Liabilities Related To Right Of Use Assets Member
Disclosure of maturity analysis of operating lease payments [line items]
Minimum Finance Lease Payments Payable	5,739	5,985
Interest Expense On Lease Liabilities 1	1,217	1,469
Minimum Finance Lease Payments Payable At Present Value	4,522	4,516
In more than two years but not more than five [Member] | Sale and leaseback liabilities [Member]
Disclosure of maturity analysis of operating lease payments [line items]
Minimum Finance Lease Payments Payable	0	0
Interest Expense On Lease Liabilities 1	0	0
Minimum Finance Lease Payments Payable At Present Value	0	0
More than five years [Member] | Lease Liabilities Related To Right Of Use Assets Member
Disclosure of maturity analysis of operating lease payments [line items]
Minimum Finance Lease Payments Payable	6,968	8,992
Interest Expense On Lease Liabilities 1	902	1,272
Minimum Finance Lease Payments Payable At Present Value	6,066	7,720
More than five years [Member] | Sale and leaseback liabilities [Member]
Disclosure of maturity analysis of operating lease payments [line items]
Minimum Finance Lease Payments Payable	0	0
Interest Expense On Lease Liabilities 1	0	0
Minimum Finance Lease Payments Payable At Present Value	$ 0	$ 0

LEASE LIABILITIES (Schedule o_3

LEASE LIABILITIES (Schedule of Outstanding Interest Bearing Loans and Borrowings) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Disclosure of maturity analysis of finance lease payments receivable [line items]
Principal		$ 176,000
Total amount paid in respect of lease liabilities	$ 2,761,000	$ 2,938,000
Sale and leaseback liabilities [Member]
Disclosure of maturity analysis of finance lease payments receivable [line items]
Currency		Euro
Nominal interest rate		4.53%
Year of maturity		2023
Principal		$ 65,000
Carrying value		65,000
Total amount paid in respect of lease liabilities		$ 176,000
Sale and leaseback liabilities Two [Member]
Disclosure of maturity analysis of finance lease payments receivable [line items]
Currency	USD	USD
Nominal interest rate	5.51%	5.51%
Year of maturity	2023	2023
Principal	$ 45,000	$ 111,000
Carrying value	$ 45,000	$ 111,000

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Narrative) (Details)	1 Months Ended	12 Months Ended
	Dec. 31, 2019 USD ($)	Dec. 31, 2022 CAD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)
Disclosure of maturity analysis of operating lease payments [line items]
Capital Commitments			$ 0	$ 440,000
Grant contingencies maximum amount payable			3,259,509	3,095,000
Contingent assets				0
Paycheck Protection Program Loan [Member]
Disclosure of maturity analysis of operating lease payments [line items]
Government Grant Received				1,800,000	$ 4,500,000
Forgiveness amount		$ 10,000	7,000	$ 4,668,000	$ 1,615,000
Darnick Company [Member]
Disclosure of maturity analysis of operating lease payments [line items]
Contribution for tax audit settlement	$ 1,231,000
Increase in settlement amount due to depreciation	$ 1,231,000		1,316,000
Repayments of borrowings			$ 177,000

RELATED PARTY TRANSACTIONS (Nar

RELATED PARTY TRANSACTIONS (Narrative) (Details)	1 Months Ended	12 Months Ended
	Dec. 31, 2019 USD ($)	Dec. 31, 2022 EUR (€)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)
Disclosure of transactions between related parties [line items]
Non executive directors fees			$ 1,639,000	$ 1,391,000	$ 2,020,000
Share-based compensation benefits			1,690,000	965,000
Share-based payments (net of capitalized amounts)			1,755,000	1,100,000	$ 792,000
Mr. O'Caoimh [Member]
Disclosure of transactions between related parties [line items]
Annual rent payable for ware house		€ 144,000	153,000
Rate of rent per squre foot			$ 16,000
Mr. O'Caoimh [Member] | Additional Space [Member]
Disclosure of transactions between related parties [line items]
Annual rent payable | €		€ 90,000
JRJ Investments [Member]
Disclosure of transactions between related parties [line items]
Term of lease		25-year	25-year
Annual rent payable		€ 381,000	$ 406,000
Mr. O'Caoimh and Dr Walsh [Member]
Disclosure of transactions between related parties [line items]
Annual rent payable		€ 787,000	838,000
Rate of rent per squre foot			43,860
Darnick Company [Member]
Disclosure of transactions between related parties [line items]
Contribution for tax audit settlement	$ 1,231,000
Repayments of borrowings			177,000
Increase in settlement amount due to depreciation	$ 1,231,000		1,316,000
Directors [Member]
Disclosure of transactions between related parties [line items]
Non executive directors fees			53,000	98,000
Share-based compensation benefits			$ 17,000	$ 61,000

RELATED PARTY TRANSACTIONS (Sch

RELATED PARTY TRANSACTIONS (Schedule of Compensation) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Disclosure of transactions between related parties [abstract]
Short-term employee benefits	$ 1,074	$ 1,065
Performance related bonus	512	227
Post-employment benefits	24	24
Share-based compensation benefits as calculated under IFRS 2	1,690	965
Total compensation	$ 3,300	$ 2,281

RELATED PARTY TRANSACTIONS (S_2

RELATED PARTY TRANSACTIONS (Schedule of Company's Shares and Share Option Plan) (Details)	12 Months Ended
	Dec. 31, 2022 Share shares	Dec. 31, 2021 Share shares	Dec. 31, 2020 Share shares
Class A Ordinary shares [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Outstanding Beginning Balance | Share	18,727,990	19,485,990	12,303,990
Granted | Share	29,400,000	0	9,100,000
Outstanding at end of year | Share	44,814,672	18,727,990	19,485,990
Class A Ordinary shares [Member] | Directors and company secretary [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Outstanding Beginning Balance	9,077,713	9,077,713
Shares of retired director	(626,600)	0
Number Of Retired Director Options	0	0
Shares Purchased During Year	2,666,664	0
Shares sold during the year	0	0
Granted	0	0
Expired / forfeited	0	0
Outstanding at end of year	11,117,777	9,077,713	9,077,713
Share Option [Member] | Directors and company secretary [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Outstanding Beginning Balance	16,738,000	17,394,000
Shares of retired director	0	0
Number Of Retired Director Options	(2,924,000)	(656,000)
Shares Purchased During Year	(2,666,664)	0
Shares sold during the year	0	0
Granted	29,400,000	0
Expired / forfeited	0	0
Outstanding at end of year	40,547,336	16,738,000	17,394,000

CAPITAL AND FINANCIAL RISK MA_3

CAPITAL AND FINANCIAL RISK MANAGEMENT (Narrative) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Disclosure of detailed information about financial instruments [abstract]
Senior secured term loan annual rate	11.25%
Senior secured term loan fixed rate	1.50%
Gross Increase Interest Income	$ 0	$ 31,000
Net interest income	$ 467,500	$ 0

CAPITAL AND FINANCIAL RISK MA_4

CAPITAL AND FINANCIAL RISK MANAGEMENT (Schedule of Fair Values of Financial Assets/Liabilities) (Details) - USD ($)	Dec. 31, 2022	Dec. 31, 2021		Dec. 31, 2020
Loans and receivables at amortised cost
Trade receivables	$ 2,691,000	$ 2,986,000		$ 3,922,000
Cash and cash equivalents	6,578,000	25,910,000
Finance lease receivable	170,000	293,000
Total maximum credit exposure	19,368,000	39,493,000
Liabilities at amortised cost
Senior secured term loan	(44,301,000)	0
Convertible note	(13,746,000)	0
Exchangeable note	(210,000)	(83,312,000)
Provisions	(50,000)	(50,000)
Fair value through profit and loss (FVPL)
Derivative liability - warrants	(1,569,000)	0
Derivative asset – prepayment option	128,000	0
Level 1 [Member]
Loans and receivables at amortised cost
Trade receivables	12,620,000	13,290,000
Cash and cash equivalents	6,578,000	25,910,000
Finance lease receivable	170,000	293,000
Total maximum credit exposure	19,368,000	39,493,000
Liabilities at amortised cost
Senior secured term loan	0
Convertible note	0
Exchangeable note	(210,000)	0	[1]
Lease liabilities	(13,943,000)	(15,845,000)
Trade and other payables (excluding deferred income)	(15,261,000)	(14,986,000)
Provisions	(50,000)	(50,000)
Total Liabilities at amortised cost	(29,464,000)	(30,881,000)
Fair value through profit and loss (FVPL)
Derivative liability - warrants	0
Derivative asset – prepayment option	0	0
Exchangeable note equity conversion option		0
Total fair value through profit and loss (FVPL)	0	0
Total fair value of financial assets liabilities	(10,096,000)	8,612,000
Level 2 [Member]
Loans and receivables at amortised cost
Trade receivables	0	0
Cash and cash equivalents	0	0
Finance lease receivable	0	0
Total maximum credit exposure	0	0
Liabilities at amortised cost
Senior secured term loan	(44,301,000)
Convertible note	(13,746,000)
Exchangeable note	0	(83,312,000)	[1]
Lease liabilities	0	0
Trade and other payables (excluding deferred income)	0	0
Provisions	0	0
Total Liabilities at amortised cost	(58,047,000)	(83,312,000)
Fair value through profit and loss (FVPL)
Derivative liability - warrants	(1,569,000)
Derivative asset – prepayment option	128,000	0
Exchangeable note equity conversion option		0
Total fair value through profit and loss (FVPL)	(1,441,000)	0
Total fair value of financial assets liabilities	(59,488,000)	(83,312,000)
Carrying Amount [Member]
Loans and receivables at amortised cost
Trade receivables	12,620,000	13,290,000
Cash and cash equivalents	6,578,000	25,910,000
Finance lease receivable	170,000	293,000
Total maximum credit exposure	19,368,000	39,493,000
Liabilities at amortised cost
Senior secured term loan	(44,301,000)
Convertible note	(13,746,000)
Exchangeable note	(210,000)	(83,312,000)	[1],[2]
Lease liabilities	(13,943,000)	(15,845,000)
Trade and other payables (excluding deferred income)	(15,261,000)	(14,986,000)
Provisions	(50,000)	(50,000)
Total Liabilities at amortised cost	(87,511,000)	(114,193,000)
Fair value through profit and loss (FVPL)
Derivative liability - warrants	(1,569,000)
Derivative asset – prepayment option	128,000	0
Exchangeable note equity conversion option		0
Total fair value through profit and loss (FVPL)	(1,441,000)	0
Total fair value of financial assets liabilities	(69,584,000)	(74,700,000)
Fair Value [Member]
Loans and receivables at amortised cost
Trade receivables	12,620,000	13,290,000
Cash and cash equivalents	6,578,000	25,910,000
Finance lease receivable	170,000	293,000
Total maximum credit exposure	19,368,000	39,493,000
Liabilities at amortised cost
Senior secured term loan	(44,301,000)
Convertible note	(13,746,000)
Exchangeable note	(210,000)	(83,312,000)	[1]
Lease liabilities	(13,943,000)	(15,845,000)
Trade and other payables (excluding deferred income)	(15,261,000)	(14,986,000)
Provisions	(50,000)	(50,000)
Total Liabilities at amortised cost	(87,511,000)	(114,193,000)
Fair value through profit and loss (FVPL)
Derivative liability - warrants	(1,569,000)
Derivative asset – prepayment option	128,000	0
Exchangeable note equity conversion option		0
Total fair value through profit and loss (FVPL)	(1,441,000)	0
Total fair value of financial assets liabilities	$ (69,584,000)	$ (74,700,000)
[1]The senior secured term loan is a variable instrument which bears interest at an annual rate equal to 11.25% plus the greater of (a) one-month Term SOFR Reference Rate and (b) one percent per annum.[2]The maturity of the Exchangeable Notes is based on the contractual maturity date of April 1, 2045 and does not take into account the potential exercise of put and call options in the next five years or the exchange agreements entered into with five exchangeable note holders in December 2021.

CAPITAL AND FINANCIAL RISK MA_5

CAPITAL AND FINANCIAL RISK MANAGEMENT (Schedule of Interest Rate Risk Effective and Repricing Analysis) (Details) - USD ($) $ in Thousands		Dec. 31, 2022		Dec. 31, 2021
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items]
Cash and cash equivalents		$ 6,578		$ 25,910
Lease receivable		170		293
Exchangeable note		(210)		(83,312)
Total interest earning financial and interest bearing financial liabilities		$ (65,452)		$ (72,985)
Cash and cash equivalents [Member]
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items]
Effective interest rate		0%		0.01%
Cash and cash equivalents		$ 6,578		$ 25,910
Finance Lease Receivable Member
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items]
Effective interest rate		4%		4%
Lease receivable		$ 170		$ 293
Exchangeable note [Member]
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items]
Effective interest rate		4.80%	[1]	4.80%
Lease receivable				$ 83,312
Exchangeable note	[1]	$ (210)
Senior Secured Term Loan [Member]
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items]
Effective interest rate	[2]	15.40%
Exchangeable note	[2]	$ (44,301)
Convertible Note [Member]
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items]
Effective interest rate	[3]	1.50%
Exchangeable note	[3]	$ (13,746)
Other borrowings [Member]
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items]
Effective interest rate				0%
Other borrowings				$ (31)
Lease payable on Right of Use assets [Member]
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items]
Effective interest rate		5%		5%
Lease payable on Right of Use assets		$ (13,898)		$ (15,668)
Lease payable on sale & leaseback transactions [Member]
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items]
Effective interest rate		5%		5%
Lease payable on sale & leaseback transactions		$ (45)		$ (177)
Six Month Or Less Member
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items]
Total interest earning financial and interest bearing financial liabilities		5,777		24,967
Six Month Or Less Member | Cash and cash equivalents [Member]
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items]
Cash and cash equivalents		6,578		25,910
Six Month Or Less Member | Finance Lease Receivable Member
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items]
Lease receivable		46		81
Six Month Or Less Member | Exchangeable note [Member]
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items]
Lease receivable				0
Exchangeable note	[1]	0
Six Month Or Less Member | Senior Secured Term Loan [Member]
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items]
Exchangeable note	[2]	0
Six Month Or Less Member | Convertible Note [Member]
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items]
Exchangeable note	[3]	0
Six Month Or Less Member | Other borrowings [Member]
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items]
Other borrowings				0
Six Month Or Less Member | Lease payable on Right of Use assets [Member]
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items]
Lease payable on Right of Use assets		(812)		(973)
Six Month Or Less Member | Lease payable on sale & leaseback transactions [Member]
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items]
Lease payable on sale & leaseback transactions		(35)		(51)
Six Month To Twelve Month Member
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items]
Total interest earning financial and interest bearing financial liabilities		(788)		(926)
Six Month To Twelve Month Member | Cash and cash equivalents [Member]
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items]
Cash and cash equivalents		0		0
Six Month To Twelve Month Member | Finance Lease Receivable Member
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items]
Lease receivable		41		61
Six Month To Twelve Month Member | Exchangeable note [Member]
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items]
Lease receivable				0
Exchangeable note	[1]	0
Six Month To Twelve Month Member | Senior Secured Term Loan [Member]
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items]
Exchangeable note	[2]	0
Six Month To Twelve Month Member | Convertible Note [Member]
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items]
Exchangeable note	[3]	0
Six Month To Twelve Month Member | Other borrowings [Member]
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items]
Other borrowings				(31)
Six Month To Twelve Month Member | Lease payable on Right of Use assets [Member]
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items]
Lease payable on Right of Use assets		(819)		(905)
Six Month To Twelve Month Member | Lease payable on sale & leaseback transactions [Member]
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items]
Lease payable on sale & leaseback transactions		(10)		(51)
One Year To Two Years Member
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items]
Total interest earning financial and interest bearing financial liabilities		(1,630)		(1,540)
One Year To Two Years Member | Cash and cash equivalents [Member]
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items]
Cash and cash equivalents		0		0
One Year To Two Years Member | Finance Lease Receivable Member
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items]
Lease receivable		49		89
One Year To Two Years Member | Exchangeable note [Member]
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items]
Lease receivable				0
Exchangeable note	[1]	0
One Year To Two Years Member | Senior Secured Term Loan [Member]
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items]
Exchangeable note	[2]	0
One Year To Two Years Member | Convertible Note [Member]
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items]
Exchangeable note	[3]	0
One Year To Two Years Member | Other borrowings [Member]
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items]
Other borrowings				0
One Year To Two Years Member | Lease payable on Right of Use assets [Member]
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items]
Lease payable on Right of Use assets		(1,679)		(1,554)
One Year To Two Years Member | Lease payable on sale & leaseback transactions [Member]
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items]
Lease payable on sale & leaseback transactions		0		(75)
Two Year To Five Years Member
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items]
Total interest earning financial and interest bearing financial liabilities		(48,789)		(4,454)
Two Year To Five Years Member | Cash and cash equivalents [Member]
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items]
Cash and cash equivalents		0		0
Two Year To Five Years Member | Finance Lease Receivable Member
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items]
Lease receivable		34		62
Two Year To Five Years Member | Exchangeable note [Member]
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items]
Lease receivable				0
Exchangeable note	[1]	0
Two Year To Five Years Member | Senior Secured Term Loan [Member]
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items]
Exchangeable note	[2]	(44,301)
Two Year To Five Years Member | Convertible Note [Member]
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items]
Exchangeable note	[3]	0
Two Year To Five Years Member | Other borrowings [Member]
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items]
Other borrowings				0
Two Year To Five Years Member | Lease payable on Right of Use assets [Member]
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items]
Lease payable on Right of Use assets		(4,522)		(4,516)
Two Year To Five Years Member | Lease payable on sale & leaseback transactions [Member]
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items]
Lease payable on sale & leaseback transactions		0		0
Greater Than Five Years Member
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items]
Total interest earning financial and interest bearing financial liabilities		(20,022)		(91,032)
Greater Than Five Years Member | Cash and cash equivalents [Member]
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items]
Cash and cash equivalents		0		0
Greater Than Five Years Member | Finance Lease Receivable Member
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items]
Lease receivable		0		0
Greater Than Five Years Member | Exchangeable note [Member]
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items]
Lease receivable				83,312
Exchangeable note	[1]	(210)
Greater Than Five Years Member | Senior Secured Term Loan [Member]
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items]
Exchangeable note	[2]	0
Greater Than Five Years Member | Convertible Note [Member]
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items]
Exchangeable note	[3]	(13,746)
Greater Than Five Years Member | Other borrowings [Member]
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items]
Other borrowings				0
Greater Than Five Years Member | Lease payable on Right of Use assets [Member]
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items]
Lease payable on Right of Use assets		(6,066)		(7,720)
Greater Than Five Years Member | Lease payable on sale & leaseback transactions [Member]
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items]
Lease payable on sale & leaseback transactions		$ 0		$ 0
[1]The maturity of the Exchangeable Notes is based on the contractual maturity date of April 1, 2045 and does not take into account the potential exercise of put and call options in the next five years or the exchange agreements entered into with five exchangeable note holders in December 2021.[2]The senior secured term loan is a variable instrument which bears interest at an annual rate equal to 11.25% plus the greater of (a) one-month Term SOFR Reference Rate and (b) one percent per annum.[3]The convertible note is a fixed rate instrument which bears a fixed rate of interest of 1.5% per annum.

CAPITAL AND FINANCIAL RISK MA_6

CAPITAL AND FINANCIAL RISK MANAGEMENT (Schedule of interest Rate Profile of Financial Assets/Liabilities) (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Variable Rate Instruments [Abstract]
Cash at bank and in hand	$ 6,578	$ 22,790
Short-term deposits	0	3,120
Variable rate financial liabilities (senior secured term loan)	(44,301)	0
Variable rate instruments	(37,723)	25,910
Fixed rate instruments
Fixed rate financial liabilities (exchangeable note)	(210)	(83,312)
Fixed rate financial liabilities (convertible note)	(13,746)	0
Fixed rate financial liabilities (borrowings)	0	(31)
Fixed rate financial liabilities (lease payables)	(13,943)	(15,844)
Financial assets (short-term deposits and short-term investments)	0	3,121
Financial assets (lease receivables)	170	293
Fixed rate instruments	$ (27,729)	$ (95,773)

CAPITAL AND FINANCIAL RISK MA_7

CAPITAL AND FINANCIAL RISK MANAGEMENT (Schedule of Liquidity Risk Estimated Interest Payments of Maturities) (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Financial liabilities
Senior secured term loan	$ 44,301	$ 0
Convertible Note	13,746	0
Exchangeable notes	210	83,312
Liquidity risk [Member]
Financial liabilities
Trade & other payables	15,261	15,127
Lease payable on Right of Use assets	13,898	15,668
Lease Payable On Sale And Leaseback Transactions	45	177
Senior secured term loan	44,301
Convertible Note	13,746
Other borrowings		31
Exchangeable notes	210	83,312	[1]
Exchangeable note interest		999
Total maturities of financial liabilities	87,461	115,314
Contractual cash flows [Member] | Liquidity risk [Member]
Financial liabilities
Trade & other payables	15,261	15,127
Lease payable on Right of Use assets	17,196	15,668
Lease Payable On Sale And Leaseback Transactions	46	177
Senior secured term loan	69,519
Convertible Note	21,900
Other borrowings		31
Exchangeable notes	397	99,900	[1]
Exchangeable note interest		93,906
Total maturities of financial liabilities	124,319	224,809
Six Month Or Less Member | Liquidity risk [Member]
Financial liabilities
Trade & other payables	15,261	15,127
Lease payable on Right of Use assets	1,120	973
Lease Payable On Sale And Leaseback Transactions	36	51
Senior secured term loan	4,194
Convertible Note	150
Other borrowings		0
Exchangeable notes	4	0	[1]
Exchangeable note interest		1,998
Total maturities of financial liabilities	20,765	18,149
Six Month To Twelve Month Member | Liquidity risk [Member]
Financial liabilities
Trade & other payables	0	0
Lease payable on Right of Use assets	1,130	905
Lease Payable On Sale And Leaseback Transactions	10	51
Senior secured term loan	3,595
Convertible Note	150
Other borrowings		31
Exchangeable notes	4	0	[1]
Exchangeable note interest		1,998
Total maturities of financial liabilities	4,889	2,985
One Year To Two Years Member | Liquidity risk [Member]
Financial liabilities
Trade & other payables	0	0
Lease payable on Right of Use assets	2,240	1,554
Lease Payable On Sale And Leaseback Transactions	0	75
Senior secured term loan	7,190
Convertible Note	300
Other borrowings		0
Exchangeable notes	8	0	[1]
Exchangeable note interest		3,996
Total maturities of financial liabilities	9,738	5,625
Two Year To Five Years Member | Liquidity risk [Member]
Financial liabilities
Trade & other payables	0	0
Lease payable on Right of Use assets	5,739	4,516
Lease Payable On Sale And Leaseback Transactions	0	0
Senior secured term loan	54,540
Convertible Note	900
Other borrowings		0
Exchangeable notes	24	0	[1]
Exchangeable note interest		11,988
Total maturities of financial liabilities	61,203	16,504
>5 years [Member] | Liquidity risk [Member]
Financial liabilities
Trade & other payables	0	0
Lease payable on Right of Use assets	6,967	7,720
Lease Payable On Sale And Leaseback Transactions	0	0
Senior secured term loan	0
Convertible Note	20,400
Other borrowings		0
Exchangeable notes	357	99,900	[1]
Exchangeable note interest		73,926
Total maturities of financial liabilities	$ 27,724	$ 181,546
[1]The maturity of the Exchangeable Notes is based on the contractual maturity date of April 1, 2045.

CAPITAL AND FINANCIAL RISK MA_8

CAPITAL AND FINANCIAL RISK MANAGEMENT (Schedule of Foreign Currency Risk Short Term Financial Assets and Liabilities) (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Disclosure of detailed information about financial instruments [line items]
Cash	$ 6,578	$ 22,790
Euro [Member]
Disclosure of detailed information about financial instruments [line items]
Cash	700	327
Trade and other receivable	1,001	464
Trade and other payables	(3,481)	(2,456)
Lease liabilities	(9,024)	(10,629)
Total exposure	(10,804)	(12,294)
GBP [Member]
Disclosure of detailed information about financial instruments [line items]
Cash	199	115
Trade and other receivable	27	58
Trade and other payables	(5)	(28)
Lease liabilities	0	0
Total exposure	221	145
SEK [Member]
Disclosure of detailed information about financial instruments [line items]
Cash	5	5
Trade and other receivable	0	0
Trade and other payables	(6)	(11)
Lease liabilities	0	0
Total exposure	(1)	(6)
CAD [Member]
Disclosure of detailed information about financial instruments [line items]
Cash	2,061	4,617
Trade and other receivable	950	488
Trade and other payables	(473)	(166)
Lease liabilities	0	0
Total exposure	2,538	4,939
BRL [Member]
Disclosure of detailed information about financial instruments [line items]
Cash	756	1,370
Trade and other receivable	1,443	1,538
Trade and other payables	(662)	(629)
Lease liabilities	(277)	(139)
Total exposure	1,260	2,140
Other [Member]
Disclosure of detailed information about financial instruments [line items]
Cash	0	0
Trade and other receivable	0	0
Trade and other payables	0	0
Lease liabilities	0	0
Total exposure	$ 0	$ 0

CAPITAL AND FINANCIAL RISK MA_9

CAPITAL AND FINANCIAL RISK MANAGEMENT (Schedule of Sensitivity Analysis) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disclosure of information about amounts that affected statement of comprehensive income as result of hedge accounting [line items]
Profit or loss	$ (41,002)	$ 929	$ (6,013)
Euro [Member] | 10% strengthening US Dollar [Member]
Disclosure of information about amounts that affected statement of comprehensive income as result of hedge accounting [line items]
Profit or loss	982	780
Euro [Member] | 10% Weakening US Dollar [Member]
Disclosure of information about amounts that affected statement of comprehensive income as result of hedge accounting [line items]
Profit or loss	$ (1,200)	$ (953)

CAPITAL AND FINANCIAL RISK M_10

CAPITAL AND FINANCIAL RISK MANAGEMENT (Schedule of Maximum Credit Exposure of Financial Assets) (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Disclosure of detailed information about financial instruments [abstract]
Third party trade receivables	$ 12,620	$ 13,290
Finance lease income receivable	170	293
Cash and cash equivalents	6,578	25,910
Total maximum credit exposure	$ 19,368	$ 39,493

CAPITAL AND FINANCIAL RISK M_11

CAPITAL AND FINANCIAL RISK MANAGEMENT (Schedule of Exposure of Trade Receivables by Geographic Location) (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Disclosure of credit risk exposure [line items]
Maximum Exposure to credit risk for trade receivables and finance lease income receivable	$ 12,790	$ 13,583
United States [Member]
Disclosure of credit risk exposure [line items]
Maximum Exposure to credit risk for trade receivables and finance lease income receivable	6,061	5,822
Euro-zone countries [Member]
Disclosure of credit risk exposure [line items]
Maximum Exposure to credit risk for trade receivables and finance lease income receivable	1,183	1,072
United Kingdom [Member]
Disclosure of credit risk exposure [line items]
Maximum Exposure to credit risk for trade receivables and finance lease income receivable	67	118
Other regions [Member]
Disclosure of credit risk exposure [line items]
Maximum Exposure to credit risk for trade receivables and finance lease income receivable	$ 5,479	$ 6,571

CAPITAL AND FINANCIAL RISK M_12

CAPITAL AND FINANCIAL RISK MANAGEMENT (Schedule of Exposure of Trade Receivables by Customer) (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Disclosure of credit risk exposure [line items]
Maximum Exposure to credit risk for trade receivables and finance lease income receivable	$ 12,790	$ 13,583
End-user customers [Member]
Disclosure of credit risk exposure [line items]
Maximum Exposure to credit risk for trade receivables and finance lease income receivable	7,365	6,923
Distributors [Member]
Disclosure of credit risk exposure [line items]
Maximum Exposure to credit risk for trade receivables and finance lease income receivable	4,630	6,220
Non-governmental organisations [Member]
Disclosure of credit risk exposure [line items]
Maximum Exposure to credit risk for trade receivables and finance lease income receivable	$ 795	$ 440

CAPITAL AND FINANCIAL RISK M_13

CAPITAL AND FINANCIAL RISK MANAGEMENT (Schedule of Ageing of Trade Receivables) (Details) - USD ($)	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items]
Trade receivables	$ 2,691,000	$ 2,986,000	$ 3,922,000
Expected credit loss rate	0%	0%
Not past due [Member]
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items]
Expected credit loss rate	0%	0%
Past due 0-30 days [Member]
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items]
Expected credit loss rate	0%	0.10%
Past due 31-120 days [Member]
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items]
Expected credit loss rate	1.50%	4.90%
Greater Than Four Months Member
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items]
Expected credit loss rate	70.50%	73%
Cost [Member]
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items]
Trade receivables	$ 15,310,000	$ 15,876,000
Cost [Member] | Not past due [Member]
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items]
Trade receivables	8,341,000	8,461,000
Cost [Member] | Past due 0-30 days [Member]
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items]
Trade receivables	1,622,000	2,423,000
Cost [Member] | Past due 31-120 days [Member]
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items]
Trade receivables	1,564,000	1,981,000
Cost [Member] | Greater Than Four Months Member
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items]
Trade receivables	3,783,000	3,011,000
Accumulated impairment Charge [member]
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items]
Trade receivables	2,691,000	2,986,000
Accumulated impairment Charge [member] | Not past due [Member]
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items]
Trade receivables	0	0
Accumulated impairment Charge [member] | Past due 0-30 days [Member]
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items]
Trade receivables	0	1,000
Accumulated impairment Charge [member] | Past due 31-120 days [Member]
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items]
Trade receivables	23,000	97,000
Accumulated impairment Charge [member] | Greater Than Four Months Member
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items]
Trade receivables	$ 2,668,000	$ 2,888,000

CAPITAL AND FINANCIAL RISK M_14

CAPITAL AND FINANCIAL RISK MANAGEMENT (Schedule of Movement in the Allowance for Impairment of Trade Receivables) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Disclosure of detailed information about financial instruments [abstract]
Balance at January 1	$ 2,986	$ 3,922
Charged to costs and expenses	1,240	76
Amounts written off during the year	(1,535)	(1,012)
Balance at December 31	$ 2,691	$ 2,986

RECONCILIATION OF LIABILITIES_3

RECONCILIATION OF LIABILITIES ARISING FROM FINANCING ACTIVITIES (Schedule of Liabilities Arising from Financing) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disclosure of reconciliation of liabilities arising from financing activities [line items]
Balance at January 1, 2022	$ 15,844
Cash-flows:
Principal amount loaned – term loan	0	$ 1,764	$ 4,520
Principal amount loaned – convertible note	20,000	0	0
Interest paid for term loan	6,424	0	0
Interest paid for convertible note	199	0	0
Interest paid for exchangeable notes	(1,293)	(3,996)	(3,996)
Repayment of exchangeable notes	(86,730)	0	0
Repayment of CEBA loan	(2,761)	(2,939)	(3,240)
Non-cash:
Interest charged	7,914
Loss on disposal of Exchangeable Notes	9,678	0	0
Balance at December 31, 2022	13,943	15,844
Borrowings & derivative financial instruments [Member]
Disclosure of reconciliation of liabilities arising from financing activities [line items]
Balance at January 1, 2022	83,343	84,065
Cash-flows:
Principal amount loaned – term loan	81,250
Principal amount loaned – convertible note	20,000
Loan origination costs paid	(3,591)
Interest paid for term loan	(6,424)
Interest paid for convertible note	(199)
Interest paid for exchangeable notes	(1,293)	(3,996)
Repayment of exchangeable notes	(86,730)
Repayment of term loan	(34,500)	0
Repayment of CEBA loan	(23)
Penalty paid for early settlement of term loan	(3,450)
Non-cash:
Interest charged		3,996
Penalty for early settlement charged	3,450
Shares issued as consideration for purchase of Exchangeable Notes	(6,133)
Equity component of convertible note at date of issue	(6,709)
Derivative financial asset at date of issue	202
Loss on disposal of Exchangeable Notes	9,678
Additions (related to Right of Use assets)	0	0
Exchange adjustment	0	0
Loan forgiven	(7)
Accretion interest	3,351	648
Fair value of derivative liability - warrants	(303)	(1,370)
Balance at December 31, 2022	59,826	83,343	84,065
Lease liabilities [Member]
Disclosure of reconciliation of liabilities arising from financing activities [line items]
Balance at January 1, 2022	15,845	18,741
Cash-flows:
Principal amount loaned – convertible note	0
Loan origination costs paid	0
Interest paid for term loan	0
Interest paid for exchangeable notes		(11)
Repayment of term loan		(2,939)
Repayment of CEBA loan	(2,761)
Penalty paid for early settlement of term loan	0
Non-cash:
Interest charged	0	0
Penalty for early settlement charged	0
Shares issued as consideration for purchase of Exchangeable Notes	0
Equity component of convertible note at date of issue	0
Derivative financial asset at date of issue	0
Loss on disposal of Exchangeable Notes	0
Additions (related to Right of Use assets)	830	71
Exchange adjustment	(628)	(820)
Loan forgiven	0
Accretion interest	657	803
Fair value of derivative liability - warrants	0	0
Balance at December 31, 2022	$ 13,943	$ 15,845	$ 18,741

POST BALANCE SHEET EVENTS (Narr

POST BALANCE SHEET EVENTS (Narrative) (Details) - USD ($) $ / shares in Units, $ in Thousands		1 Months Ended		12 Months Ended
	Jan. 09, 2023	Apr. 30, 2023	Feb. 21, 2023	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disclosure of non-adjusting events after reporting period [line items]
Revenue				$ 74,779	$ 92,965	$ 101,980
Strategic partnership with imaware, Inc. [Member]
Disclosure of non-adjusting events after reporting period [line items]
Agreement Term	5-year
Convertible note	$ 1,500
Amendment And Restatement Of Term Loan [Member]
Disclosure of non-adjusting events after reporting period [line items]
Increase term loan			$ 5,000
Outstanding term loan			$ 20,000
Warrants issued shares			2,500,000
Warrants Per Ads Price			$ 1.071
Share price per ADS			$ 1.3
Divestiture Of Fitzgerald Life Sciences Business [Member]
Disclosure of non-adjusting events after reporting period [line items]
Proceeds from cash		$ 30,000
Revenue				$ 12,000
Senior secured term loan [Member]
Disclosure of non-adjusting events after reporting period [line items]
Proceeds from cash		11,000
Repayment of secured debt		10,100
Early repayment penalty		$ 900

ACCOUNTING ESTIMATES AND JUDG_2

ACCOUNTING ESTIMATES AND JUDGEMENTS (Narrative) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disclosure of changes in accounting estimates [line items]
Deferred income	$ 114,000	$ 141,000	$ 4,445,000
Description of useful life	expenditure is capitalised at cost within intangible assets and amortised over its expected useful life of 15 years
Carrying amounts	$ 35,269,000	35,981,000
Inventories net of provisions	$ 16,274,000	$ 12,063,000	$ 9,781,000
Percentage of gross inventory	42%	29.30%	24.50%
Repayments of bonds, notes and debentures	$ 86,730,000	$ 0	$ 0
Impairment loss additions	5,839,000	6,944,000	17,779,000
Amortisation expense	923,000	917,000	1,403,000
Total impairment loss	1,200,000
Provision for inventory	3,500,000
Inventory written down	300,000
Raw materials and work in progress of inventory written down	900,000
Allowance for impairment of receivables	2,691,000	2,986,000	3,922,000
Net current assets	29,300,000
Proceeds from sale of business	30,000,000
Reduction of gross debt	10,000,000
Capitalised development expenditure [member]
Disclosure of changes in accounting estimates [line items]
Carrying amounts	17,008,000	17,679,000
Impairment loss charge	4,623,000
Impairment loss additions	4,475,000
Amortisation expense	479,000
2% of gross inventory [Member]
Disclosure of changes in accounting estimates [line items]
Change in allowance	$ 800,000	$ 800,000	$ 800,000

GROUP UNDERTAKINGS (Details)

GROUP UNDERTAKINGS (Details)	12 Months Ended
	Dec. 31, 2022
Trinity Biotech Manufacturing Limited [Member]
Disclosure Of Composition Of Group [Line Items]
Name of subsidiary	Trinity Biotech Manufacturing Limited
Address of entity's registered office	IDA Business Park, Bray County Wicklow, Ireland
Principal activity	Manufacture and saleof diagnostic test kits
Principal Country of incorporation and operation	Ireland
Group % holding	100%
Trinity Research Limited [Member]
Disclosure Of Composition Of Group [Line Items]
Name of subsidiary	Trinity Research Limited
Address of entity's registered office	IDA Business Park, Bray County Wicklow, Ireland
Principal activity	Research anddevelopment
Principal Country of incorporation and operation	Ireland
Group % holding	100%
Benen Trading Limited [Member]
Disclosure Of Composition Of Group [Line Items]
Name of subsidiary	Benen Trading Limited
Address of entity's registered office	IDA Business Park, Bray County Wicklow, Ireland
Principal activity	Trading
Principal Country of incorporation and operation	Ireland
Group % holding	100%
Trinity Biotech Manufacturing Services Limited [Member]
Disclosure Of Composition Of Group [Line Items]
Name of subsidiary	Trinity Biotech Manufacturing Services Limited
Address of entity's registered office	IDA Business Park, Bray County Wicklow, Ireland
Principal activity	Dormant
Principal Country of incorporation and operation	Ireland
Group % holding	100%
Trinity Biotech Luxembourg Sarl [Member]
Disclosure Of Composition Of Group [Line Items]
Name of subsidiary	Trinity Biotech Luxembourg Sarl
Address of entity's registered office	1, rue Bender, L-1229 Luxembourg
Principal activity	Investment andprovision of financialservices
Principal Country of incorporation and operation	Luxembourg
Group % holding	100%
Trinity Biotech Inc [Member]
Disclosure Of Composition Of Group [Line Items]
Name of subsidiary	Trinity Biotech Inc
Address of entity's registered office	Girts Road, Jamestown, NY 14702, USA
Principal activity	Holding Company
Principal Country of incorporation and operation	U.S.A.
Group % holding	100%
Clark Laboratories Inc [Member]
Disclosure Of Composition Of Group [Line Items]
Name of subsidiary	Clark Laboratories Inc Trading as Trinity Biotech (USA)
Address of entity's registered office	Girts Road, Jamestown NY14702, USA
Principal activity	Manufacture and saleof diagnostic test kits
Principal Country of incorporation and operation	U.S.A.
Group % holding	100%
Mardx Diagnostics Inc. [Member]
Disclosure Of Composition Of Group [Line Items]
Name of subsidiary	Mardx Diagnostics Inc
Address of entity's registered office	5919 Farnsworth Court Carlsbad CA 92008, USA
Principal activity	Dormant
Principal Country of incorporation and operation	U.S.A.
Group % holding	100%
Fitzgerald Industries International, Inc [Member]
Disclosure Of Composition Of Group [Line Items]
Name of subsidiary	Fitzgerald Industries International, Inc
Address of entity's registered office	2711 Centerville Road, Suite 400 Wilmington, New Castle Delaware, 19808, USA
Principal activity	Management servicescompany
Principal Country of incorporation and operation	U.S.A.
Group % holding	100%
Biopool US Inc [Member]
Disclosure Of Composition Of Group [Line Items]
Name of subsidiary	Biopool US Inc (trading as Trinity Biotech Distribution)
Address of entity's registered office	Girts Road, Jamestown NY14702, USA
Principal activity	Sale of diagnostic testkits
Principal Country of incorporation and operation	U.S.A.
Group % holding	100%
Primus Corporation [Member]
Disclosure Of Composition Of Group [Line Items]
Name of subsidiary	Primus Corporation
Address of entity's registered office	4231 E 75th Terrace Kansas City, MO 64132, USA
Principal activity	Manufacture and saleof diagnostic test kitsand instrumentation
Principal Country of incorporation and operation	U.S.A.
Group % holding	100%
Phoenix Bio Tech Corp [Member]
Disclosure Of Composition Of Group [Line Items]
Name of subsidiary	Phoenix Bio-tech Corp.
Address of entity's registered office	1166 South Service Road West Oakville, ON L6L 5T7 Canada.
Principal activity	Dormant
Principal Country of incorporation and operation	Canada
Group % holding	100%
Fiomi Diagnostics Holding Ab [Member]
Disclosure Of Composition Of Group [Line Items]
Name of subsidiary	Fiomi Diagnostics Holding AB
Address of entity's registered office	Dag Hammarskjöldsv 52A SE-752 37 Uppsala Sweden
Principal activity	Holding Company
Principal Country of incorporation and operation	Sweden
Group % holding	100%
Fiomi Diagnostics Ab [Member]
Disclosure Of Composition Of Group [Line Items]
Name of subsidiary	Fiomi Diagnostics AB
Address of entity's registered office	Dag Hammarskjöldsv 52A SE-752 37 Uppsala Sweden
Principal activity	Discontinued operation
Principal Country of incorporation and operation	Sweden
Group % holding	100%
Trinity Biotech Do Brasil [Member]
Disclosure Of Composition Of Group [Line Items]
Name of subsidiary	Trinity Biotech Do Brasil
Address of entity's registered office	Comercio e Importacao Ltda Rua Silva Bueno 1.660 – Cj. 101/102 Ipiranga Sao Paulo Brazil
Principal activity	Sale of diagnostic testkits
Principal Country of incorporation and operation	Brazil
Group % holding	100%
Trinity Biotech (Uk) Ltd [Member]
Disclosure Of Composition Of Group [Line Items]
Name of subsidiary	Trinity Biotech (UK) Ltd
Address of entity's registered office	Mills and Reeve LLP Botanic House 100 Hills Road Cambridge, CB2 1PH United Kingdom
Principal activity	Sales & marketingactivities
Principal Country of incorporation and operation	UK
Group % holding	100%
Immco Diagnostics Inc Member
Disclosure Of Composition Of Group [Line Items]
Name of subsidiary	Immco Diagnostics Inc
Address of entity's registered office	60 Pineview Drive Buffalo NY 14228, USA
Principal activity	Manufacture and sale ofautoimmune productsand laboratory services
Principal Country of incorporation and operation	U.S.A.
Group % holding	100%
Nova Century Scientific Inc [Member]
Disclosure Of Composition Of Group [Line Items]
Name of subsidiary	Nova Century Scientific Inc
Address of entity's registered office	5022 South Service Road Burlington Ontario Canada
Principal activity	Manufacture and sale ofautoimmune products and infectious diseases
Principal Country of incorporation and operation	Canada
Group % holding	100%
Trinity Biotech Investment Ltd [Member]
Disclosure Of Composition Of Group [Line Items]
Name of subsidiary	Trinity Biotech Investment Ltd
Address of entity's registered office	PO Box 309 Ugland House Grand Cayman KY1-1104 Cayman Islands
Principal activity	Investment andprovision of financialservices
Principal Country of incorporation and operation	Cayman Islands
Group % holding	100%